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The	  Autism	  Phenotype	  
The	  year	  2013	  marks	  the	  70th	  anniversary	  of	  Leo	  Kanner’s	  initial	  report	  of	  a	  
condition	  he	  termed	  “autistic	  disturbances	  of	  affective	  contact”	  [1].	  His	  series	  of	  eleven	  
case	  reports	  laid	  the	  foundation	  for	  past	  and	  present	  research,	  and	  remains	  the	  starting	  
point	  for	  what	  is	  today	  considered	  the	  autism	  phenotype.	  With	  the	  publication	  of	  the	  
fifth	  edition	  of	  the	  Diagnostic	  and	  Statistical	  Manual	  of	  Mental	  Disorders	  (DSM-­‐5)	  this	  
year,	  changes	  made	  to	  the	  diagnostic	  criteria	  for	  autism	  disorder	  were	  among	  the	  most	  
controversial.	  At	  the	  heart	  of	  these	  controversies	  lies	  the	  latest	  attempt	  in	  a	  seventy-­‐
year	  ongoing	  effort	  to	  define	  the	  autism	  phenotype	  more	  accurately.	  	  
Autism	  spectrum	  disorder	  (ASD),	  or	  simply	  autism,	  is	  a	  neurodevelopmental	  
disorder	  characterized	  by	  impairments	  in	  two	  domains:	  1)	  verbal	  and	  non-­‐verbal	  
communication	  and	  impaired	  social	  reciprocity	  and	  2)	  restricted	  interests	  and	  repetitive	  
behaviors.	  Often	  noticed	  early	  in	  life,	  individuals	  with	  ASD	  display	  a	  spectrum	  of	  
impairments	  ranging	  from	  mild	  to	  severe,	  with	  some	  individuals	  displaying	  well	  above	  
average	  intelligence	  while	  others	  showing	  profound	  intellectual	  disability.	  While	  no	  age	  
of	  onset	  is	  required,	  symptoms	  must	  be	  present	  at	  an	  early	  age	  even	  if	  they	  do	  not	  fully	  
manifest	  until	  the	  demands	  exceed	  the	  subject’s	  capacities.	  Individuals	  with	  ASD	  may	  
show	  communication	  deficits	  such	  as	  inappropriate	  responses,	  misreading	  of	  nonverbal	  
cues,	  and	  difficulties	  in	  building	  and	  maintaining	  relationships.	  Many	  ASD	  individuals	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may	  show	  high	  sensitivity	  to	  changes	  in	  their	  environment,	  intense	  focus	  on	  individual	  
items,	  and	  dependence	  on	  routines.	  	  
No	  diagnostically	  informative	  biological	  tests	  for	  ASD	  exists,	  however,	  there	  are	  
behavioral	  instruments	  that	  perform	  with	  high	  sensitivity	  and	  specificity.	  Standardized	  
interviews	  and	  direct	  age-­‐adjusted	  observation	  tools	  have	  gained	  acceptance	  in	  
research	  settings	  [2,	  3],	  and	  currently	  a	  routine	  battery	  of	  psychometric	  and	  cognitive	  
assessments	  have	  standardized	  the	  diagnostic	  routine	  in	  a	  clinical	  setting	  [4,	  5].	  
Examples	  of	  these	  instruments	  include	  the	  autism	  diagnostic	  interview	  revised	  (ADI-­‐R),	  a	  
semi-­‐structured	  interview	  given	  to	  the	  child’s	  primary	  caregiver	  that	  consists	  of	  93	  
questions,	  and	  the	  autism	  diagnostic	  observational	  schedule	  (ADOS),	  an	  observational	  
session	  and	  an	  interview	  with	  the	  child.	  The	  “gold	  standard”	  for	  diagnosing	  ASD	  is	  using	  
a	  combination	  of	  ADI-­‐R	  and	  ADOS	  and	  a	  clinician’s	  best	  judgment	  [6].	  
Diverse	  arrays	  of	  disorders	  are	  often	  co-­‐morbid	  with	  an	  ASD	  diagnosis.	  These	  
include	  epilepsy,	  sensory,	  motor,	  gastrointestinal,	  and	  sleep	  abnormalities	  [7].	  Likewise,	  
a	  number	  of	  co-­‐occurring	  neuropsychiatric	  conditions	  are	  often	  seen	  including	  attention	  
deficit	  hyperactivity	  disorder	  (ADHD),	  anxiety,	  aggression,	  and	  obsessive-­‐compulsive	  
behaviors	  [8-­‐10].	  Intellectual	  disability	  (ID),	  previously	  known	  as	  mental	  retardation,	  has	  
historically	  been	  cited	  as	  being	  present	  in	  >70%	  of	  ASD	  subjects,	  however,	  recent	  
reports	  put	  ID	  and	  ASD	  co-­‐occurrence	  rate	  significantly	  lower	  at	  40-­‐55%	  [11,	  12].	  	  
The	  public	  health	  impact	  of	  ASD	  is	  substantial,	  and	  support	  services	  are	  often	  
required	  throughout	  the	  individual’s	  lifetime.	  In	  2006,	  it	  was	  estimated	  that	  the	  societal	  
cost	  of	  caring	  for	  and	  treating	  an	  ASD	  individual	  is	  $3.2M	  over	  the	  course	  of	  that	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Table	  1.1:	  Diagnostic	  criteria	  for	  Autism	  Spectrum	  Disorder,	  DSM-­‐V	  (APA,	  2013)	  	  
Autism	  Spectrum	  Disorders	  299.00	  (F84.0)	  
	  
1. Persistent	  deficits	  in	  social	  communication	  and	  social	  interaction	  across	  multiple	  contexts,	  
as	  manifested	  by	  the	  following,	  currently	  or	  by	  history	  (examples	  are	  illustrative,	  not	  
exhaustive;	  see	  text):	  
1. Deficits	  in	  social-­‐emotional	  reciprocity,	  ranging,	  for	  example,	  from	  abnormal	  social	  
approach	  and	  failure	  of	  normal	  back-­‐and-­‐forth	  conversation;	  to	  reduced	  sharing	  of	  
interests,	  emotions,	  or	  affect;	  to	  failure	  to	  initiate	  or	  respond	  to	  social	  interactions.	  
2. Deficits	  in	  nonverbal	  communicative	  behaviors	  used	  for	  social	  interaction,	  ranging,	  
for	  example,	  from	  poorly	  integrated	  verbal	  and	  nonverbal	  communication;	  to	  
abnormalities	  in	  eye	  contact	  and	  body	  language	  or	  deficits	  in	  understanding	  and	  use	  
of	  gestures;	  to	  a	  total	  lack	  of	  facial	  expressions	  and	  nonverbal	  communication.	  
3. Deficits	  in	  developing,	  maintaining,	  and	  understanding	  relationships,	  ranging,	  for	  
example,	  from	  difficulties	  adjusting	  behavior	  to	  suit	  various	  social	  contexts;	  to	  
difficulties	  in	  sharing	  imaginative	  play	  or	  in	  making	  friends;	  to	  absence	  f	  interest	  in	  
peers.	  
2. Restricted,	  repetitive	  patterns	  of	  behavior,	  interests,	  or	  activities,	  as	  manifested	  by	  at	  least	  
two	  of	  the	  following,	  currently	  or	  by	  history	  (examples	  are	  illustrative,	  not	  exhaustive;	  see	  
text):	  
i. Stereotyped	  or	  repetitive	  motor	  movements,	  use	  of	  objects,	  or	  speech	  (e.g.,	  simple	  
motor	  stereotypies,	  lining	  up	  toys	  or	  flipping	  objects,	  echolalia,	  idiosyncratic	  
phrases).	  
ii. Insistence	  on	  sameness,	  inflexible	  adherence	  to	  routines,	  or	  ritualized	  patterns	  of	  
verbal	  or	  nonverbal	  behavior	  (e.g.,	  extreme	  distress	  at	  small	  changes,	  difficulties	  
with	  transitions,	  rigid	  thinking	  patterns,	  greeting	  rituals,	  need	  to	  take	  same	  route	  or	  
eat	  same	  food	  every	  day).	  
iii. Highly	  restricted,	  fixated	  interests	  that	  are	  abnormal	  in	  intensity	  or	  focus	  (e.g.,	  
strong	  attachment	  to	  or	  preoccupation	  with	  unusual	  objects,	  excessively	  
circumscribed	  or	  perseverative	  interests).	  
iv. Hyper-­‐	  or	  hyporeactivity	  to	  sensory	  input	  or	  unusual	  interest	  in	  sensory	  aspects	  of	  
the	  environment	  (e.g.,	  apparent	  indifference	  to	  pain/temperature,	  adverse	  
response	  to	  specific	  sounds	  or	  textures,	  excessive	  smelling	  or	  touching	  of	  objects,	  
visual	  fascination	  with	  lights	  or	  movement).	  
3. Symptoms	  must	  be	  present	  in	  the	  early	  developmental	  period	  (but	  may	  not	  become	  fully	  
manifest	  until	  social	  demands	  exceed	  limited	  capacities,	  or	  may	  be	  masked	  by	  learned	  
strategies	  in	  later	  life).	  	  
4. Symptoms	  cause	  clinically	  significant	  impairment	  in	  social,	  occupational,	  or	  other	  important	  
areas	  of	  current	  functioning.	  
5. These	  disturbances	  are	  not	  better	  explained	  by	  intellectual	  disability	  (intellectual	  
developmental	  disorder)	  or	  global	  developmental	  delay.	  Intellectual	  disability	  and	  autism	  
spectrum	  disorder	  frequently	  co-­‐occur;	  to	  make	  comorbid	  diagnoses	  of	  autism	  spectrum	  
disorder	  and	  intellectual	  disability,	  social	  communication	  should	  be	  below	  that	  expected	  for	  
general	  developmental	  level.	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subject’s	  lifetime	  [13].	  More	  importantly,	  the	  impact	  of	  ASD	  on	  affected	  individuals	  and	  
their	  families	  is	  universally	  life	  changing,	  and	  currently	  there	  is	  no	  curative	  treatment.	  
Once	  considered	  untreatable,	  it	  wasn’t	  until	  the	  late	  1980s	  that	  Lovaas	  demonstrated	  
early	  behavioral	  therapy	  could	  reduce	  symptoms	  of	  the	  disorder	  [14].	  Today,	  it	  is	  widely	  
believed	  that	  intervention	  services	  received	  at	  younger	  ages	  show	  the	  largest	  gains	  in	  
cognitive	  and	  adaptive	  functioning	  in	  cases	  compared	  with	  those	  that	  did	  not	  receive	  
treatment	  [15-­‐18].	  Unlike	  behavioral	  treatment,	  which	  attempts	  to	  target	  core	  
symptoms	  of	  ASD,	  pharmacotherapy	  aims	  to	  decrease	  symptoms	  like	  aggression,	  
compulsive	  behaviors,	  attention	  problems,	  and	  hyperactivity.	  Treatment	  with	  
medications	  is	  quite	  common	  in	  ASD	  with	  estimates	  as	  high	  as	  50%	  of	  ASD	  adolescents,	  
and	  ASD	  adult	  individuals	  having	  been	  prescribed	  at	  least	  one	  psychotropic	  medication	  
[19,	  20].	  That	  said,	  there	  is	  no	  consensus	  approach	  to	  treatment,	  and	  numerous	  
approaches	  are	  often	  used	  tailored	  to	  specific	  behavioral	  problems	  and	  response	  to	  
treatments	  with	  most	  ASD	  individuals	  receiving	  combinations	  of	  these	  over	  the	  course	  
of	  their	  lifetimes	  [21,	  22].	  Risperidone,	  an	  atypical	  antipsychotic,	  has	  been	  shown	  to	  
work	  in	  treating	  aggression	  and	  repetitive	  behavior	  [23].	  Multiple	  studies	  have	  reported	  
benefits	  from	  the	  selective	  serotonin	  reuptake	  inhibitors	  (SSRIs)	  clomipramine	  
(Anafranil),	  fluoxetine	  (Prozac),	  and	  sertraline	  (Zoloft)	  in	  treating	  symptoms	  [24-­‐26].	  
The	  public	  health	  impact	  of	  ASD	  is	  substantial	  and	  support	  services	  are	  often	  
required	  throughout	  the	  individual’s	  lifetime.	  In	  2006,	  it	  was	  estimated	  that	  the	  societal	  
cost	  of	  caring	  for,	  and	  treating	  an	  ASD	  individual	  is	  $3.2M	  over	  the	  course	  of	  that	  
subject’s	  lifetime	  [13].	  More	  importantly,	  the	  impact	  of	  ASD	  on	  affected	  individuals	  and	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their	  families	  is	  universally	  life	  changing,	  and	  currently	  there	  is	  no	  curative	  treatment.	  
Once	  considered	  untreatable,	  it	  wasn’t	  until	  the	  late	  1980s	  that	  Lovaas	  demonstrated	  
early	  behavioral	  therapy	  could	  reduce	  symptoms	  of	  the	  disorder	  [14].	  Today,	  it	  is	  widely	  
believed	  that	  intervention	  services	  at	  younger	  ages	  show	  the	  largest	  gains	  in	  cognitive	  
and	  adaptive	  functioning	  compared	  to	  those	  that	  did	  not	  receive	  treatment	  [15-­‐18].	  
Unlike	  behavioral	  treatment,	  which	  attempts	  to	  target	  core	  symptoms	  of	  ASD,	  
medication	  treatments	  aim	  to	  decrease	  symptoms	  like	  aggression,	  compulsive	  
behaviors,	  attention	  problems,	  and	  hyperactivity.	  Medication	  use	  is	  quite	  common	  in	  
ASD	  with	  estimates	  as	  high	  as	  50%	  of	  ASD	  adolescents	  and	  ASD	  adult	  individuals	  having	  
used	  at	  least	  one	  psychotropic	  medication	  [19,	  20].	  That	  said,	  there	  is	  no	  consensus	  on	  
treatment	  and	  numerous	  approaches	  are	  often	  used,	  with	  most	  ASD	  individuals	  
receiving	  combinations	  of	  these	  over	  the	  course	  of	  their	  lifetimes	  [21,	  22].	  Risperidone,	  
a	  dopamine	  antagonist,	  has	  been	  shown	  to	  work	  in	  treating	  aggression	  and	  repetitive	  
behavior	  [23].	  Likewise,	  three	  studies	  have	  reported	  benefits	  from	  the	  selective	  
serotonin	  reuptake	  inhibitors	  (SSRIs)	  clomipramine,	  fluoxetine,	  and	  sertraline	  in	  treating	  
symptoms	  [24-­‐26].	  	  
	  
Autism	  and	  the	  DSM	  
In	  his	  series	  of	  cases	  histories	  drawn	  from	  the	  records	  of	  more	  than	  120	  children	  
seen	  in	  his	  John	  Hopkins	  psychiatry	  clinic,	  Kanner	  did	  not	  so	  much	  define	  autism	  as	  
much	  as	  portray	  it.	  Kanner	  believed,	  the	  essential	  feature	  of	  autism	  was	  the	  subject’s	  
inability	  to	  relate	  [27],	  and	  eventually	  identified	  two	  features	  that	  he	  believed	  all	  his	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patients	  had	  in	  common:	  profound	  “autistic	  aloneness”	  and	  “obsessive	  insistence	  on	  the	  
preservation	  of	  sameness.”	  Interestingly,	  Kanner	  saw	  that	  the	  parents	  were	  almost	  as	  
distinctive	  as	  the	  children	  and	  noted	  many	  were	  highly	  intelligent.	  Kanner	  went	  so	  far	  as	  
to	  describe	  such	  parents	  as	  “successfully	  autistic.”	  [28,	  29].	  Thirty-­‐years	  after	  his	  initial	  
characterization,	  Kanner	  wrote:	  “there	  is	  a	  resemblance	  between	  their	  make-­‐up	  and	  
that	  of	  their	  children,	  except	  that	  their	  aloofness	  has	  not	  reached	  the	  gross	  proportions	  
of	  a	  psychotic	  illness.”	  [30]	  Although	  Kanner	  wavered	  on	  this	  in	  his	  later	  years,	  he	  was	  
initially	  adamant	  about	  the	  distinction	  of	  autism	  from	  schizophrenia,	  and	  he	  argued	  that	  
the	  disorder	  was	  not	  associated	  with	  a	  specific	  medical	  conditions	  and	  was	  “inborn”	  [1].	  
With	  great	  insight	  for	  his	  time,	  Kanner	  conclude	  his	  discussion	  by	  saying:	  “We	  must	  
assume	  that	  these	  children	  have	  come	  into	  the	  world	  with	  an	  innate	  inability	  to	  form	  
the	  usual,	  biologically	  provided	  affective	  contact	  with	  people,	  just	  as	  other	  children	  
come	  into	  the	  world	  with	  innate	  physical	  and	  intellectual	  handicaps.	  If	  this	  assumption	  is	  
correct,	  a	  further	  study	  of	  our	  children	  may	  help	  to	  furnish	  concrete	  criteria	  regarding	  
the	  still	  diffuse	  notion	  about	  the	  constitutional	  components	  of	  emotional	  reactivity”	  [1].	  	  
Kanner’s	  use	  of	  the	  term	  autism,	  which	  had	  been	  previously	  used	  to	  describe	  the	  
symptoms	  of	  idiosyncratic	  and	  self-­‐centered	  thinking	  often	  observed	  in	  schizophrenic	  
patients	  was	  intended	  to	  suggest	  the	  notion	  of	  the	  child	  living	  in	  his	  or	  her	  “own	  world”	  
[27],	  however,	  the	  use	  of	  this	  word	  immediately	  suggested	  something	  else:	  childhood	  
schizophrenia.	  It	  was	  during	  this	  time	  when	  clinicians	  began	  applying	  an	  inclusive	  
diagnosis	  of	  schizophrenia	  to	  children	  at	  earlier	  ages	  than	  ever	  before	  [31].	  
Unfortunately,	  interpretation	  of	  the	  origins	  were	  done	  in	  context	  of	  the	  period’s	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prevailing	  psychoanalytic	  theories,	  which	  argued,	  in	  the	  case	  of	  autism,	  that	  the	  
condition	  represented	  a	  child’s	  response	  to	  an	  emotionally	  cold	  and	  distant	  mother.	  This	  
argument	  was	  popularized	  by	  Bruno	  Bettelheim,	  and	  placed	  the	  brunt	  of	  the	  blame	  on	  
the	  “refrigerator	  mother.”	  So	  popular	  was	  this	  link	  between	  schizophrenia	  and	  autism	  
that	  the	  second	  edition	  of	  the	  DSM,	  published	  in	  1968,	  mentioned	  autism	  only	  in	  the	  
context	  of	  childhood	  schizophrenia.	  In	  1971,	  Kolvin	  released	  a	  series	  of	  clinical	  reports	  
demonstrating	  that	  autism	  and	  childhood	  schizophrenia	  were	  distinctive	  in	  course,	  
family	  history,	  and	  clinical	  manifestations.	  Near	  this	  time,	  psychologists	  began	  to	  
criticize	  the	  “refrigerator	  mother”	  theory	  and	  stress	  a	  neurological	  and/or	  biological	  
etiology	  [27,	  32].	  	  
While	  Kanner	  claimed	  that	  autism	  was	  incompatible	  with	  ID,	  it	  would	  be	  shown	  
that	  children	  with	  autism	  have	  a	  wide	  range	  of	  intellectual	  ability.	  Once	  intelligence	  and	  
autism	  were	  no	  longer	  considered	  mutually	  exclusive,	  autism	  began	  to	  be	  described	  in	  
children	  with	  known	  syndromes.	  Following	  the	  first	  descriptions	  of	  autism	  in	  a	  series	  of	  
children	  with	  congenital	  rubella	  [33],	  autism	  was	  diagnosed	  in	  a	  wide	  number	  of	  
neurological	  disorders.	  Current	  estimates	  have	  ~10%	  of	  all	  ASD	  individuals	  with	  a	  known	  
syndrome,	  including	  Fragile-­‐X	  syndrome	  (~1-­‐2%	  of	  ASD	  cases),	  tuberous	  sclerosis	  (~1%),	  
Rett	  syndrome	  (~0.5%),	  neurofibromatosis	  (<1%),	  and	  many	  others	  [34].	  Studies	  would	  
later	  uncover	  a	  high	  frequency	  of	  epilepsy	  in	  ASD	  adolescence	  [35],	  and	  establish	  solid	  
evidence	  that	  autism	  has	  a	  strong	  genetic	  basis	  [36].	  	  
Autism	  first	  appeared	  as	  a	  separate	  category	  in	  1980	  with	  the	  publication	  of	  the	  
DSM-­‐3.	  Officially	  acknowledged	  as	  a	  “pervasive	  developmental	  disorder,”	  this	  shift	  in	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ethos	  was	  to	  emphasize	  its	  distinctiveness	  from	  schizophrenia,	  however,	  the	  DSM-­‐3	  did	  
not	  explicitly	  address	  the	  multiple	  co-­‐morbidities	  of	  ASD	  such	  as	  intellectual	  disability	  
and	  epilepsy.	  The	  DSM-­‐3	  identified	  three	  essential	  features	  for	  autism,	  all	  developing	  in	  
the	  first	  30	  months	  of	  life.	  They	  were	  (i)	  lack	  of	  interest	  in	  people,	  (ii)	  gross	  impairment	  
in	  communication,	  and	  (iii)	  “bizarre	  responses”	  to	  aspects	  in	  the	  environment.	  Seven	  
years	  later,	  the	  DSM-­‐3-­‐Revised	  dropped	  the	  age	  of	  requirement	  and	  offered	  a	  new	  
category,	  “Pervasive	  Developmental	  Disorder,	  Not	  Otherwise	  Specified”	  (PDD-­‐NOS),	  to	  
encompass	  children	  who	  did	  note	  meet	  the	  full	  criteria	  for	  autistic	  disorder.	  	  
While	  more	  specific	  language	  was	  introduced	  into	  the	  diagnostic	  criteria	  of	  the	  
DSM-­‐IV,	  published	  in	  1994,	  it	  paradoxically	  became	  more	  inclusive	  than	  that	  of	  its	  
predecessor.	  Asperger	  syndrome,	  a	  condition	  similar	  to	  Kanner’s	  description	  of	  autistic	  
disorder,	  appeared	  for	  the	  first	  time	  allowing	  for	  children	  without	  language	  delays	  or	  
cognitive	  impairment.	  Asperger	  syndrome,	  named	  after	  the	  Austrian	  pediatrician	  Hans	  
Asperger	  was	  described	  unbeknownst	  to	  Kanner	  in	  1944.	  Ultimately,	  the	  DSM-­‐	  IV	  
created	  a	  wide	  umbrella	  allowing	  in	  a	  tremendous	  range	  of	  individuals	  with	  various	  
degrees	  of	  cognitive	  and	  social	  deficits.	  Not	  unlike	  the	  previous	  edition,	  the	  DSM-­‐	  IV	  
moved	  towards	  more	  inclusive	  diagnostic	  criteria	  for	  ASD	  (Table	  1.2).	  	  
The	  DSM-­‐V	  criteria	  in	  a	  move	  toward	  a	  framework	  that	  recognizes	  the	  spectrum	  
nature	  of	  autism	  eliminates	  PDD-­‐NOS,	  Asperger	  disorder,	  and	  the	  other	  autism	  
subcategories	  in	  favor	  of	  a	  single	  “autism	  spectrum	  disorder.”	  The	  three	  domains	  first	  
introduced	  in	  the	  DSM-­‐III	  are	  reduced	  to	  two	  and	  there	  is	  less	  flexibility	  from	  the	  
diagnostic	  interviewer	  in	  choosing	  from	  diagnostic	  checklists	  (Table	  1.2).	  For	  example,	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Table	  1.2:	  Changes	  in	  nomenclature	  and	  major	  shifts	  in	  the	  diagnostic	  criteria	  and	  definitions	  of	  autism	  
	   Kanner	  and	  
Eisenberg	  
Rutter	   DSM-­‐3	   DSM-­‐3-­‐R	   DSM-­‐4	   DSM-­‐5	  
Date	  published	  
	  




-­‐	   -­‐	   PDD	   PDD	   PDD	   -­‐	  



















By	  30	  months	   By	  30	  months	   During	  infancy	  or	  
childhood	  
By	  36	  months	   None	  specified	  
Related	  
disorders	  
-­‐	   Other	  infantile	  
psychoses	  
Atypical	  PDD	   PDD-­‐NOS	   PDD-­‐NOS;	  	  






PDD	  =	  pervasive	  developmental	  disorder	  
NOS	  –	  not	  otherwise	  specified	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children	  must	  meet	  all	  three	  subcategories	  with	  social	  communication	  and	  two	  of	  the	  
four	  with	  rigid	  or	  repetitive	  behavior.	  Children	  who	  have	  deficits	  only	  in	  social	  
communication	  will	  be	  considered	  to	  have	  “social	  communication	  disorder.”	  [37]	  In	  a	  
historical	  context,	  the	  DSM-­‐5	  can	  be	  seen	  as	  an	  effort	  to	  accentuate	  the	  “autism	  
spectrum”	  much	  as	  Kanner	  sought	  to	  accentuate	  the	  “distinctiveness	  of	  autism.”	  
	  
Autism	  epidemiology	  and	  risk	  factors	  
ASD	  affects	  more	  than	  2	  million	  individuals	  in	  the	  US	  and	  millions	  more	  
worldwide.	  ASD	  is	  often	  cited	  as	  among	  the	  most	  common	  of	  the	  DSM	  defined	  
neuropsychiatric	  diseases	  with	  a	  current	  prevalence	  in	  the	  US	  estimated	  at	  1	  in	  88.	  ASD	  
is	  demonstrated	  to	  equally	  affect	  all	  socioeconomic	  and	  geographic	  backgrounds	  [38,	  
39].	  	  
Today	  the	  likelihood	  of	  a	  child	  receiving	  an	  ASD	  diagnosis	  is	  nearly	  doubled	  from	  
that	  just	  five	  years	  ago	  (72%	  increase)	  [38],	  and	  continues	  on	  a	  trend	  that	  began	  
decades	  ago.	  Not	  surprisingly,	  this	  sharp	  increase	  in	  autism	  rates	  (or	  case	  identification)	  
has	  generated	  great	  controversy,	  leading	  some	  groups	  to	  claim	  it	  an	  “epidemic.”	  
However,	  controversy	  and	  autism	  prevalence	  have	  gone	  hand-­‐in-­‐hand	  since	  1943.	  In	  
fact,	  Kanner	  wrote	  in	  a	  1965	  paper	  that	  “almost	  overnight,	  the	  country	  seemed	  to	  be	  
populated	  by	  a	  multitude	  of	  autistic	  children”	  [40],	  and	  this	  was	  a	  time	  when	  the	  rate	  of	  
autism	  was	  <1	  in	  10,000.	  Since	  the	  1960s,	  many	  prevalence	  surveys	  of	  autism	  have	  been	  
conducted,	  and	  a	  number	  of	  scientific	  reviews	  summarizing	  these	  surveys	  are	  published	  
[27,	  41].	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Throughout	  the	  1980s,	  ASD	  was	  believed	  to	  be	  relatively	  infrequent	  and	  
considered	  more	  of	  an	  intriguing	  clinical	  dilemma	  than	  a	  major	  public	  health	  problem	  
[42].	  Studies	  published	  prior	  to	  1985	  estimate	  ASD	  at	  approximately	  5	  per	  10,000	  
children	  and	  approximately	  2	  per	  10,000	  for	  the	  more	  narrowly	  defined	  condition	  
(previously	  “autistic	  disorder”),	  but	  since	  1985,	  there	  has	  been	  a	  dramatic	  increase	  in	  
case	  identification	  and	  ASD	  is	  now	  thought	  to	  be	  second	  only	  to	  ID	  among	  the	  most	  
common	  of	  the	  serious	  developmental	  disabilities,	  which	  include:	  ID,	  ASD,	  epilepsy,	  
cerebral	  palsy,	  fetal	  alcohol	  syndrome	  and	  other	  disorders	  occurring	  before	  age	  18)	  [11,	  
43].	  The	  current	  prevalence	  estimate	  of	  1	  in	  88	  represents	  a	  two-­‐fold	  increase	  from	  a	  
decade	  ago,	  a	  ten-­‐fold	  increase	  from	  the	  mid	  90s,	  and	  a	  dramatic	  increase	  of	  more	  than	  
twenty	  fold	  since	  1985	  (Figure	  1.1).	  	  
Some	  have	  seen	  the	  rise	  in	  ASD	  rates	  as	  evidence	  of	  an	  “epidemic,”	  identifying	  
potential	  culprits	  like	  vaccines	  or	  environmental	  triggers	  [39],	  while	  others	  see	  it	  as	  a	  
blessing	  with	  more	  children	  being	  identified	  earlier	  than	  before	  and	  more	  becoming	  
eligible	  for	  special	  education	  services.	  While	  the	  origins	  of	  this	  substantial	  increase	  in	  
prevalence	  estimates	  remain	  under	  debate,	  it	  is	  largely	  believed	  to	  reflect	  changes	  in	  
how	  individuals	  are	  identified,	  and	  not	  necessarily	  a	  “true”	  increase	  in	  the	  number	  of	  
ASD	  cases	  [39].	  It	  is	  hard	  to	  contest	  the	  fact	  that	  the	  ever-­‐changing	  diagnostic	  criteria	  
have	  confounded	  the	  task	  for	  epidemiologists.	  The	  heightened	  public	  awareness,	  due	  in	  
large	  part	  to	  efforts	  of	  parent	  and	  advocacy	  groups,	  the	  availability	  of	  more	  medical	  and	  
educational	  resources,	  increased	  media	  coverage,	  and	  more	  training	  and	  information	  
for	  physicians	  and	  service	  providers	  have	  complicated	  interpretation	  of	  the	  data	  [11].	  	  







Figure	  1.1:	  Rising	  rates	  of	  ASD	  prevalence.	  Figure	  is	  reproduced	  from	  estimates	  
according	  to	  CDC’s	  Autism	  and	  Developmental	  Disabilities	  Monitoring	  (ADDM)	  Network.	  
Equivalent	  prevalence	  rates	  are	  reported	  to	  occur	  in	  all	  racial	  and	  socioeconomic	  
groups.	  Many	  factors	  are	  responsible	  for	  the	  increasing	  rate	  of	  cases,	  however,	  it	  is	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Overall,	  many	  factors	  are	  at	  play,	  and	  it	  has	  proven	  quite	  challenging	  to	  dissect	  out	  
legitimate	  factors	  contributing	  to	  the	  observed	  increase	  in	  rates.	  
The	  largest	  effect	  and	  most	  well	  known	  risk	  factor	  for	  an	  ASD	  diagnosis	  is	  a	  
family	  history	  of	  a	  sibling	  or	  parent	  diagnosed	  with	  autism.	  Numerous	  studies	  suggest	  
that	  the	  ASD	  phenotype	  extends	  beyond	  the	  DSM	  boundaries	  to	  a	  “subclinical”	  realm	  
known	  as	  the	  broader	  autism	  phenotype	  (BAP);	  for	  example,	  studies	  have	  shown	  an	  
increase	  in	  subclinical	  ASD-­‐like	  features	  among	  the	  relatives	  of	  ASD	  cases	  compared	  to	  
controls	  [44].	  Twin	  and	  family	  studies	  have	  strongly	  suggested	  that	  ASD	  is	  principally	  a	  
genetic	  condition,	  however,	  the	  genetics	  are	  highly	  complex	  exhibiting	  profound	  
heterogeneity	  (discussed	  in	  Chapter	  2),	  and	  opportunity	  for	  epigenetic	  and	  gene-­‐gene	  
interaction	  effects.	  An	  unexplained	  yet	  robust	  sex	  bias	  exists,	  with	  males	  being	  more	  
likely	  affected	  (4.3:1	  Male:Female	  ratio).	  This	  sex	  bias	  is	  modified	  substantially	  by	  
cognitive	  impairment,	  so	  when	  ID	  and	  ASD	  are	  co-­‐morbid	  the	  sex	  ratio	  is	  approximately	  
2:1	  [45].	  In	  addition	  to	  being	  male	  and	  having	  a	  family	  history	  of	  ASD	  (or	  BAP),	  other	  risk	  
factors	  are	  more	  difficult	  to	  detect.	  Of	  them,	  the	  two	  most	  replicated	  are	  advanced	  
paternal	  age	  and	  a	  family	  history	  of	  psychiatric	  conditions.	  	  
Less	  certain	  than	  (i)	  family	  history,	  (ii)	  sex,	  and	  (iii)	  paternal	  age,	  are	  possible	  
prenatal	  risk	  factors	  such	  as	  maternal	  infection	  and	  immune	  dysfunction[46].	  Perinatal	  
complications	  and	  obstetric	  factors	  such	  as	  labor	  and	  delivery	  complications	  are	  also	  
additional	  factors	  [47].	  Environmental	  exposures	  including	  prescription	  drugs,	  metals,	  
and	  chemicals	  have	  all	  been	  implicated	  in	  extremely	  rare	  ASD	  cases	  [47].	  Gardener	  et	  al.	  
perform	  a	  meta-­‐analysis	  on	  more	  than	  50	  prenatal	  factors	  studied	  in	  64	  epidemiological	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ASD	  studies	  and	  conclude	  that	  evidence	  suggests	  prenatal	  conditions	  will	  increase	  risk,	  
yet	  at	  the	  time	  of	  publication	  claim	  insufficient	  evidence	  to	  implicate	  any	  specific	  
prenatal	  factor	  [48].	  Unfortunately,	  studies	  looking	  at	  neonatal	  risk	  factors	  have	  
relatively	  small	  sample	  sizes	  and	  the	  results	  are	  often	  contradictory.	  Despite	  evidence	  
for	  some	  associations	  with	  ASD,	  it	  remains	  unclear	  if	  these	  neonatal	  risks	  are	  causal	  or	  
play	  a	  “secondary”	  role	  in	  determining	  the	  clinical	  manifestations	  of	  an	  individual	  with	  a	  
genetic	  predisposition	  to	  ASD	  [49].	  
There	  was	  much	  speculation	  about	  the	  initial	  suggestion	  that	  the	  measles,	  
mumps,	  and	  rubella	  (MMR)	  vaccine	  might	  be	  an	  autism	  risk	  factor	  [50],	  however,	  the	  
initial	  report	  was	  retracted	  [51]	  and	  today’s	  scientific	  consensus	  rejects	  any	  
epidemiological	  relationship	  between	  vaccines	  containing	  thimerosal	  and/or	  mercury	  
and	  ASD	  [52,	  53].	  On	  the	  other	  hand,	  prenatal	  exposure	  to	  valproate	  has	  been	  
demonstrated	  to	  increase	  ASD	  risk,	  and	  it	  has	  also	  been	  suggested	  that	  prenatal	  
psychotropic	  medication	  exposure,	  particularly	  during	  early	  gestation,	  modestly	  
increases	  ASD	  risk	  [54].	  Lastly,	  recent	  findings	  on	  parental	  education	  and	  socioeconomic	  
status	  have	  put	  the	  once	  believed	  associations	  with	  ASD	  in	  doubt.	  It	  is	  now	  believed	  that	  
the	  long	  suspected	  associations	  were	  a	  result	  of	  ascertainment	  bias,	  and	  no	  association	  
between	  ASD	  socioeconomic	  status	  exist	  [55-­‐57].	  
	   	  
Summary	  
In	  summary,	  the	  history	  of	  autism	  spectrum	  disorder	  is	  fascinating	  and	  has	  
provided	  a	  new	  appreciation	  for	  the	  progress	  made	  and	  the	  challenges	  that	  lie	  ahead.	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Diagnostic	  criteria	  have	  become	  more	  inclusive	  over	  time	  reflecting	  the	  growing	  
conviction	  that	  autism	  represents	  a	  wider	  spectrum	  phenotype	  with	  varying	  degrees	  of	  
ability	  and	  cognition.	  This	  change	  in	  ideology	  largely	  explains	  the	  increasing	  prevalence	  
rates.	  Hundreds	  of	  potential	  risk	  factors	  have	  been	  examined	  for	  a	  correlation	  to	  autism,	  
however,	  the	  most	  consistent	  risk	  factors	  (family	  history	  and	  sex)	  are	  also	  the	  ones	  with	  
the	  largest	  effect	  sizes.	  It	  is	  currently	  believed	  that	  the	  etiology	  of	  ASD	  predominately	  
resides	  in	  the	  genes	  we	  are	  born	  with,	  and	  an	  unknown	  number	  of	  non-­‐heritable	  factors	  
also	  influencing	  risk	  in	  an	  unknown	  way.	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CHAPTER	  II	  
	  
Autism	  as	  a	  complex	  genetic	  disease	  
	  
Introduction	  
	  It	  is	  now	  accepted	  that	  genetics	  contribute	  substantially	  to	  ASD	  risk,	  however,	  
identifying	  specific	  genes	  involved	  has	  been	  difficult	  to	  detect.	  The	  fact	  that	  many	  early	  
risk	  loci	  implicated	  by	  genome-­‐wide	  linkage	  and	  then	  genome-­‐wide	  association	  failed	  to	  
replicate	  in	  later	  studies,	  it	  is	  often	  misunderstood	  that	  research	  geneticists	  have	  not	  
identified	  many	  ASD	  genes.	  This	  misconception	  suggests	  that	  the	  rarity	  of	  many	  of	  these	  
risk	  variations	  have	  made	  it	  difficult	  to	  appreciate	  the	  amount	  of	  progress	  made	  [58].	  
The	  fact	  remains	  that	  the	  efforts	  of	  many	  talented	  individuals	  have	  identified	  hundreds	  
of	  genes	  and	  pathways	  contributing	  risk	  to	  the	  disorder.	  
It	  was	  the	  classical	  twin	  studies	  of	  concordance	  in	  the	  late	  1970s	  that	  first	  
established	  a	  strong	  genetic	  component	  for	  ASD	  [36,	  59].	  When	  considering	  the	  broader	  
autism	  phenotype	  (BAP)	  concordance	  rates	  for	  dizygotic	  and	  monozygotic	  twins	  are	  
estimated	  at	  10%	  and	  92%,	  respectively	  [36,	  60,	  61].	  Furthermore,	  reports	  of	  sibling	  
recurrence	  rates,	  was	  once	  estimated	  to	  be	  4.5%,	  is	  now	  estimated	  to	  be	  ~25%	  [62-­‐65].	  
Likewise,	  the	  approximate	  two-­‐fold	  increase	  in	  concordance	  in	  full	  siblings	  compared	  to	  
half	  siblings	  [66],	  and	  the	  observed	  higher	  rate	  of	  BAP	  in	  first-­‐degree	  relatives	  in	  ASD	  
multiplex	  families	  [44]	  support	  a	  genetic	  etiology.	  	  
Once	  established	  to	  be	  predominately	  genetic	  it	  was	  hoped	  that	  finding	  ASD	  risk	  
genes	  would	  come	  easy,	  however,	  established	  risk	  loci	  proved	  extremely	  difficult	  to	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characterize	  due	  to	  the	  genetic	  complexity	  of	  the	  disorder	  [34,	  67,	  68].	  This	  genetic	  
complexity	  derives	  from	  a	  combination	  of	  allelic	  and	  locus	  heterogeneity,	  variable	  
expressivity,	  and	  incomplete	  penetrance.	  In	  spite	  of	  this	  complexity	  it	  is	  estimated	  that	  
researchers	  can	  account	  for	  ~	  40%	  of	  the	  attributable	  genetic	  risk	  (Figure	  2.1)	  [69].	  	  
Numerous	  “pathogenic”	  loci	  have	  been	  identified	  in	  ASD	  individuals	  with	  known	  
Mendelian	  or	  genetic	  disorders	  that	  exhibit	  a	  phenotype	  inclusive	  of	  ASD.	  Rare	  CNVs	  
detectable	  by	  (clinical	  or	  research)	  Chromosomal	  Microarray	  (CMA)	  testing	  estimates	  
that	  ~10-­‐15%	  of	  ASD	  cases	  are	  afflicted	  with	  a	  causal	  single	  gene,	  copy	  number,	  or	  
chromosomal	  abnormality	  [34].	  Some	  of	  the	  most	  frequently	  identified	  recurrent	  
genomic	  factors	  interpreted	  as	  pathogenic	  include	  CNV	  duplications	  at	  15q11-­‐q13	  (seen	  
in	  ~1%	  of	  ASD	  cases).	  Fragile	  X	  (~1-­‐2	  %),	  tuberous	  sclerosis	  (~1%),	  Rett	  syndrome	  
(~0.5%),	  Williams	  syndrome,	  Smith-­‐Lemli-­‐Opitz	  syndrome	  and	  other	  less	  common	  
disorders	  have	  also	  been	  observed	  with	  ASD	  [70,	  71].	  
Some	  of	  the	  earliest	  genetic	  studies	  used	  microsattelite	  markers	  spanning	  the	  
genome	  (or	  at	  least	  autosomes)	  and	  tested	  for	  evidence	  of	  genetic	  linkage	  in	  samples	  of	  
multiple	  ASD	  families.	  Other	  studies	  used	  family-­‐based	  collections	  or	  case-­‐control	  
samples	  to	  test	  for	  common	  variant	  association	  at	  candidate	  genes.	  Virtually	  all	  of	  these	  
studies	  assumed	  a	  common	  variant-­‐common	  disease	  risk	  scenario.	  These	  studies	  
identified	  genetic	  linkage	  and	  genic	  SNP	  associations	  to	  every	  chromosome,	  and	  in	  the	  
majority	  of	  cases,	  these	  linkage	  or	  associations	  were	  not	  replicated.	  This	  exemplifies	  the	  
Winner’s	  Curse	  phenomenon,	  frequently	  observed	  in	  studying	  the	  genetics	  of	  highly	  
complex	  disorders	  [72].	  Associating	  risk	  let	  alone	  causality	  to	  any	  particular	  finding	  





Figure	  2.1:	  The	  percentage	  of	  variance	  explained	  by	  various	  forms	  of	  genetic	  risk	  
factors	  for	  ASD.	  Common	  variants	  acting	  additively	  capture	  a	  large	  percentage	  of	  
population	  risk	  for	  ASD,	  though	  each	  locus	  is	  expected	  to	  be	  of	  small	  effect,	  whereas,	  
rare	  variants	  explain	  a	  smaller	  proportion	  of	  risk,	  each	  locus	  is	  expected	  to	  be	  of	  larger	  
effect.	  Since	  syndromic	  forms	  of	  ASD	  (estimates	  as	  high	  as	  15%)	  are	  typically	  excluded	  
from	  most	  population-­‐level	  studies	  they	  are	  not	  included	  here.	  Figure	  is	  reproduced	  
from	  Stein	  et	  al.	  Neuron	  77	  (2013).
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proved	  difficult	  for	  two	  reasons:	  few	  rare	  variant	  loci	  were	  common	  enough	  in	  the	  ASD	  
population	  and	  many	  positive	  common	  variant	  associations	  would	  fail	  to	  replicate	  in	  
later	  studies.	  	  
Newer	  methodological	  approaches	  such	  as	  microarray-­‐based	  (SNP)	  genome-­‐
wide	  association	  (GWA)	  studies	  in	  very	  large	  samples	  sizes	  and	  next-­‐generation	  
sequencing	  (NGS)	  have	  changed	  the	  landscape	  of	  ASD	  genetics	  and	  have	  provided	  
tremendous	  insight	  into	  the	  genetic	  architecture	  of	  ASD.	  In	  the	  past	  few	  years	  alone,	  
well	  over	  a	  hundred	  of	  genes	  and	  dozens	  of	  genomic	  loci	  have	  been	  associated	  with	  ASD	  
and/or	  ASD-­‐related	  syndromes	  (Reviewed	  in	  [58]).	  
	  
Contributions	  of	  common	  and	  rare	  variation	  in	  ASD	  
Considering	  the	  potential	  (and	  emerging)	  nature	  of	  ASD	  genetic	  susceptibility,	  it	  
is	  important	  to	  understand	  in	  general	  potential	  genetic	  frameworks	  in	  which	  the	  
frequency	  (common	  vs	  rare)	  of	  risk-­‐conferring	  variants	  might	  contribute	  to	  the	  genetic	  
liabilty	  of	  this	  as	  one	  example	  of	  complex	  disease	  [73].	  As	  stated	  above,	  the	  genetic	  
architecture	  of	  ASD	  is	  highly	  complex	  with	  tremendous	  heterogeneity,	  therefore	  two	  
models	  (not	  mutually	  exclusive)	  have	  been	  proposed	  to	  explain	  genetic	  risk	  in	  common	  
complex	  disorders	  like	  ASD:	  	  (i)	  Common	  Disease	  –	  Common	  Variation	  (CD-­‐CV),	  and	  (ii)	  
Common	  Disease	  –	  Rare	  Variation	  (CD-­‐RV).	  CD-­‐CV	  suggests	  that	  common	  variants,	  those	  
found	  widely	  distributed	  in	  the	  population,	  are	  associated	  with	  small	  to	  modest	  increase	  
in	  baseline	  (population)	  risk,	  while	  the	  CD-­‐RV	  model	  suggests	  that	  a	  number	  of	  rare,	  and	  
sometimes	  de	  novo,	  variants	  of	  high	  to	  major	  risk	  effect	  underlie	  the	  disorder.	  This	  idea	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is	  illustrated	  in	  Figure	  2.2	  and	  the	  CD-­‐CV	  and	  CD-­‐RV	  models	  have	  very	  different	  
implications	  regarding	  gene-­‐discovery	  strategies.	  During	  the	  course	  of	  these	  studies	  
considerable	  evidence	  supporting	  both	  hypothetical	  extremes	  has	  emerged	  for	  ASD,	  
however,	  the	  most	  realistic	  genetic	  framework	  of	  ASD	  includes	  functional	  variants	  that	  
span	  the	  territory	  between	  the	  two	  (common	  or	  rare)	  extremes.	  
	  
The	  contribution	  of	  common	  alleles	  
Since	  ASD	  (and	  subclinical	  traits)	  is	  common	  in	  the	  general	  population,	  it	  was	  
thought	  that	  common	  variants	  would	  be	  the	  prevailing	  mode	  of	  risk	  heritability	  (i.e.	  the	  
CD-­‐CV	  model).	  First	  tested	  in	  studies	  using	  candidate	  gene	  SNP	  genotyping	  or	  variable	  
number	  tandem	  repeat	  (VNTR)	  polymorphism	  genotyping	  and	  subsequent	  association	  
analyses,	  and	  later	  by	  large	  “unbiased”	  GWA	  studies.	  After	  much	  effort	  by	  multiple	  
groups	  over	  a	  short	  span	  of	  approximately	  4	  years,	  there	  is	  considerable	  evidence	  that	  
individual	  common	  variants	  of	  main	  effect	  also	  do	  not	  contribute	  substantially	  to	  ASD	  
genetic	  liability	  [74-­‐78].	  However,	  we	  now	  understand	  that	  when	  common	  variation	  
acros	  the	  genome	  is	  analyzed	  in	  the	  aggregate,	  a	  very	  different	  picture	  emerges	  in	  which	  
many	  common	  variants	  that	  may	  include	  those	  conferring	  small	  main	  effects	  on	  ASD	  risk	  
(ORs	  1.05-­‐1.20),	  can	  act	  additively	  to	  contribute	  substantially	  to	  genetic	  risk	  [79,	  80].







Figure	  2.2:	  	  Feasibility	  of	  identifying	  genetic	  variants	  by	  risk	  allele	  frequency	  and	  
strength	  of	  genetic	  effect	  (odds	  ratio).	  Most	  emphasis	  and	  interest	  lies	  in	  identifying	  
associations	  with	  characteristics	  shown	  within	  diagonal	  dotted	  lines.	  Figure	  is	  
reproduced	  from	  Manolio	  et	  al.	  Nature	  461	  2009.
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  Until	  recently,	  the	  impact	  of	  common	  variations	  in	  ASD	  risk	  was	  largely	  assessed	  
not	  by	  GWA	  studies	  but	  more	  by	  selecting	  candidate	  genes	  based	  on	  their	  biological	  
plausibility	  and	  what	  was	  known	  about	  ASD	  neurobiology.	  These	  studies	  assessed	  the	  
contribution	  of	  one	  (or	  several)	  common	  allele(s)	  in	  or	  near	  these	  hypothetical	  risk	  loci.	  
For	  many	  candidate	  genes	  considered,	  the	  majority	  did	  not	  detect	  statistically	  significant	  
associations	  and	  those	  that	  did	  often	  do	  not	  replicate	  convincingly	  in	  independent	  
datasets	  (the	  “Winner’s	  Curse”).	  While	  only	  a	  minority	  of	  the	  common	  associated	  alleles	  
identified	  in	  the	  pre-­‐GWA	  era	  yielded	  solid	  evidence	  for	  association,	  even	  fewer	  exhibit	  
functional	  effects,	  however,	  a	  handful	  of	  findings	  continue	  to	  warrant	  attention.	  SNPs	  
associated	  with	  the	  serotonin	  transporter	  (SERT;	  gene	  symbol:	  SLC6A4)	  [81-­‐83],	  the	  
receptor	  tyrosine	  kinase	  (MET)	  [84-­‐86],	  loci	  within	  15q11-­‐15q13	  that	  encodes	  the	  E6-­‐AP	  
ubiquitin	  protein	  ligase	  (UBE3A)	  and	  three	  GABAA	  receptor	  subunits	  (GABRB3,	  GABRA5,	  
and	  GABRG3)	  [87-­‐90],	  the	  contactin-­‐associated	  protein	  2	  (CNTNAP2)	  [91,	  92],	  
orthologous	  to	  Drosophila	  neurexin	  4,	  integrin	  beta	  3	  (ITGB3)	  [83,	  93,	  94],	  and	  reelin	  
(RELN)	  [95-­‐97]	  genes	  are	  several	  examples	  of	  positive	  associations	  that	  have	  been	  
identified	  using	  a	  candidate	  gene	  approach.	  	  
Concurrently	  with	  amassing	  sample	  sizes	  and	  improvements	  in	  microarray	  SNP	  
platforms,	  there	  was	  a	  general	  shift	  from	  candidate	  gene	  studies	  to	  the	  GWA	  (i.e.	  
hypothesis	  independent)	  studies.	  This	  change	  in	  approach	  was	  matched	  by	  a	  focus	  on	  
larger	  sample	  sizes,	  SNP	  markers	  capturing	  a	  greater	  degree	  of	  linkage	  disequilibrium	  
across	  the	  genome,	  and	  on	  the	  development	  of	  pipelines	  for	  GWA	  methodology	  and	  
analysis.	  At	  present,	  three	  large,	  independent	  GWA	  studies	  have	  been	  performed,	  with	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each	  looking	  at	  approximately	  one-­‐half	  million	  to	  one	  million	  SNP	  markers	  [75-­‐77].	  In	  
these	  three	  studies,	  respectively,	  GW	  significant	  association	  was	  reported	  at	  three	  
different	  loci	  rs4307059	  at	  5p14.1,	  rs10513025	  at	  5p15.2,	  and	  rs4141463	  at	  20p12.1,	  
replicating	  across	  all	  the	  other	  studies.	  Noticeably,	  all	  associated	  SNPs	  in	  candidate	  
genes	  are	  absent	  at	  GW	  significant	  loci	  [75-­‐77],	  however,	  some	  candidate	  genes	  such	  as	  
RELN	  and	  SLC25A12	  were	  represented	  in	  nominally	  significant	  SNPs	  in	  sub-­‐GW-­‐
significant	  space.	  While	  well	  planned	  and	  executed,	  all	  GWA	  studies	  remain	  dramatically	  
underpowered	  compared	  to	  those	  in	  another	  field,	  schizophrenia,	  which	  now	  show	  
replicated	  common	  alleles	  at	  >100	  loci	  suggesting	  many	  thousands	  of	  more	  ASD	  samples	  
are	  needed	  to	  reach	  the	  inflection	  point	  at	  which	  CV	  association	  studies	  will	  detect	  
replicable	  association.	  Overall,	  GWA	  studies	  in	  ASD	  have	  not	  yet	  demonstrated	  
convincing	  evidence	  of	  individual	  common	  variants	  of	  main	  effect.	  (Table	  2.1)	  
	  
The	  contribution	  of	  rare	  variants	  
In	  the	  last	  decade,	  direct	  sequencing	  of	  candidate	  genes	  has	  implicated	  a	  
number	  of	  related	  genes	  as	  risk	  factors	  in	  ASD.	  Early	  examples	  include	  the	  discovery	  of	  
mutations	  in	  the	  X-­‐linked	  neuroligins	  3	  and	  4	  (NLGN3	  and	  NLGN4)	  loci,	  which	  encode	  
neuronal	  adhesion	  molecules	  present	  in	  the	  postsynaptic	  density	  (PSD)	  of	  glutamatergic	  
synapses	  [98].	  Later	  studies	  identified	  rare	  functional	  mutations	  in	  NRXN1,	  encoding	  a	  
presynaptic	  binding	  partner	  for	  neuroligins	  [99,	  100],	  and	  multiple	  SHANK	  genes	  
(SHANK2,	  SHANK3)	  which	  act	  as	  postsynaptic	  scaffolding	  molecules	  that	  interact	  with
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Table	  2.1	  ASD	  associated	  variants	  revealed	  by	  GWAS	  	  
	  
	   	   	   	   	  Study	   Stage	   Families	   Type	   Findings	  
Wang	  et	  al.	  (2009)	   1	   780,	  3101	  participants	   Multiplex	   Top	  SNP	  rs4307059	  (p	  =	  1.1x10-­‐9)	  
located	  between	  CDH8	  and	  CDH10*	  
	   2	   1204	  cases,	  6491	  controls	   Case/control	   Top	  SNP	  rs4307059	  (p	  =	  2.2x10-­‐4)*	  
	   3	   Combined	   	   Top	  SNP	  rs4307059	  (p	  =	  3.4x10-­‐8)	  
	   	   	   	   	  
Weiss	  et	  al.	  (2009)	   1	   1031	  families,	  4233	  
participants	  
Multiplex	  and	  simplex	   Top	  SNP	  rs10513025	  (p	  =	  1.7x10-­‐6)	  
located	  between	  SEMA5A	  and	  TAS2R1*	  
	   2	   2073	  Trios	   Multiplex	  and	  simplex	   Top	  SNP	  rs10513025	  (p	  =	  2.1x10-­‐7)*	  
	   	   	   	   	  
Anney	  et	  al.	  (2010)	   1	   1369	  families,	  1385	  cases	   Multiplex	  and	  simplex	   Top	  SNP	  rs4141463	  (p=2.1x10-­‐8)	  in	  
MACROD2	  (intronic)	  
	  	   2	   2179	  families	   Multiplex	  and	  simplex	   Top	  SNP	  rs4141463	  (p=4.7x10-­‐8)	  in	  
MACROD2	  (intronic)	  
*	  Not	  genome-­‐wide	  significant	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PSD95	  [101-­‐103].	  Candidate	  gene	  sequencing	  studies	  implicated	  ADORA3,	  NRXN3,	  
PTCHD1/PTCHD1AS,	  ASTN2,	  CDH8	  and	  CNTNAP2	  as	  harboring	  ASD	  risk	  loci	  [101,	  104-­‐
109].	  
Paradoxically,	  it	  appears	  the	  microarray	  fluorescent	  intensity	  and	  SNP	  genotype	  
data	  garnered	  from	  what	  were	  also	  designed	  as	  GW	  CV	  association	  studies	  have	  
arguably	  made	  the	  most	  important	  contributions	  in	  the	  study	  of	  rare	  variation	  with	  their	  
ability	  to	  detect	  copy	  number	  variation	  (CNV)	  [110].	  CNVs,	  often	  in	  the	  range	  of	  1	  kb	  –	  
(>)10	  Mb,	  are	  known	  to	  contribute	  to	  ASD	  susceptibility	  in	  ~10%	  of	  cases	  [71,	  111].	  
Typically	  too	  small	  for	  karyotype	  detection,	  CNVs	  ≤	  Mb	  can	  involve	  a	  single	  gene	  or	  
comprise	  many	  genes.	  In	  only	  a	  few	  years,	  CNV	  discovery	  and	  analysis	  have	  produced,	  a	  
rapid,	  reliable,	  and	  unbiased	  look	  at	  variations	  of	  that	  genomic	  size.	  Sebat	  and	  
colleagues	  (including	  families	  from	  our	  collection)	  were	  the	  first	  to	  show	  that	  rare	  de	  
novo	  variations	  (DNVs)	  were	  over-­‐represented	  in	  ASD	  simplex	  families	  compared	  to	  
controls,	  and	  compared	  to	  families	  in	  which	  there	  were	  multiple	  affected	  individuals	  
[112].	  Since	  then,	  five	  additional	  studies	  have	  been	  conducted	  to	  look	  at	  de	  novo	  and	  
inherited	  CNVs	  (Table	  2.2).	  The	  observed	  excess	  of	  de	  novo	  CNVs	  in	  cases	  compared	  to	  
controls	  has	  been	  repeatedly	  replicated	  [101,	  112-­‐114],	  on	  the	  other	  hand,	  inherited	  
CNVs	  are	  not	  observed	  to	  be	  increased	  overall	  in	  cases	  compared	  with	  controls	  [112-­‐
116].	  Longstanding	  precedence	  in	  study	  of	  human	  genetic	  disease	  attributes	  (in	  general)	  
a	  greater	  probability	  of	  rare	  de	  novo	  CNVs	  as	  being	  likely	  risk	  factors	  that	  confer	  risk	  of	  
relatively	  large	  effect	  size.	  In	  clinical	  practice	  this	  can	  range	  from	  rare	  de	  novo	  CNVs	  
observed	  in	  multiple	  unrelated	  ASD	  cases	  but	  not	  controls	  being	  interpreted	  as	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pathogenic,	  to	  such	  de	  novo	  CNVs	  observed	  significantly	  more	  often	  in	  cases	  than	  
controls,	  or	  rare	  inherited	  CNVs	  transmitted	  to	  ASD	  cases	  but	  not	  seen	  in	  control	  as	  risk	  
factors,	  but	  not	  necessarily	  “pathogenic.”	  They	  confer	  large	  effect	  sizes,	  have	  large	  ORs,	  
but	  not	  be	  fully	  penetrant	  by	  virtue	  of	  “unaffected”	  parental	  carriers,	  or	  rare	  “controls”	  
that	  are	  carriers	  but	  not	  affected	  by	  ASD.	  Rare,	  recurrent	  deletions	  of	  16p11.2	  are	  a	  
prime	  example	  of	  this	  phenomenon.	  A	  significant	  majority	  of	  16p11.2	  deletions	  are	  de	  
novo,	  found	  in	  cases	  typically	  presenting	  clinically	  with	  an	  ASD	  phenotype.	  However,	  
infrequent	  instances	  of	  transmitted	  deletions	  have	  been	  described.	  When	  carefully	  
examined,	  the	  carrier	  parent	  may	  have	  subclinical	  features	  of	  ASD	  or	  other	  
neuropsychiatric	  phenotypes,	  but	  clearly	  not	  ASD	  [111].	  	  As	  a	  general	  phenomenon,	  
genomic	  variants	  arising	  de	  novo	  in	  an	  affected	  individual	  are	  likely	  to	  confer	  effect	  sizes	  
of	  OR	  >5	  [114].	  	  
Cumulatively	  identified	  in	  less	  than	  2%	  of	  “idiopathic”	  ASD,	  CNVs	  at	  16p11.2	  and	  
15q11–q13	  are	  two	  of	  the	  most	  frequently	  observed	  “pathogenic	  (i.e.	  causal)	  CNVs”	  in	  
ASD	  cases	  with	  estimates	  at	  ~0.8%	  and	  ~1%	  respectively	  [112,	  116,	  117].	  In	  the	  case	  of	  
the	  16p11.2	  locus,	  the	  gestalt	  across	  many	  studies	  is	  that	  duplications	  confer	  a	  lower	  
risk,	  and	  more	  likely	  to	  be	  inherited	  in	  ASD	  compared	  with	  deletions.	  Further,	  
duplications	  or	  deletions	  at	  this	  locus	  demonstrate	  increased	  liability	  for	  schizophrenia	  
and	  ID	  [112,	  117,	  118].	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Table	  2.2	  Large-­‐scale	  CNV	  studies	  that	  reveal	  common	  and	  rare	  variants	  associated	  with	  ASD	  
References	   Participants	   All	  CNVs	  (de	  novo	  and	  
inherited)	  
Cases-­‐controls	   De	  novo	  CNVs	  only	   Recurrent	  CNVs	  
in	  cases	  
Single	  genes,	  ASD-­‐
associated	  genes	  in	  de	  
novo	  CNVs	  
Sebat	  et	  al.	  
(2007)	  
264	  families	  (simplex,	  
multiplex	  and	  control)	  









(multiplex)	  196	  cases,	  
292	  unaffected	  sibs	  
624	  total.	  No	  
difference	  in	  
frequency	  of	  CNVs	  in	  
cases	  vs.	  controls	  
1.2	  CNVs/genome	  
cases	  (mean	  =	  3.4	  Mb)	  
and	  1.27	  CNVs/genome	  
controls	  (mean	  =	  4.2	  
Mb)	  
5.1%	  of	  cases,	  2.1%	  of	  
controls	  
47	  CNVs	  in	  cases	   NRXN1	  
Marshall	  et	  
al.	  (2008)	  
427	  families	  (simplex	  
and	  multiple)	  427	  
cases	  and	  1652	  
controls	  
2873	  total.	  No	  
difference	  in	  
frequency	  of	  CNVs	  in	  
cases	  vs.	  controls	  
3.1	  CNVs/genome	  
cases	  (mean	  =	  603	  kb)	  
and	  3.1	  CNVs/genome	  
in	  controls	  (mean	  =	  470	  
kb)	  
27	  ASD	  cases	  with	  







CDH18,	  DPYD,	  NLGN4,	  
DPP6,	  DLGAP2,	  
ANKRD11,	  SHANK3	  
Pinto	  et	  al.	  
(2010)	  
876	  families	  (simplex	  
and	  multiplex)	  996	  
cases,	  ~3000	  controls	  
5478.	  1.19	  fold	  
increase	  in	  cases	  over	  
controls	  
219	  inherited	  CNVs	  not	  
in	  controls	  
50	  out	  of	  876	  ASD	  
harbor	  de	  novo	  
events.	  




1124	  families	  (SSC),	  
1124	  cases,	  872	  
unaffected	  sibs	  
No	  difference	  in	  
frequency	  of	  inherited	  
CNVs	  in	  cases	  vs.	  
controls	  









Levy	  et	  al.	  
(2011)	  
887	  families	  (SSC)	  858	  
cases	  and	  863	  
unaffected	  sibs	  
No	  difference	  in	  
frequency	  of	  inherited	  
CNVs	  in	  cases	  vs.	  
controls	  
-­‐	   7.9%	  in	  cases	  (median	  
genes/CNV	  =	  4),	  2%	  in	  
unaffected	  sibs	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Table	  2.3	  Whole-­‐exome	  gene	  sequencing	  studies	  that	  reveal	  common	  and	  rare	  variants	  associated	  with	  ASD	  
Ref	   Families	  
De	  novo	  variant	  
characteristics	   Single	  gene	  implicated	   Novel	  findings	   Trends	  





Equal	  frequency	  of	  de	  
novo	  mutations	  in	  cases	  
and	  controls	  
KATNAL2	  and	  CHD8	  harbor	  
de	  novo	  mutations	  in	  
cases,	  none	  found	  in	  
controls	  
Enriched	  number	  of	  protein	  
interactions	  among	  genes	  
with	  functional3	  de	  novo	  
mutations	  
Greater	  paternal	  age	  
correlates	  with	  de	  
novo	  mutation	  
number	  





Equal	  frequency	  of	  de	  
novo	  mutations	  in	  cases	  
and	  controls	  
ASD	  cases	  harbor	  protein	  
disrupting	  mutations	  in	  
GRIN2B,	  LAMC3,	  and	  
SCN1A.	  
β-­‐catenin	  chromatin	  
remodeling	  protein	  network	  
enriched	  for	  ASD	  candidate	  
genes	  
Greater	  paternal	  age	  
correlates	  with	  de	  
novo	  mutation	  
number	  
Sanders	  et	  al.	  
(2012)	  
238	  families2,	  
simplex,	  trios,	  and	  
quads	  
Equal	  frequency	  of	  de	  
novo	  mutations	  in	  cases	  
and	  controls	  
SCN2A	  significantly	  
associated	  with	  ASD.	  
KATNAL2,	  CHD8,	  and	  
SCN2A	  associated	  with	  
ASD	  when	  combined	  with	  
Neale	  et	  al.	  and	  O'Roak	  et	  
al.	  	  
Greater	  non-­‐synonymous	  
and	  nonsense	  de	  novo	  
mutations	  in	  cases	  than	  
unaffected	  sibs	  
Greater	  paternal	  age	  
correlates	  with	  de	  
novo	  mutation	  
number	  





Equal	  frequency	  of	  de	  
novo	  mutations	  in	  cases	  
and	  controls	  
KATNAL2,	  CHD8,	  SCN2A,	  
DYRK1A,	  and	  POGZ	  
associated	  when	  
combining	  all	  studies	  
Enriched	  functional3	  de	  novo	  
mutations	  in	  cases	  than	  in	  
unaffected	  sibs	  	  
Greater	  paternal	  age	  
correlates	  with	  de	  
novo	  mutation	  
number	  
1	  Boston	  Autism	  Consortium	  
2	  Simons	  Simplex	  Collection	  
3	  Functional	  is	  defined	  as	  missense,	  nonsense,	  consensus	  splice	  site,	  and	  frameshift	  
Table	  modified	  and	  reproduced	  from	  Berg	  and	  Geschwind,	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Similar	  to	  observations	  related	  to	  16p11.2,	  additional	  observations	  of	  identical	  
(or	  overlapping)	  CNVs	  were	  discovered	  and	  associated	  with	  autism,	  ADHD,	  epilepsy,	  ID,	  
and	  schizophrenia.	  After	  these	  discoveries,	  it	  soon	  became	  clear	  that	  variable	  
(phenotypic)	  expressivity	  was	  a	  central	  feature	  of	  CNV	  risk,	  and	  likely	  other	  ASD	  risk-­‐
related	  variation	  [111].	  	  In	  other	  words,	  many	  well-­‐recognized	  “ID	  CNVs”	  may	  also	  be	  
observed	  in	  the	  context	  of	  “autism,”	  or	  similarly	  “schizophrenia.”	  Identical	  highly	  
penetrant	  CNVs	  that	  confer	  large	  risk	  effects	  may	  be	  seen	  in	  different	  individuals	  
presenting	  clinically	  with	  a	  range	  of	  disorders	  such	  as	  ID,	  schizophrenia,	  and	  autism.	  
These	  findings	  suggest	  that	  a	  number	  of	  genes	  (haploinsufficiency,	  duplication	  or	  other	  
genic	  variation	  in	  which)	  cause	  a	  continuum	  of	  neurodevelopmental	  disorders,	  which	  
may	  manifest	  themselves	  in	  very	  different	  ways.	  Notably,	  these	  highly	  penetrant	  factors	  
occur	  (or	  re-­‐occur)	  on	  different	  genetic	  backgrounds,	  and	  other	  loci	  in	  the	  genome	  may	  
influence,	  even	  compensate	  for,	  phenotypic	  expression	  in	  any	  one	  individual.	  It	  is	  
believed	  that	  specific	  CNVs	  will	  exhibit	  different	  penetrance	  and	  expressivity	  depending	  
on	  the	  copy	  number	  sensitivity	  and	  function	  of	  the	  gene	  or	  genes	  they	  affect	  [111].	  It	  is	  
interesting	  to	  speculate	  how	  reciprocal	  changes	  in	  copy	  number	  (e.g.	  1	  vs.	  3)	  can	  have	  
diverse	  outcomes.	  A	  fascinating	  example,	  involves	  CNVs	  at	  7q11.23,	  duplications	  of	  
which	  are	  implicated	  in	  ASD,	  while	  deletions	  lead	  to	  Williams	  syndrome,	  and	  in	  
schizophrenia	  (duplication/deletion)	  [114,	  119].	  	  
Many	  CNVs	  observed	  to	  carry	  large	  effect	  sizes	  in	  ASD	  are	  identified	  as	  such	  
because	  they	  arise	  as	  de	  novo	  events,	  and	  thus	  not	  present	  constitutionally	  in	  parents	  
and	  not	  present	  in	  the	  general	  or	  control	  populations	  (e.g.	  16p11.2	  deletion;	  15q11-­‐q13	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duplication;	  1q21.1	  deletion;	  15q13.3	  deletions,	  etc.)	  [120,	  121].	  Inherited	  CNVs	  on	  the	  
other	  hand,	  are	  a	  priori,	  presumed	  to	  confer	  less	  severe	  effects	  sizes	  in	  comparison	  (e.g.,	  
15q11.2	  deletion,	  16p11.2	  duplications,	  etc),	  and	  may	  require	  additional	  risk	  factors	  in	  
order	  to	  cross	  a	  threshold	  for	  expression	  of	  disease	  [99,	  122].	  Many	  presumed	  inherited	  
risk-­‐conferring	  CNVs	  may	  also	  demonstrate	  incomplete	  penetrance,	  and	  if	  true,	  this	  may	  
help	  explain	  how	  many	  CNVs	  are	  observed	  in	  population	  controls	  [34].	  	  
	  
De	  novo	  single	  nucleotide	  variants	  (SNVs)	  
	   Advances	  in	  high	  throughput	  or	  massively	  paralleled	  sequencing	  provide	  a	  
powerful	  new	  approach	  to	  discover	  rare	  de	  novo	  and	  inherited	  variants	  [123].	  In	  2012,	  a	  
series	  of	  reports	  in	  Nature,	  Neuron	  and	  PLoS	  Genetics	  presented	  results	  from	  large	  scale	  
ASD	  WES	  studies.	  All	  together,	  four	  groups	  (one	  of	  which	  included	  our	  lab)	  conducted	  
WES	  on	  approximately	  1000	  ASD	  families	  and	  over	  1000	  independent	  cases	  and	  controls	  
[124-­‐127].	  Strikingly,	  across	  all	  studies	  (Table	  2.3)	  a	  positive	  correlation	  between	  
increased	  paternal	  age	  and	  number	  of	  “functional”	  DNVs	  was	  detected,	  which	  may	  help	  
explain	  the	  paternal-­‐age-­‐dependent	  risk	  of	  ASD	  seen	  in	  epidemiological	  studies	  [128-­‐
131].	  Another	  commonality	  between	  these	  studies	  was	  the	  finding	  that	  the	  rate	  of	  DNVs	  
overall	  is	  not	  increased	  in	  ASD	  cases	  compared	  with	  controls,	  however,	  when	  studies	  are	  
pooled	  and	  the	  class	  of	  variation	  is	  restricted	  to	  loss	  of	  function	  mutation	  (premature	  
termination,	  consensus	  splice	  site),	  a	  significant	  increase	  in	  rate	  of	  DNV	  present	  in	  cases	  
vs.	  controls.	  Additionally,	  genes	  involved	  are	  not	  random	  and	  cluster	  onto	  specific	  
biological	  themes,	  for	  example	  chromatin	  remolding,	  or	  the	  β-­‐catenin	  signaling	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pathways	  [124,	  125].	  It	  is	  not	  how	  many	  DNVs	  a	  subject	  carries,	  per	  se,	  it	  is	  what	  type	  
and	  where	  these	  variants	  are	  located	  in	  the	  genome	  that	  ultimately	  affects	  risk.	  In	  this	  
respect,	  it	  should	  not	  be	  surprising	  that	  an	  enrichment	  of	  highly	  damaging	  (i.e.	  
nonsense,	  frameshift,	  consensus	  splice	  site)	  DNVs	  are	  present	  in	  ASD	  individuals	  
compared	  to	  chance	  expectation.	  Nonsynonymous	  de	  novo	  point	  mutations	  are	  
extremely	  rare,	  with	  estimates	  at	  slightly	  more	  than	  one	  “functional”	  DNV	  per	  exome.	  
Initial	  reports	  highlighted	  no	  single	  gene	  that	  harbored	  more	  DNVs	  than	  expected	  by	  
chance,	  however,	  all	  studies	  demonstrated	  an	  increase	  in	  de	  novo	  nonsense	  variants.	  In	  
total	  there	  are	  three	  genes	  (CHD8,	  KATNAL2,	  and	  SCN2A)	  that	  were	  shown	  to	  have	  
recurrent	  nonsense	  DNVs.	  
	  
Challenges	  and	  opportunities	  
Defining	  and	  understanding	  pathways	  or	  mechanisms	  of	  dysfunction	  alongside	  
identification	  of	  ASD	  risk	  genes	  are	  critical	  steps	  moving	  forward.	  Efforts	  to	  explain	  
ASD’s	  genetic	  risk	  in	  the	  context	  of	  neurobiological	  pathways	  or	  relevant	  biology	  have	  
faced	  many	  challenges	  due	  in	  large	  part	  to	  the	  genetic	  heterogeneity	  of	  the	  disorder.	  
With	  new	  and	  suspected	  ASD	  susceptibility	  loci	  becoming	  more	  frequent	  with	  every	  
publication,	  these	  newly	  discovered	  loci	  (often	  times	  disparate)	  may	  be	  the	  key	  to	  
exposing	  relevant	  ASD	  biology.	  To	  do	  this,	  studies	  need	  to	  go	  beyond	  single	  mutations	  
and	  their	  molecular	  dissections	  and	  examine	  the	  variations	  in	  a	  biological	  context.	  
Leading	  this	  effort	  have	  been	  multiple	  studies	  demonstrating	  associated	  SNPs	  and	  CNVs	  
converge	  onto	  biological	  pathways.	  For	  example,	  the	  first	  mutations	  identified	  in	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idiopathic	  autism	  involved	  glutamatergic	  synaptic	  genes	  like	  NLGN3	  and	  NLGN4X	  or	  
SHANK3.	  Later	  CNV	  and	  DNV	  analysis	  results	  support	  these	  first	  findings	  for	  a	  role	  of	  
synaptic	  genes	  in	  ASD	  [132].	  In	  the	  past	  few	  years,	  dozens	  of	  biological	  pathways	  have	  
emerged	  from	  literature	  as	  risk	  factors,	  however,	  two	  that	  have	  garnered	  the	  most	  
scientific	  support	  include	  those	  in	  chromatin	  modification	  (e.g.,	  CHD8)	  and	  ion	  channels	  
(e.g.,	  SCN2A)	  [124,	  126,	  127,	  133].	  
	  
Summary	  
The	  data	  presented	  in	  this	  chapter	  support	  the	  view	  that	  the	  genetic	  architecture	  
of	  autism	  spectrum	  disorder	  is	  highly	  complex	  involving	  hundreds	  of	  loci,	  with	  variation	  
being	  inherited	  and	  de	  novo,	  common	  and	  rare,	  and	  existing	  in	  a	  spectrum	  of	  
penetrance	  and	  expressivity.	  In	  spite	  of	  these	  tremendous	  challenges,	  much	  progress	  
has	  been	  made	  with	  recent	  advances	  in	  genetic	  methodologies	  providing	  significant	  
insights	  into	  the	  biology	  of	  ASD.	  Furthermore,	  by	  examining	  converging	  pathways	  
researchers	  are	  beginning	  to	  gain	  a	  more	  complete	  picture	  of	  ASD	  biology.	  	  
It	  is	  worth	  stressing	  that	  many	  of	  these	  genetic	  findings	  and	  interpretations	  
would	  not	  have	  been	  possible	  without	  the	  availability	  of	  large	  cohorts	  of	  ASD	  and	  
control	  participants	  and	  shared	  databases.	  In	  particular,	  the	  formation	  of	  the	  Autism	  
Genetic	  Resource	  Exchange	  (AGRE),	  the	  Simons	  Simplex	  Collection	  (SSC),	  the	  Autism	  
Genome	  Project	  (AGP),	  and	  the	  NIH	  ARRA	  Autism	  Sequencing	  Consortium	  were	  critical.	  
The	  last	  three	  of	  which	  the	  Sutcliffe	  lab	  has	  played	  an	  important	  role.	  Many	  important	  
web	  resources	  cataloging	  ASD	  genetic	  liability	  are	  equally	  important	  in	  these	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discoveries.	  They	  include	  the	  National	  Database	  for	  Autism	  Research	  (NDAR)	  
(http://ndar.nih.gov),	  the	  SFARI	  Gene	  database	  (https://gene.sfari.org/autdb/),	  the	  
AutDB	  database	  (http://mindspec.org/autdb.html)	  and	  the	  Autism	  Chromosome	  
Rearrangement	  Database	  (http://projects.tcga.ca.autism).	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CHAPTER	  III	  
	  
Monoamine	  transporter	  dysfunction	  as	  a	  genetic	  and	  biological	  risk	  factor	  	  
in	  psychiatric	  illness	  
	  
Introduction	  
	   The	  monoamine	  neurotransmitters	  serotonin	  (5-­‐HT),	  dopamine	  (DA),	  and	  
norepinephrine	  (NE)	  play	  important	  roles	  in	  mood,	  cognition,	  learning,	  reward,	  sleep,	  
and	  motor	  activities.	  The	  availability	  of	  extracellular	  5-­‐HT,	  DA,	  and	  NE	  is	  maintained	  and	  
tightly	  regulated	  by	  their	  presynaptic	  transporters,	  SERT,	  DAT	  and	  NET	  respectively	  [134,	  
135].	  Monoamine	  transporters	  serve	  as	  targets	  for	  antipsychotics,	  antidepressants,	  and	  
drugs	  of	  abuse,	  emphasizing	  the	  important	  role	  these	  molecules	  play	  in	  
neurotransmission	  and	  pathologies	  of	  psychiatric	  disorders.	  [134,	  135]	  Among	  these	  
drugs	  include	  fluoxetine	  (Prozac™),	  methylphenidate	  (Ritalin™),	  3,4-­‐methylenedioxy-­‐N-­‐
methylamphetamine	  (MDMA;	  “ecstasy”),	  and	  cocaine.	  
The	  monoamine	  transporters,	  SERT,	  DAT	  and	  NET	  belong	  to	  a	  group	  of	  SLC6	  
(solute	  carrier	  family	  6)	  Na+	  and	  Cl-­‐	  dependent	  neurotransmitter	  symporters	  [134,	  136-­‐
139].	  Each	  monoamine	  transporter	  type	  is	  responsible	  for	  reuptake	  of	  their	  respective	  
neurotransmitter	  by	  sequential	  binding	  and	  transport	  of	  Na+	  and	  Cl-­‐	  ions.	  In	  the	  case	  for	  
DAT,	  two	  Na+	  ions	  and	  one	  Cl-­‐	  are	  required	  for	  transport,	  while	  SERT	  and	  NET,	  only	  one	  
Na+	  and	  one	  Cl-­‐	  ion	  are	  required	  [134].	  The	  monoamine	  transporters	  in	  this	  family	  share	  
numerous	  structural	  features,	  including	  twelve	  transmembrane	  spanning	  domains,	  a	  
large	  second	  extracellular	  loop,	  multiple	  post-­‐translational	  modification	  sites,	  and	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cytoplasmic	  amino	  (-­‐NH2)	  and	  carboxy	  (-­‐COOH)	  termini.	  The	  monoamine	  transporter’s	  
primary	  function	  is	  reuptake	  of	  synaptic	  neurotransmitter	  for	  further	  repackaging	  for	  
later	  release.	  	  	  
	   The	  reuptake	  ability	  of	  the	  monoamine	  transporters	  is	  directly	  influenced	  by	  the	  
numbers	  of	  cell	  surface	  transporters	  available,	  and	  by	  the	  activity	  of	  these	  individual	  
transporters	  [134].	  Regulation	  of	  monoamine	  transporter	  activity	  is	  primarily	  
accomplished	  through	  phosphorylation	  and	  post-­‐translational	  modifications.	  Perhaps	  
the	  best	  understood	  of	  these	  is	  phosphorylation	  by	  the	  second	  messenger	  protein	  
kinase	  C	  (PKC).	  PKC	  has	  been	  shown	  to	  downregulate	  SERT,	  DAT,	  and	  NET	  function	  
through	  internalization	  of	  the	  transporter	  from	  the	  cell	  surface	  to	  cytoplasmic	  vesicles	  
[134].	  In	  addition,	  modulation	  of	  monoamine	  transporters	  may	  occur	  through	  formation	  
of	  protein-­‐protein	  complexes	  including	  syntaxin	  1A,	  secretory	  carrier	  membrane	  protein	  
2	  (SCAMP2),	  transforming	  growth	  factor	  beta-­‐1-­‐induced	  transcript	  1	  protein	  (Hic-­‐5),	  
neuronal	  nitric	  oxide	  synthase	  (nNOS),	  and	  integrin	  β-­‐3.	  [140]	  
	  
SERT	  in	  psychiatric	  disease	  
	   SERT	  and	  its	  gene	  SLC6A4	  are	  perhaps	  the	  most	  widely	  studied	  in	  psychiatry.	  5-­‐
HT	  plays	  an	  important	  modulatory	  role	  in	  emotion,	  motivation	  and	  cognition,	  and	  
disruption	  of	  normal	  5-­‐HT	  levels	  is	  implicated	  in	  conditions	  including	  affective	  disorders,	  
schizophrenia,	  and	  impulse	  control	  disorders.	  [141]	  Selective	  serotonin	  reuptake	  
inhibitors	  (SSRIs)	  are	  drugs	  that	  –	  with	  varying	  degrees	  of	  selectivity	  –	  target	  SERT	  and	  
are	  used	  in	  treatment	  of	  depression,	  obsessive-­‐compulsive	  disorder,	  and	  anxiety	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disorders,	  thus	  making	  these	  antagonists	  the	  most	  prescribed	  group	  of	  compound	  dugs	  
[141].	  	  
Given	  the	  significance	  of	  SERT	  in	  regulating	  5-­‐HT	  function	  and	  being	  a	  target	  for	  
many	  widely	  used	  medications,	  the	  serotonin	  transporter	  gene,	  SLC6A4	  has	  been	  an	  
attractive	  gene	  for	  study	  in	  neuropsychiatric	  disorders.	  Genetically	  speaking,	  SLC6A4	  has	  
been	  associated	  with	  a	  number	  of	  neuropsychiatric	  disorders	  including	  obsessive	  
compulsive	  disorder	  (OCD)	  [142,	  143],	  anorexia	  [144,	  145],	  social	  anxiety	  disorder	  [146],	  
seasonal	  affective	  disorder	  (SAD),	  alcoholism	  [147,	  148]	  and	  major	  depressive	  disorder	  
(MDD)	  [149,	  150]	  (Table	  3.1).	  	  
A	  significant	  focus	  of	  SLC6A4	  genetic	  studies	  involves	  a	  common	  44-­‐base	  pair	  
insertion/deletion	  of	  a	  repetitive	  sequence	  (a.k.a.	  5-­‐HTTLPR)	  in	  the	  promoter	  region	  
reported	  to	  impact	  SLC6A4	  gene	  expression	  [146].	  The	  long	  allelic	  version	  or	  “L”	  is	  
higher	  expressing	  while	  the	  more	  common	  and	  short	  allelic	  version	  or	  “S”	  displays	  lower	  
expression	  [151].	  Quite	  simply,	  the	  length	  of	  the	  promoter	  has	  been	  shown	  to	  influence	  
mRNA,	  protein,	  and	  5-­‐HT	  uptake	  levels	  in	  lymphoblastoid	  cell	  lines	  (LCLs),	  platelets,	  and	  
serotonergic	  neurons	  [146,	  152,	  153],	  although	  one	  report	  has	  shown	  that	  SERT	  mRNA	  is	  
independent	  of	  5HTTLPR	  genotype	  in	  post-­‐mortem	  pons	  tissue	  sections	  containing	  
serotonergic	  neurons[154].	  Most	  reported	  findings	  of	  association	  have	  pointed	  to	  the	  
more	  frequent	  S-­‐allele	  as	  a	  risk	  factor	  in	  anxiety-­‐related	  behaviors	  and	  for	  increased	  risk	  
of	  depression	  [155].	  Homberg	  and	  Lesch	  (2010)	  argue	  because	  of	  its	  high	  allele	  
frequency	  in	  the	  general	  population,	  any	  negative	  consequences	  of	  carrying	  a	  copy	  of	  
the	  S-­‐allele	  (e.g.	  anxiety	  related	  behaviors)	  would	  be	  explained	  evolutionarily	  if	  it	  were	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Table	  3.1:	  Association	  of	  SLC6A4	  with	  human	  disease	  including	  genetic	  variation	  and	  imaging	  studies	  
Gene	  
Symbol	   Aliases	  
Disease	  







SLC6A4	   SERT	   Anxiety	   17q11.1-­‐q12	   I425V,	  F465L,	  L550V	   OCD	   	  
PET	  
SPECT	   Depression	   Brain	  
	   	  
Autism	  
	  
I425V	   Anorexia	  nervosa	   	   	   Neuroticism	   PNS	  






	   	   Mood	  disorders	   Placenta	  
	   	  
Gastrointestinal	  	  
	  
G56A,	  I425L,	  L550V	   	   	   Bipolar	  disorder	  
Epithelium	  
cells	  
	   	  
Schizophrenia	  
	  
G56A,	  I425L,	  F465L,	  
L550V,	  K605N	   Autism	   	   	   Impulsivity	   Platelets	  
	   	  
OCD	  
	  
VNTR	  9	   Smoking	   	   	   Aggression	   	  
	   	   	   	  
VNTR	  10	   Migraine	   	   	  
Depression	  w/	  
bipolar	  disorder	   	  
	   	   	   	   	   	  
	   	   Parkinson	  disease	   	  
	   	   	   	  
5HTTLPR	  short	   Suicide	   	   	  
Major	  depressive	  
disorder	   	  
	   	   	   	   	  
Autism	   	   	   Autism	   	  
	   	   	   	   	  
Antidepressant	  
response	   	   	   	  
	   	   	   	   	  
Depression	  
	   	   	  
	   	   	   	   	  
Alcoholism	  
	   	   	  
	   	   	   	   	  
PTSD	  
	   	   	  
	   	   	   	   	  
Drug	  abuse	  
	   	   	  
	   	   	   	  
5HTTLPR	  long	   OCD	  
	   	   	  
	   	   	   	   	  
Suicide	  behavior	  
	   	   	  
	   	   	   	   	  
Antidepressant	  
response	  
	   	   	  	  	   	  	   	  	   	  	   	  	   Schizophrenia	   	  	   	  	   	  	  
Table	  modified	  from	  original	  production	  of	  Pramod	  et	  al,	  Molecular	  Aspects	  of	  Medicine	  34:2013	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counterbalanced	  or	  completely	  offset	  by	  an	  evolutionary	  gain	  [156].	  They	  argue	  this	  
may	  additionally	  help	  explain	  the	  inconsistent	  reports	  but	  more	  importantly	  “also	  lead	  
to	  a	  more	  refined	  appreciation	  of	  allelic	  variation	  on	  5-­‐HTT	  function”	  [156].	  
SERT	  knockout	  mice	  have	  provided	  a	  useful	  tool	  to	  examine	  mechanisms	  by	  
which	  SERT	  may	  regulate	  emotional	  behavior.	  Numerous	  studies	  have	  shown	  alterations	  
in	  multiple	  behavioral	  phenotypes	  including	  anxiety,	  depression-­‐like	  symptoms,	  and	  
altered	  responses	  to	  drugs	  of	  abuse	  [157-­‐161].	  In	  fact,	  altered	  SERT	  function	  in	  mice	  is	  
associated	  to	  more	  than	  50	  different	  phenotypic	  changes	  in	  vivo	  [162,	  163].	  Finally,	  SERT	  
knockout	  mice	  have	  reduced	  platelet	  and	  brain	  levels	  of	  5HT,	  and	  elevated	  synaptic	  5-­‐
HT	  as	  measured	  by	  in	  vivo	  microdialysis	  [164].	  
	  
Evidence	  for	  serotonin	  transporter	  involvement	  in	  autism	  spectrum	  disorders	  
	   It	  has	  been	  suggested	  that	  SERT	  dysfunction	  contributes	  both	  to	  the	  (i)	  genetic	  
predisposition	  and	  (ii)	  neuropathologies	  of	  ASD	  [165-­‐167].	  Consistent	  with	  a	  SERT	  
dysfunction	  hypothesis	  are	  clinical	  and	  scientific	  findings	  demonstrating	  heritable	  
hyperserotonemia,	  or	  elevated	  levels	  of	  platelet	  5-­‐HT,	  in	  an	  estimated	  25-­‐40%	  of	  ASD	  
families	  [168-­‐172].	  Hyperserotonemia,	  a	  heritable	  trait,	  is	  the	  oldest	  and	  most	  replicated	  
biomarker	  in	  autism	  [172].	  The	  presence	  of	  SERT	  on	  the	  platelet	  surface	  and	  its	  role	  in	  
acquiring	  5-­‐HT	  from	  the	  blood	  provides	  a	  plausible	  biological	  mechanism	  for	  SERT	  
involvement	  in	  hyperserotonemia.	  Several	  variables	  have	  shown	  correlations	  for	  
platelet	  5-­‐HT	  levels	  including	  age,	  sex,	  and	  ethnicity	  [173].	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Supporting	  a	  serotonin	  role	  in	  ASD	  are	  findings	  of	  reduced	  symptoms	  in	  SSRI	  
treatment	  [24,	  26,	  174,	  175],	  a	  worsening	  of	  symptoms	  in	  individuals	  depleted	  for	  
tryptophan	  (a	  5-­‐HT	  precursor),	  and	  a	  single	  PET	  study	  showing	  altered	  5-­‐HT	  synthesis	  in	  
some	  children	  with	  ASD.	  [24,	  26,	  174-­‐179].	  Moreover,	  studies	  of	  an	  animal	  model	  
treated	  with	  a	  serotonin	  analog	  that	  reduces	  available	  5-­‐HT	  levels	  have	  lead	  to	  
abnormal	  behaviors	  in	  postnatal	  animals	  reminiscent	  to	  those	  seen	  in	  ASD	  [162,	  163,	  
180,	  181].	  Collectively,	  these	  data	  provides	  a	  compelling	  case	  for	  SERT’s	  potential	  
involvement	  in	  ASD.	  	  
Similar	  to	  other	  psychiatric	  disorders,	  most	  ASD	  studies	  have	  focused	  on	  the	  
common	  SLC6A4	  alleles	  of	  5-­‐HTTLPR	  and	  VNTR,	  and	  show	  inconsistent	  results	  with	  both	  
the	  S	  and	  L	  alleles	  being	  over-­‐transmitted	  to	  ASD	  cases.	  Confounding	  many	  of	  the	  5-­‐
HTTLPR	  analyses	  are	  two	  SNPs	  in	  the	  promoter	  region	  (rs25531	  and	  rs25532)	  that	  can	  
modulate	  activity	  of	  the	  L	  allele	  and	  reduce	  its	  expression	  [82,	  155,	  182,	  183].	  Despite	  
this,	  significant	  linkage	  to	  the	  SLCA4	  locus	  (Chr17q11.2-­‐q12)	  is	  documented	  and	  
replicated	  [81,	  184].	  To	  ask	  if	  rare	  variants	  contribute	  to	  the	  linkage,	  Sutcliffe	  and	  
colleagues	  resequenced	  exons	  in	  families	  with	  the	  greatest	  degree	  of	  linkage	  (allele	  
sharing)	  and	  identified	  four	  SLC6A4	  coding	  variants	  in	  several	  of	  these	  “linked”	  families	  
in	  which	  affected	  individuals	  had	  relatively	  more	  severe	  rigid-­‐compulsive	  traits,	  as	  
indexed	  from	  items	  on	  the	  ADI	  [81,	  185].	  When	  these	  variants	  are	  introduced	  into	  a	  
human	  SERT	  expression	  construct,	  all	  SLC6A4	  ASD-­‐associated	  variants	  display	  elevated	  
SERT	  activity	  (i.e.	  gain-­‐of-­‐function	  effect).	  This	  suggests	  a	  possible	  mechanistic	  
relationship	  between	  5-­‐HT	  availability	  and	  ASD	  [81,	  186-­‐188].	  The	  commonalities	  of	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altered	  transporter	  function	  revealed	  by	  the	  SLC6A4	  variants	  warrant	  special	  attention	  
given	  the	  substantial	  number	  of	  ASD	  individuals	  who	  are	  hyperserotonemic.	  
Sequencing	  the	  coding	  region	  of	  SLC6A4	  in	  unrelated	  ASD	  probands	  from	  
families	  without	  obligate	  allele	  sharing	  (linkage)	  at	  17q11.2,	  	  another	  group	  did	  not	  
detect	  a	  similar	  pattern	  of	  enriched	  coding	  variants	  [189].	  It	  is	  likely	  that	  screening	  of	  
multiplex	  probands	  with	  allele	  sharing	  in	  this	  region	  was	  an	  important	  factor	  in	  the	  
initial	  discovery	  of	  novel,	  functional	  variants.	  Akin	  to	  Sutcliffe	  et	  al.,	  the	  results	  from	  
Ozaki	  et	  al.	  support	  a	  role	  of	  SLC6A4	  coding	  variants	  in	  ASD.	  They	  report	  an	  Ile425Val	  
variant	  in	  pedigrees	  harboring	  multiple	  psychiatric	  phenotypes,	  including	  Asperger’s,	  
OCD,	  and	  anxiety	  disorders	  being	  the	  most	  prominent	  [144,	  190].	  	  
Functional	  characterization	  of	  the	  Sutcliffe	  et	  al.	  ASD-­‐associated	  SERT	  variants	  
reveal	  each	  elevate	  5-­‐HT	  transport	  function	  via	  altered	  protein	  kinase	  G	  (PKG)	  and/or	  
p38	  mitogen	  activated	  protein	  kinase	  (MAPK)	  regulation	  [187,	  188].	  Characterization	  of	  
one	  of	  these	  variants	  (Gly56Ala)	  in	  knock-­‐in	  transgenic	  mice	  revealed	  elevated	  5-­‐HT	  
clearance	  and	  a	  p38	  MAPK-­‐dependent	  transporter	  hyperphosphorylation	  in	  vivo.	  These	  
effects	  were	  accompanied	  by	  deficits	  in	  behavioral	  domains	  associated	  with	  ASD	  [191].	  	  
Collectively,	  these	  results	  demonstrate	  that	  altered	  5-­‐HT	  availability	  and	  SERT	  
activity	  (or	  regulation)	  represent	  an	  important	  biological	  endpoint	  in	  ASD	  risk	  in	  a	  subset	  
of	  individuals.	  These	  results	  suggest	  that	  the	  functional	  impact	  of	  genetic	  variation	  at	  
genes	  contributing	  to	  SERT	  regulation	  may	  be	  ASD	  risk	  factors.	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DAT	  in	  psychiatric	  disease	  
The	  neurotransmitter	  DA	  has	  an	  important	  role	  in	  the	  central	  nervous	  system	  by	  
regulating	  a	  variety	  of	  functions,	  including	  motor	  activity,	  motivation,	  attention	  and	  
reward	  [192-­‐195].	  The	  importance	  of	  a	  dopaminergic	  role	  in	  psychiatric	  disease	  has	  
been	  speculated	  for	  quite	  some	  time	  based	  on	  several	  observations.	  For	  example,	  many	  
antipsychotic	  drugs	  target	  the	  dopamine	  system	  either	  via	  action	  at	  dopamine	  receptors	  
or	  alterations	  in	  dopamine	  metabolism	  [196]	  and,	  amphetamine	  (a	  DAT	  substrate)	  
abuse	  can	  mimic	  many	  of	  the	  symptoms	  of	  psychosis.	  	  
Similar	  to	  SLC6A4,	  the	  DAT	  gene,	  SLC6A3,	  has	  been	  the	  target	  of	  numerous	  
genetic	  studies	  with	  the	  majority	  of	  studies	  examining	  the	  3’	  untranslated	  region	  of	  the	  
gene	  containing	  a	  common	  VNTR	  polymorphism	  (Table	  3.2).	  The	  VNTR	  polymorphism	  is	  
associated	  with	  substance	  dependence,	  response	  to	  medication	  (methylphenidate),	  
ADHD,	  bipolar	  disorder,	  schizophrenia	  and	  major	  depressive	  disorder	  (MDD)	  [197,	  198].	  
Several	  coding	  variants	  in	  SLC6A3	  were	  identified	  pre-­‐NGS	  and,	  of	  these,	  at	  least	  two	  
have	  shown	  in	  vitro	  functional	  consequences	  as	  a	  result	  of	  the	  mutation.	  Mazei-­‐Robison	  
and	  colleagues	  identified	  A559V	  in	  two	  ADHD	  subjects,	  and	  another	  group	  identified	  the	  
variant	  in	  a	  family	  with	  bipolar	  disorder	  [199,	  200].	  The	  A559V	  is	  of	  special	  interest	  as	  
ADHD	  is	  a	  common	  comorbid	  phenotype	  observed	  in	  approximately	  one-­‐third	  of	  ASD	  [8,	  
201-­‐204].	  ADHD,	  like	  ASD,	  is	  heritable	  although	  analyses	  has	  revealed	  a	  complex	  genetic	  
architecture	  [205].	  	  
In	  comparison	  to	  SERT	  there	  is	  much	  less	  convincing	  evidence	  for	  dopamine	  
transporter	  involvement	  in	  ASD.	  That	  said,	  variants	  in	  DA	  receptor	  subtype	  genes,	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Table	  3.2:	  Association	  of	  SLC6A3	  with	  human	  disease	  including	  genetic	  variation	  and	  imaging	  studies	  
Gene	  
Symbol	   Aliases	   Disease	  Association	   Gene	  Locus	   Disease	  Association	  from	  SNPs	  
Imaging	  
Technique	   Biomarker	  Association	  
Tissue	  
Distribution	  
SLC6A3	   DAT	   Parkinson	  disease	   5p15.3	   A559V;	  rs40184	   Bipolar	  disorder	   PET	   Parkinson	  disease	   Brain	  




Intron	  8	   ADHD	  
	  
Dementia	  with	  ley	  
bodies	  
	  
	   	  
ADHD	  
	  




	   	  
Addiction	  
	  








VNTR	  9	   Smoking	  
	  
	  
Sleep	  behavior	  disorder	  
	  
	   	   	   	  




	   	   	   	  




	   	   	   	  
Intron	  8	   OCD	  
	   	   	  
	   	   	   	  
VNTR	  10	   Alcoholism	  
	   	   	  
	   	   	   	  
VNTR	  9	   Epilepsy	  
	   	   	  
	   	   	   	  
VNTR	  11	   Parkinson	  disease	  
	   	   	  
	   	   	   	  
VNTR	  9	   Tourette	  syndrome	  
	   	   	  
	   	   	   	  
VNTR	  9	   Methylphenidate	  
	   	   	  	  	   	  	   	  	   	  	   T356M	   Autism	   	  	   	  	   	  	  
Table	  modified	  from	  original	  production	  of	  Pramod	  et	  al,	  Molecular	  Aspects	  of	  Medicine	  34:2013	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including	  DRD1,	  DRD3	  and	  DRD4	  have	  shown	  association	  with	  increased	  risk	  for	  ASD,	  
and	  correlation	  to	  the	  repetitive	  or	  stereotyped	  behaviors	  domain	  with	  ASD	  [206].	  In	  a	  
single	  positron	  emission	  tomography	  (PET)	  study	  in	  adults	  with	  ASD,	  DAT	  binding	  was	  
significantly	  elevated	  in	  the	  orbitofrontal	  cortex	  [207].	  It	  is	  important	  to	  note	  that	  this	  
study	  has	  not	  been	  replicated	  as	  of	  this	  writing.	  	  
	  
Hypothesis	  and	  thesis	  aims	  
This	  thesis	  sought	  to	  address	  the	  hypothesis	  that	  monoamine	  transporter	  gene	  
alleles	  are	  associated	  with	  autism	  and	  to	  elaborate	  the	  functional	  impact	  of	  autism	  
associated	  alleles	  in	  context	  of	  monoamine	  transporter	  dysfunction.	  Perhaps	  most	  
broadly,	  the	  objective	  of	  this	  thesis	  was	  to	  use	  genetic	  tools	  to	  discover	  and	  describe	  
novel	  ASD-­‐associated	  risk	  factors	  within	  a	  biological	  context.	  Building	  upon	  the	  work	  of	  
many	  before	  me,	  the	  foundation	  for	  this	  project	  is	  that	  many	  genes	  involved	  in	  ASD	  will	  
converge	  to	  biological	  systems	  and	  therefore	  those	  systems,	  including	  monoamine	  
neurotransmitter	  networks,	  are	  likely	  to	  provide	  a	  biological	  framework	  for	  ASD	  risk.	  
Hypothesis:	  Given	  that	  monoamine	  transporters	  are	  important	  in	  maintaining	  
monoamine	  tone	  in	  the	  brain,	  I	  hypothesize	  that	  monoamine	  transporter	  dysfunction	  is	  a	  
convergent	  point	  in	  the	  biology	  of	  ASD,	  and	  thereby	  is	  source	  of	  genetic	  risk	  in	  a	  subset	  
of	  ASD	  individuals.	  
To	  test	  my	  hypothesis,	  the	  aims	  of	  my	  thesis	  were	  required	  to	  be	  independent	  
yet	  complementary.	  Toward	  this	  end,	  the	  following	  aims	  were	  undertaken:	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AIM	  1:	  A	  link	  between	  ASD	  and	  SERT	  dysfunction	  is	  well	  established	  in	  some	  individuals	  
with	  ASD	  (as	  described	  earlier).	  SERT	  activity	  is	  subject	  to	  acute	  modulation	  through	  
multiple	  signaling	  pathways	  including	  activation	  of	  PKG	  and	  p38	  MAPK	  dependent	  
pathways.	  Therefore	  the	  objective	  of	  this	  AIM	  was	  to	  investigate	  a	  PKG	  and	  p38	  MAPK	  
activating	  receptor,	  the	  adenosine	  A3	  receptor	  (A3AR),	  for	  autism	  associated	  variation.	  
A	  proof	  of	  principle	  that	  variants	  in	  SERT	  regulatory	  proteins	  can	  also	  contribute	  to	  ASD	  
genetic	  risk	  comes	  from	  a	  combination	  of	  work	  conducted	  by	  Carneiro	  and	  colleagues	  in	  
which	  they	  found	  that	  a	  common	  variant	  in	  ITGB3	  (rs5918),	  confers	  allelic	  dependent	  
effects	  on	  SERT	  activity	  and	  regulation	  [93,	  208,	  209],	  and	  Weiss	  et	  al	  previously	  
demonstrated	  that	  this	  variant	  is	  statistically	  associated	  with	  ASD.	  Since	  my	  hypothesis	  
is	  supported	  from	  observations	  of	  elevated	  SERT	  reuptake	  activity	  in	  multiple	  rare	  
autism	  associated	  SERT	  coding	  variants	  [81,	  144,	  187,	  188],	  basic	  understanding	  of	  any	  
functional	  effects	  conferred	  by	  A3AR-­‐associated	  variants	  in	  vitro	  will	  be	  conducted.	  	  
Sub	  aim	  A:	  To	  analyze	  the	  A3AR	  locus	  (ADORA3)	  for	  ASD	  related	  variation.	  
A3AR	  was	  evaluated	  for	  (a)	  evidence	  of	  common	  (≥5%	  MAF)	  allele	  association	  
and	  (b)	  discovery	  of	  novel	  variants	  in	  ASD	  subjects	  and	  gene	  based	  association	  
testing	  of	  rare	  variants.	  
Sub	  aim	  B:	  To	  investigate	  the	  functional	  impact	  of	  putative	  A3AR	  ASD-­‐
associated	  variation	  on	  protein	  function	  and	  SERT	  activity.	  Functional	  analysis	  
of	  variants	  will	  be	  prioritized	  on	  the	  basis	  of	  evidence	  for	  genetic	  risk	  to	  ASD,	  
likelihood	  for	  damaging	  effect	  on	  the	  protein	  in	  question,	  and	  knowledge	  of	  SERT	  
regulatory	  pathways	  and	  ASD	  risk	  loci.	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AIM	  2:	  DAT	  is	  strongly	  implicated	  in	  ADHD,	  a	  common	  co-­‐morbidity	  in	  ASD,	  and	  DA	  
dysfunction	  is	  linked	  to	  several	  other	  psychiatric	  diseases.	  Little	  is	  known	  regarding	  DAT	  
dysfunction	  in	  autism,	  therefore,	  the	  objective	  of	  this	  aim	  was	  to	  functionally,	  
structurally,	  and	  behaviorally	  characterize	  a	  de	  novo	  variant	  identified	  in	  a	  single	  ASD	  
proband.	  
	  
To	  test	  my	  hypothesis	  that	  dysfunction	  of	  monoamine	  transporters	  is	  a	  biological	  risk	  
factor	  in	  ASD,	  I	  set	  out	  to	  identify	  ASD-­‐associated	  variants	  in	  a	  SERT-­‐regulatory	  gene	  
(ADORA3),	  then	  to	  test	  identified	  variants	  for	  functional	  effects	  on	  SERT	  (Chapter	  4).	  
Next,	  I	  set	  out	  to	  characterize	  the	  functional	  consequences	  of	  a	  de	  novo	  variant	  in	  DAT	  
identified	  in	  an	  ASD	  proband	  (Chapter	  5).	  Lastly,	  novel	  methodological	  techniques	  were	  
conducted	  that	  validated	  the	  use	  of	  lymphoblastoid	  cell	  line	  (LCL)	  derived	  DNA,	  a	  
common	  source	  of	  DNA	  for	  discovery	  of	  novel	  variation.	  Through	  these	  next	  chapters	  I	  
set	  out	  to	  demonstrate	  that	  genetically	  derived	  monoamine	  transporter	  dysfunction	  
contributes	  to	  ASD	  liability.	  	  	   	  
	   46	  
Chapter	  IV	  
	  
Rare	  coding	  variants	  of	  the	  adenosine	  A3	  receptor	  are	  increased	  in	  autism:	  on	  the	  trail	  
of	  the	  serotonin	  transporter	  regulome	  
	  
Introduction	  
The	  genetic	  and	  functional	  analysis	  of	  ASD-­‐associated	  adenosine	  A3	  receptor	  (A3AR)	  
variants	  is	  the	  focus	  of	  this	  chapter	  and	  much	  of	  this	  work	  can	  be	  found	  in	  Campbell	  et	  
al.	  [104].	  The	  publication	  of	  this	  manuscript	  encompasses	  AIM1	  of	  my	  thesis	  and	  is	  
summarized	  in	  this	  chapter.	  
Modulation	  of	  synaptic	  5-­‐HT	  tone	  is	  a	  dynamic	  and	  tightly	  controlled	  process	  subject	  
to	  influence	  through	  multiple	  signaling	  pathways	  and	  interacting	  proteins	  that	  act	  on	  
SERT	  [140].	  SERT,	  a	  monoamine	  transporter,	  is	  the	  main	  pharmacological	  target	  of	  
numerous	  psychiatric	  medications,	  and	  dysregulation	  of	  SERT	  is	  implicated	  in	  a	  wide	  
array	  of	  psychiatric	  disorders	  (discussed	  in	  Chapter	  3).	  Additionally,	  the	  gene	  encoding	  
the	  SERT	  protein,	  SLC6A4,	  is	  the	  target	  of	  numerous	  genetic	  studies	  across	  multiple	  
psychiatric	  conditions.	  	  
It	  has	  been	  shown	  that	  SERT	  activity	  can	  be	  enhanced	  via	  PKG	  and	  p38	  MAPK	  
signaling	  pathways	  acting	  through	  (i)	  trafficking-­‐dependent	  and	  (ii)	  trafficking-­‐
independent	  mechanisms	  [140,	  210,	  211].	  A	  trigger	  for	  both	  of	  these	  uptake-­‐enhancing	  
pathways	  is	  activation	  of	  the	  A3	  adenosine	  receptor	  (A3AR,	  gene	  symbol:	  ADORA3).	  
A3ARs	  are	  G-­‐protein-­‐coupled	  receptors	  (GPCR),	  which	  exert	  their	  influence	  on	  SERT	  
activity	  via	  a	  Gq-­‐linked	  stimulation	  of	  guanyl	  cyclase	  (GC)-­‐mediated	  cGMP	  synthesis	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[212].	  A3ARs	  have	  been	  shown	  to	  be	  expressed	  and	  physically	  interact	  with	  SERT	  at	  
synaptic	  terminals	  in	  5-­‐HT	  synthesizing	  neurons	  in	  vivo	  [210,	  213].	  Moreover,	  A3AR	  
stimulation	  of	  SERT	  activity	  is	  lost	  in	  A3AR	  knockout	  mice	  [214].	  	  
In	  light	  of	  the	  role	  of	  A3ARs	  in	  SERT	  regulation,	  a	  reasonable	  approach	  to	  address	  if	  
SERT	  regulating	  proteins	  harbor	  functional	  ASD-­‐associated	  variants,	  was	  to	  leverage	  
ADORA3	  as	  a	  candidate	  locus	  and	  ask	  if	  rare	  or	  common	  functional	  variants	  at	  this	  locus	  
are	  correlated	  with	  ASD	  risk.	  To	  test	  for	  common	  allele	  effects	  on	  ASD	  risk,	  SNPs	  
indexing	  common	  haplotypes	  at	  ADORA3	  were	  genotyped	  and	  assessed	  using	  family-­‐
based	  association	  methods.	  The	  alternative	  rare	  variant	  hypothesis	  was	  tested	  by	  direct	  
Sanger	  sequencing	  of	  the	  ADORA3	  transcript	  in	  a	  sample	  of	  ASD	  probands	  and	  an	  
ethnically	  comparison	  group.	  Initial	  rare	  variant	  association	  analysis	  was	  followed-­‐up	  in	  
a	  replication	  analysis	  using	  WES	  data	  generated	  from	  a	  large	  cohort	  of	  independent	  ASD	  
cases	  and	  matched	  controls.	  Moreover,	  two	  nonsynonymous	  variants	  identified	  as	  being	  
increased	  in	  cases	  from	  these	  studies	  were	  evaluated	  for	  changes	  in	  basal	  and	  agonist-­‐
activated	  modulation	  of	  SERT	  activity	  by	  heterologous	  expression	  of	  wildtype	  and	  
variant	  A3ARs	  in	  vitro.	  	  
	  
Methods	  
Sample	  for	  allelic	  association	  analysis	  
The	  sample	  for	  analysis	  of	  common	  alleles	  consisted	  of	  958	  combined	  simplex	  and	  
multiplex	  ASD	  families	  (1649	  probands;	  4150	  samples)	  recruited	  across	  multiple	  centers	  
or	  obtained	  from	  the	  NIMH	  Genetics	  Repository	  (http://nimhgenetics.org).	  All	  ASD	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probands	  were	  assessed	  with	  the	  Autism	  Diagnostic	  Interview	  (ADI)	  or	  its	  revision	  (ADI-­‐
R)	  [2]	  and	  most	  with	  the	  Autism	  Diagnostic	  Observation	  Schedule	  (ADOS)	  [3].	  Affection	  
status	  was	  assigned	  using	  a	  classification	  scheme	  employed	  by	  the	  Autism	  Genome	  
Project	  [77].	  Other	  “unaffected”	  family	  members	  were	  designated	  as	  “unknown”	  for	  
purposes	  of	  genetic	  analyses	  described	  in	  this	  chapter.	  Demographic	  information	  for	  this	  
sample	  is	  shown	  in	  Table	  4.1.	  Studies	  were	  approved	  by	  the	  Vanderbilt	  Institutional	  
Review	  Board	  and	  with	  the	  informed	  consent	  of	  participating	  families.	  
	  
Genotyping	  and	  analysis	  of	  common	  variants	  
Tag-­‐SNPs	  were	  selected	  to	  capture	  common	  alleles	  across	  the	  ADORA3	  loci	  at	  an	  r2	  ≥	  
0.8	  and	  minor	  allele	  frequency	  (MAF)	  ≥5%.	  TaqMan™	  allelic	  discrimination	  assays	  for	  
four	  SNPs	  that	  span	  14.4	  kb	  (Figure	  4.1)	  were	  obtained	  from	  Applied	  Biosystems	  (ABI,	  
Foster	  City,	  CA)	  as	  Assays-­‐on-­‐Demand	  or	  designed	  as	  Assays-­‐by-­‐Design.	  
PCR	  amplification	  was	  conducted	  in	  a	  5	  μl	  volume,	  and	  went	  as	  follows:	  Cycling	  
conditions	  included	  an	  initial	  denaturation	  at	  95°C	  for	  7	  min,	  followed	  by	  50	  cycles	  of	  
92°C	  for	  15	  s	  and	  60°C	  for	  1	  min.	  Allelic	  discrimination	  was	  performed	  on	  the	  ABI	  
7900HT	  and	  genotypes	  called	  using	  the	  ABI	  Sequence	  Detection	  System	  software.	  
Quality	  control	  procedures	  included	  genotype	  completeness	  (≥98%),	  inter-­‐	  and	  intra-­‐
plate	  replicates,	  and	  removal	  of	  families	  containing	  Mendelian	  inconsistencies	  identified	  
by	  PEDCHECK	  [215].	  	  
Single	  marker	  analysis	  was	  conducted	  using	  the	  family	  based	  association	  test	  (FBAT)	  
[216]	  under	  the	  additive	  model,	  and	  significance	  determined	  using	  the	  empirical	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variance	  (-­‐e)	  option	  -­‐	  as	  this	  provides	  a	  more	  conservative	  estimate	  of	  association	  -­‐	  
given	  the	  presence	  of	  multiplex	  families	  in	  the	  dataset.	  Power	  calculations	  were	  
conducted	  using	  the	  Genetic	  Power	  Calculator	  [217]	  under	  the	  following	  conditions:	  
Prevalence	  rate	  of	  1	  in	  a	  100	  and	  a	  sample	  size	  of	  1000	  trios,	  assuming	  minor	  allele	  
frequencies	  (MAFs)	  of	  5%,	  10%,	  and	  30%,	  respectively	  and	  a	  D'=0.8.	  Based	  on	  these	  	  
calculations,	  we	  would	  have	  ≥80%	  power	  to	  detect	  odds	  ratios	  (ORs)	  of	  ≥1.59,	  ≥1.44	  and	  
≥1.36	  for	  risk	  allele	  frequencies	  of	  ≥5%,	  10%,	  and	  30%,	  respectively.	  
	  
Determination	  of	  sample	  ancestry	  
To	  permit	  association	  analysis	  within	  the	  major	  subset	  of	  the	  family-­‐based	  sample	  
and	  for	  matching	  of	  cases	  and	  controls	  (see	  below),	  ancestry	  was	  determined	  using	  
multiple	  platforms	  and	  two	  methods:	  STRUCTURE	  [218]	  and	  multidimensional	  scaling	  
(MDS)	  in	  PLINK	  [219].	  Many	  multiplex	  families	  were	  genotyped	  by	  the	  Autism	  Genome	  
Project	  (AGP)	  using	  the	  Affymetrix	  10k	  SNP	  platform	  and	  analyzed	  using	  STRUCTURE	  
[99].	  Other	  families	  had	  genotypes	  from	  Illumina	  550k	  and/or	  1M	  SNP	  arrays	  and	  
analyzed	  using	  MDS	  [75].	  Coincidently,	  numerous	  families	  were	  genotyped	  and	  analyzed	  
using	  both	  applications,	  allowing	  for	  confirmation	  that	  both	  STRUCTURE	  and	  MDS	  
yielded	  consistent	  and	  robust	  assignments	  that	  also	  agreed	  with	  self-­‐report	  information.	  
A	  small	  number	  of	  families	  from	  the	  overall	  association	  sample	  did	  not	  have	  genome-­‐
wide	  genotypes,	  in	  which	  case	  self	  report	  information	  determined	  classification,	  or	  had	  
neither	  genome-­‐wide	  genotype	  data	  nor	  self-­‐report	  information,	  in	  which	  case	  they	  
were	  classified	  as	  being	  of	  “unknown”	  ancestry.	  	  












Table	  4.1:	  Demographics	  of	  the	  sample	  cohort	  of	  common	  allele	  analysis	  at	  ADORA3	  
	  
	  	   All	   Caucasian	   African	   Asian	   Hispanic	   Otherb	  
Families	   958	   763	   29	   26	   39	   101	  
Individuals	   4150	   3311	   116	   134	   171	   418	  
ASD	  diagnosisa	   1649	   1316	   48	   52	   69	   164	  
Female	   316	   248	   8	   8	   21	   31	  
Male	   1333	   1068	   40	   44	   48	   133	  
Number	  of	  families	  with:	   	  	  
1	  affected	   317	   252	   9	   2	   13	   41	  
2	  or	  more	  affected	   641	   511	   20	   24	   26	   60	  
	  
	  
a	  Indicates	  number	  of	  individuals	  who	  met	  criteria	  for	  (i)	  "autism"	  on	  the	  ADI-­‐R	  "ASD"	  on	  both	  
the	  ADI-­‐R	  and	  ADOS	  or	  "autism"	  on	  the	  ADOS	  alone	  
	  
b	  Represents	  families	  with	  two	  ancestry	  calls	  or	  families	  with	  at	  least	  one	  founder	  of	  
undetermined	  or	  unknown	  ancestry	  
	  






Figure	  4.1:	  Chromosomal	  location	  of	  the	  four	  ADORA3	  genotyped	  SNPs.	  Genotyped	  SNPs	  are	  shown	  above	  the	  basepair	  position	  
ruler	  and	  a	  vertical	  red	  harsh	  highlights	  positions.	  Tag	  SNPs	  were	  chosen	  to	  index	  haplotypes	  ≥5%	  across	  the	  locus	  using	  an	  r2	  cutoff	  
of	  0.8.	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Discovery	  and	  analysis	  of	  rare	  variants	  
Initial	  screening	  for	  sequence	  variants	  at	  ADORA3	  utilized	  whole	  blood	  derived	  DNA	  
samples	  from	  185	  unrelated	  cases.	  Non-­‐clinical	  comparison	  samples	  were	  drawn	  from	  
reference	  collections	  and	  consisted	  of	  lymphoblastoid	  cell	  line	  (LCL)	  derived	  DNA	  from	  
288	  samples	  of	  European	  ancestry	  taken	  from	  the	  Coriell	  Human	  Genome	  Diversity	  
panel	  and	  from	  the	  Human	  Random	  Control	  (HRC)	  collection.	  Twenty-­‐four	  additional	  
non-­‐clinical	  comparison	  samples	  were	  obtained	  from	  the	  neurologically	  normal	  
NINDS/Coriell	  African-­‐American	  panel	  to	  allow	  for	  appropriate	  associations	  between	  
case	  and	  control.	  While	  limited	  in	  power	  to	  detect	  rare	  risk	  variants,	  my	  a	  priori	  
expectation	  was	  that	  functional	  ADORA3	  risk	  variants	  would	  confer	  large	  genetic	  effects,	  
thereby	  allowing	  for	  detection	  in	  a	  small	  data	  set.	  Admittedly,	  this	  study	  would	  be	  
significantly	  underpowered	  if	  hypothetical	  rare	  variants	  conferred	  ORs	  <2.	  
PCR	  amplifying	  primers	  (Table	  4.2)	  were	  designed	  using	  Primer3	  and	  subjected	  to	  a	  
BLAST-­‐Like	  Alignment	  Tool	  search	  to	  ensure	  no	  matches	  existed	  elsewhere	  in	  the	  
genome.	  Amplification	  was	  optimized	  using	  a	  gradient	  of	  annealing	  temperatures,	  
typically	  ranging	  from	  56-­‐64°C,	  followed	  by	  agarose	  gel	  electrophoresis	  to	  determine	  
ideal	  annealing	  temperature.	  PCR	  was	  performed	  on	  the	  case	  (N=185)	  and	  control	  
(N=305)	  screening	  samples	  containing	  7.1	  nm	  of	  amplifying	  primers,	  10	  μl	  of	  2X	  
Mastermix,	  and	  12	  ng	  of	  DNA	  in	  a	  final	  volume	  of	  20	  μl.	  Amplification	  parameters	  were	  
7	  min	  at	  95°C,	  40	  cycles	  of	  15	  s	  at	  95°C,	  12	  s	  at	  the	  annealing	  temperature,	  and	  60	  s	  at	  
72°C,	  with	  a	  final	  extension	  at	  72°C	  for	  7	  min.	  	  
	   	  







Table	  4.2:	  ADORA3	  PCR	  amplifying	  primers	  
	  
Primer	  	  





1	   CGCCATTGTTGTTACTGCTG	   CAGCAAAGATCCTTGGTCAAA	   585	   60.2°C	  
2	   GGCTAAGCAGGTGTGATGCT	   TTCAGGGGTGTTTCAGGAAG	   469	   60.2°C	  
3	   TGCTCTTTCCATCTTTTTGCT	   GCCAGCAAGATCCGTCTGTA	   425	   58.3°C	  
4	   AGACTGTCACTGCACATGGA	   GCCCTCTTTCAACATCAAGG	   589	   60.2°C	  
5	   GCAGAAGATTGGAGAATTAAGAGA	   AATCAGAGGGATGGCAGACC	   700	   60.2°C	  
6	   CCAACTCCATGATGAACCCTA	   GGCTCCAAGTAGCAAGCAAG	   749	   62.3°C	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Following	  PCR,	  each	  product	  was	  examined	  by	  gel-­‐electrophoresis,	  and	  once	  
verified	  for	  expected	  size	  and	  specificity,	  excess	  primers	  and	  nucleotides	  were	  removed	  
using	  Millipore	  96	  well	  filter	  plates.	  Samples	  were	  quantitated,	  subjected	  to	  Sanger	  
sequencing	  by	  the	  DNA	  Sequencing	  Core	  at	  Vanderbilt	  University,	  and	  data	  analyzed	  
using	  Sequencher	  v4.9	  (Gene	  Codes	  Corporation,	  Ann	  Arbor,	  MI).	  Specific	  variants	  were	  
validated	  by	  independent	  PCR,	  and	  segregation	  analysis	  performed	  by	  sequencing	  
available	  family	  members,	  affected	  or	  unaffected.	  
Variants	  were	  assessed	  using	  five	  diverse	  approaches	  including	  (i)	  documentation	  in	  
dbSNP	  or	  the	  1000	  Genomes	  project,	  (ii)	  in	  silico	  algorithms	  such	  as	  PolyPhen2,	  SIFT	  and	  
SNAP	  to	  predict	  amino	  acid	  substitution	  as	  “damaging”	  or	  benign	  [220-­‐222]	  (iii)	  cross-­‐
species	  conservation	  of	  the	  amino	  acid	  and	  surrounding	  residues,	  (iv)	  available	  literature	  
regarding	  structural	  features	  of	  the	  A3AR	  protein,	  and	  (v)	  a	  global	  burden	  test	  of	  rare	  
(<1%)	  coding	  variants.	  CAST,	  the	  cohort	  allelic	  sums	  test,	  is	  a	  gene	  burden	  test	  in	  which	  
the	  number	  of	  individuals	  with	  one	  or	  more	  variants	  in	  a	  gene	  is	  compared	  between	  
affected	  and	  unaffected	  individuals	  [223,	  224].	  Rare	  variant	  counts	  in	  matched	  cases	  
and	  controls	  in	  a	  2	  x	  2	  contingency	  table	  were	  tallied	  and	  a	  Fisher’s	  Exact	  test	  
performed.	  
An	  independent	  replication	  sample	  corresponded	  to	  ASD	  cases	  and	  controls	  from	  
the	  NIMH	  Repository.	  Cases	  and	  controls	  were	  pair-­‐matched	  for	  ancestry,	  and	  samples	  
used	  for	  WES	  analysis	  were	  described	  in	  Neale	  et	  al.	  [125],	  with	  the	  exception	  that	  a	  
number	  of	  case-­‐control	  pairs	  were	  excluded	  if	  control	  subjects	  had	  any	  history	  of	  
obsessive	  compulsive	  behavior,	  anxiety	  disorders,	  and	  substance	  abuse	  -­‐	  three	  disorders	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associated	  to	  SERT	  dysregulation.	  WES	  variants	  at	  ADORA3	  in	  339	  case-­‐control	  pairs	  
were	  examined	  for	  “functional”	  (i.e.	  missense,	  nonsense,	  consensus	  splice	  site	  and	  read-­‐
through)	  variants.	  Details	  regarding	  quality	  control	  procedures	  and	  read	  depth	  for	  case	  
and	  control	  samples	  are	  detailed	  in	  the	  Supplemental	  Material	  of	  Neale	  et	  al.	  
	  
Functional	  Studies	  
Constructs:	  A	  full-­‐length	  human	  SERT	  cDNA	  in	  the	  mammalian	  expression	  vector	  
pcDNA3.1,	  and	  a	  full-­‐length	  human	  A3AR	  (myc-­‐A3AR/pCMV)	  cDNA	  were	  used	  in	  this	  
study	  and	  are	  described	  in	  [213,	  214].	  In	  vitro	  mutagenesis	  of	  the	  A3AR	  cDNA	  clones	  to	  
introduce	  Val90	  and	  Ile171	  variants	  were	  performed	  using	  the	  QuikChange	  mutagenesis	  
kit	  (Stratagene,	  La	  Jolla,	  CA),	  and	  variants	  were	  confirmed	  by	  Sanger	  sequencing	  at	  the	  
DNA	  Sequencing	  Core	  at	  Vanderbilt	  University.	  	  
Cell	  culture	  and	  transfection:	  Chinese	  Hamster	  Ovary	  (CHO)	  cells	  were	  maintained	  at	  
37°C	  in	  Dulbecco’s	  modified	  Eagle’s	  medium	  containing	  10%	  fetal	  bovine	  serum,	  1%	  L-­‐
glutamine,	  100	  IU/mL	  penicillin,	  and	  100	  μg/mL	  streptomycin.	  Transient	  transfections	  
were	  performed	  using	  the	  TransIT–CHO	  Transfection	  reagent	  (Mirus,	  Madison,	  WI).	  In	  
brief,	  50	  ng/well	  SERT	  and	  20	  ng/well	  of	  A3AR	  cDNAs	  were	  pre-­‐incubated	  with	  Mirus	  
reagent	  for	  30	  min	  at	  room	  temperature	  prior	  to	  adding	  to	  plated	  cells,	  seeded	  at	  
20,000	  cells/well.	  Transfected	  cells	  were	  cultured	  for	  an	  additional	  24-­‐48	  hr	  after	  
transfection	  and	  prior	  to	  functional	  analyses.	  
cGMP	  activity	  assays:	  The	  concentration	  of	  the	  second	  messenger	  cyclic	  guanosine	  
monophosphate	  (cGMP)	  was	  measured	  using	  the	  CatchPoint	  cGMP	  fluorescent	  assay	  kit	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(Molecular	  Devices,	  Sunnyvale,	  CA).	  In	  brief,	  CHO	  cells	  were	  co-­‐transfected	  with	  
wildtype	  A3AR	  or	  A3AR	  coding	  variants	  and	  SERT	  cDNAs	  were	  plated	  at	  50,000	  
cells/well.	  Cells	  were	  initially	  washed	  in	  a	  Krebs-­‐Ringer	  bicarbonate	  pre-­‐stimulation	  
buffer	  containing	  0.8	  mM	  3-­‐isobutyl-­‐1-­‐methylxanthine	  (IBMX),	  an	  inhibitor	  of	  cGMP-­‐
phosphodiesterases.	  Following	  a	  10	  min	  incubation	  period,	  cGMP	  accumulation	  was	  
measured	  in	  response	  to	  a	  1	  μM	  IB-­‐MECA	  or	  vehicle	  treatment	  at	  various	  time	  points	  (0	  
min,	  10	  min,	  20	  min,	  30	  min,	  40	  min,	  60	  min)	  according	  to	  the	  manufacture’s	  protocol.	  
The	  1	  μM	  IB-­‐MECA	  concentration	  was	  selected	  on	  the	  basis	  of	  previous	  studies	  that	  
found	  optimal	  stimulation	  of	  A3ARs	  under	  those	  conditions	  [210,	  213,	  214].	  All	  values	  
were	  normalized	  to	  basal	  wildtype	  cGMP	  levels	  (i.e.	  WT	  at	  time	  =	  0	  min).	  Statistical	  
analyses	  comparing	  the	  treatment	  effects	  of	  the	  adenosine	  A3	  selective	  agonist	  and	  
adenosine	  analog	  IB-­‐MECA	  on	  variant	  and	  wildtype	  A3ARs	  cells	  were	  performed	  with	  
Prism	  (GraphPad,	  La	  Jolla,	  CA)	  using	  two-­‐way	  analysis	  of	  variance	  (ANOVA).	  A	  t-­‐test	  to	  
compare	  overall	  differences	  over	  the	  full	  time	  course	  of	  IB-­‐MECA	  treatment	  was	  
calculated	  with	  Prism	  using	  total	  cGMP	  production.	  Statistical	  means	  and	  standard	  
errors	  of	  the	  mean	  were	  calculated	  and	  P-­‐values	  <	  0.05	  were	  considered	  significant.	  
5-­‐HT	  transport	  assays:	  Assays	  measuring	  transport	  of	  [3H]5-­‐HT	  were	  conducted	  as	  
described	  previously	  [210,	  213,	  214].	  Briefly,	  media	  from	  CHO	  cells	  were	  removed	  and	  
cells	  washed	  with	  Krebs-­‐Ringer-­‐Hepes	  (KRH)	  buffer	  containing	  130	  nM	  NaCl,	  1.3	  nM	  KCl,	  
2.2	  mM	  CaCl2,	  1.2	  mM	  MgSO4,	  1.2	  mM	  KH2P04,	  1.8	  g/L	  glucose,	  10	  mM	  HEPES,	  pH	  7.4,	  
100	  mM	  pargyline,	  and	  100	  mM	  ascorbic	  acid.	  Cells	  were	  incubated	  in	  triplicate	  at	  37°C	  
with	  and	  without	  IB-­‐MECA	  treatment.	  Following	  treatment	  with	  IB-­‐MECA,	  cells	  were	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incubated	  for	  10	  min	  with	  [3H]5-­‐HT	  (20	  nM)	  at	  37°C.	  Cells	  were	  washed	  with	  ice-­‐cold	  
KRH	  buffer,	  solubilized	  with	  0.5	  mL	  Microscint-­‐20,	  and	  [3H]5-­‐HT	  accumulation	  was	  
quantified	  using	  a	  TopCount	  plate	  scintillation	  counter	  (PerkinElmer	  Life	  and	  Analytical	  
Sciences,	  Waltham,	  MA).	  Specific	  5-­‐HT	  uptake	  was	  determined	  by	  subtracting	  the	  
amount	  of	  [3H]5-­‐HT	  accumulated	  in	  the	  presence	  of	  10	  μM	  paroxetine,	  a	  selective	  SERT	  
inhibitor.	  A	  minimum	  of	  three	  independent	  replicates	  was	  performed	  for	  each	  
experiment.	  Analyses	  comparing	  basal	  and	  agonist-­‐induced	  uptake	  in	  wildtype	  and	  
variant	  A3AR/SERT	  co-­‐transfections	  at	  individual	  time	  points	  was	  calculated	  and	  plotted	  
using	  the	  software	  package	  Prism.	  
	  
Molecular	  modeling	  of	  A3AR	  coding	  variants	  	  
The	  A3AR	  residue	  positions	  of	  Leu90	  and	  Val171	  were	  determined	  for	  the	  human	  
adenosine	  A2a	  receptor	  (A2aAR)	  by	  amino	  acid	  sequence	  alignment	  and	  correspond	  to	  
residues	  Val84	  and	  Val171,	  respectively.	  The	  relative	  positions	  and	  structural	  
conformation	  of	  the	  corresponding	  A2aAR	  residues	  were	  determined	  using	  structural	  
data	  obtained	  using	  an	  adenosine-­‐bound	  thermostabilized	  A2aAR	  (PDB	  ID:	  Y2DO)	  as	  a	  
model.	  Images	  were	  prepared	  using	  PyMOL	  (DeLano	  Scientific	  Ltd).	  
	  
Results	  
Family	  based	  association	  analysis	  
To	  test	  if	  common	  alleles	  at	  ADORA3	  contribute	  significant	  genetic	  risk	  in	  a	  sample	  
of	  958	  ASD	  families,	  four	  SNPs	  representing	  common	  haplotypes	  spanning	  the	  locus	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were	  genotyped.	  FBAT	  analyses	  of	  genotype	  data	  showed	  no	  evidence	  to	  support	  
common	  variant	  association	  at	  ADORA3	  at	  the	  SNPs	  tested	  (Table	  4.3).	  Analysis	  of	  
haplotypes	  (>5%)	  across	  the	  locus	  that	  were	  captured	  by	  these	  SNPs	  also	  showed	  no	  
significant	  association,	  consistent	  with	  single	  marker	  analysis	  (data	  not	  shown).	  	  
	  
Sequence	  discovery	  of	  functional	  variation	  at	  ADORA3	  
To	  identify	  potential	  functional	  risk	  variants	  in	  ADORA3,	  all	  exons	  and	  the	  promoter	  
region	  in	  185	  unrelated	  ASD	  cases	  and	  305	  non-­‐clinical	  comparison	  samples	  by	  direct	  
Sanger	  sequencing	  were	  screened.	  Numerous	  synonymous	  and	  nonsynonymous	  
variants	  were	  identified	  and	  are	  documented	  in	  Table	  4.4.	  Three	  novel	  variants,	  two	  
nonsynonymous	  and	  one	  synonymous,	  were	  detected	  in	  cases	  (Leu90Val,	  Val171Ile,	  
Cys194).	  A	  novel	  Ala195Thr	  substitution	  was	  identified	  in	  a	  single	  control	  sample.	  	  
Parental	  transmission	  was	  analyzed	  and	  no	  de	  novo	  variants	  were	  detected.	  
Bioinformatic	  algorithms	  applied	  to	  rare	  (<1%)	  ns-­‐variants	  predicted	  Val171Ile	  to	  be	  
“damaging”,	  however,	  Leu90Val	  along	  with	  Ala195Thr	  were	  predicted	  to	  be	  benign	  
substitutions.	  Following	  discovery	  of	  Leu90Val	  and	  Ile171Val	  variants,	  but	  during	  follow-­‐
up	  functional	  and	  genetic	  experiments,	  both	  ASD	  identified	  variants	  emerged	  from	  1k	  













Table	  4.3:	  Association	  analysis	  of	  common	  variants	  at	  the	  ADORA3	  loci	  
	  
SNP	   Major/	  minor	  allele	   MAFa	   Inf	  famsb	   Major	  TOBSc	   Major	  TEXPd	   Minor	  TOBS	   Minor	  TEXP	   Z	   p-­‐valuee	  
rs7517018	   T/C	   0.145	   266	   671	   668.2	   283	   285.8	   0.247	   0.809	  
rs923	   A/G	   0.180	   287	   723	   710.5	   303	   315.5	   1.025	   0.338	  
rs10776728	   A/T	   0.323	   403	   883	   861.2	   535	   556.8	   1.453	   0.162	  
rs2298191	   T/C	   0.336	   395	   801	   815.7	   589	   574.3	   0.983	   0.343	  
	  
aMAF	  indicates	  minor	  allele	  frequency	  
bInf	  Fams	  indicates	  number	  of	  informative	  families	  
cTOBS	  indicates	  transmissions	  observed;	  equivalent	  to	  the	  “S”	  statistic	  in	  FBAT	  
dTEXP	  indicates	  transmissions	  expected;	  equivalent	  to	  the	  “E(S)”	  statistic	  in	  FBAT	  
ep-­‐value	  corresponds	  to	  empirical	  variance	  “-­‐e”	  option	  in	  FBAT	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Leu90Val	  and	  Val171Ile	  were	  detected	  only	  in	  ASD	  cases	  and	  not	  controls	  (3/370	  
case	  chromosomes	  for	  each	  variant	  vs.	  0/562	  control	  chromosomes).	  A	  case-­‐control	  
comparison	  of	  these	  individual	  rare	  alleles	  does	  not	  reach	  significance	  given	  the	  small	  
number	  of	  observations	  (Fisher’s	  Exact	  p=0.064	  for	  Leu90Val	  and	  Val171Ile	  each).	  Due	  
to	  the	  limitation	  in	  power	  to	  compare	  rates	  of	  single	  rare	  alleles,	  a	  gene-­‐wide	  collapsing	  
method	  suggests	  a	  better	  approach	  is	  to	  model	  all	  “functional”	  (i.e.	  nonsynonymous,	  
consensus	  splice	  site	  and	  read-­‐through)	  rare	  variants	  simultaneously	  for	  case-­‐control	  
comparisons.	  CAST	  testing	  on	  total	  rare	  “functional”	  variants	  obtained	  from	  sequence	  
discovery	  revealed	  a	  significant	  burden	  effect	  (6/185	  ASD	  individuals	  vs.	  1/310	  controls;	  
p=0.013;	  OR=10.19,	  CI	  =	  1.20-­‐81.56)	  (Table	  4.5A).	  	  
Consistent	  with	  published	  data	  on	  accepted	  risk	  CNVs	  (e.g.	  16p11.2,	  1q21.1,	  
22q11.2,	  22q13.3,	  etc.)	  [111,	  118,	  121]	  novel	  variants	  Leu90Val	  and	  Val171Ile	  did	  not	  
always	  segregate	  to	  only	  -­‐	  or	  all	  -­‐	  affected	  individuals	  in	  a	  family,	  consistent	  with	  
incomplete	  penetrance	  (Figure	  4.2).	  
	  
In-­‐silico	  analysis	  reveals	  functional	  effects	  of	  ASD	  associated	  variants	  
The	  availability	  of	  crystal	  structure	  for	  a	  human	  ligand-­‐bound	  adenosine	  A2a	  
receptor	  (A2aAR)	  [225]	  provides	  an	  important	  source	  of	  structure-­‐function	  information	  
that	  can	  inform	  predictions	  of	  a	  functional	  impact	  of	  the	  Leu90Val	  and	  Ile171Leu	  
variants.	  Figure	  4.3	  depicts	  the	  structure	  of	  the	  A2aAR,	  modeling	  the	  residues	  
equivalent	  to	  A3AR-­‐Leu90	  and	  -­‐Val171,	  in	  relation	  to	  bound	  adenosine.	  This	  model	  
demonstrates	  that	  the	  A3AR-­‐Leu90	  and	  -­‐Val171	  residues	  flank	  the	  binding	  site,	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Table	  4.4	  :	  Sanger	  sequencing	  discovery	  of	  variation	  at	  ADORA3	  





African	  American	  controls	  
SNP	  ID	   HGVSa	  
mRNA	  
positionb	  
(NM_000677.3)	   mRNA	  Locationc	  	   Chromosomesd	   MAFe	  
	  
Chromosomesd	   MAFe	  
	  
Chromosomesd	   MAFe	  
rs10776728	   c.108-­‐13736A>T	  
	  
-­‐376	   105/370	   0.284	  
	  
178/562	   0.317	  
	  
17/48	   0.354	  
rs140137165	   c.108-­‐13682G>C	  
	  
-­‐322	   0/370	   0.000	  
	  
0/562	   0.000	  
	  




-­‐283	   0/370	   0.000	  
	  
1/562	   0.002	  
	  
0/48	   0.000	  
rs10776727	   c.108-­‐13642G>T	  
	  
-­‐282	   164/370	   0.443	  
	  
251/562	   0.447	  
	  
13/48	   0.271	  
rs114241928	   c.108-­‐13599C>G	  
	  
-­‐239	   0/370	   0.000	  
	  
0/562	   0.000	  
	  




-­‐172	   1/370	   0.003	  
	  
0/562	   0.000	  
	  




-­‐11	   0/370	   0.000	  
	  
2/562	   0.004	  
	  
0/48	   0.000	  
	  
c.-­‐724G>A	   44	   5'UTR	   1/370	   0.003	  
	  
1/562	   0.002	  
	  
0/48	   0.000	  
rs1544223	   c.-­‐581G>A	   187	   5'UTR	   71/370	   0.192	  
	  
119/562	   0.212	  
	  
11/48	   0.229	  
rs1544224	   c.-­‐564T>C	   204	   5'UTR	   73/370	   0.197	  
	  
130/562	   0.231	  
	  
11/48	   0.229	  
	  
c.-­‐563G>A	   205	   5'UTR	   0/370	   0.000	  
	  
1/562	   0.002	  
	  
0/48	   0.000	  
	  
c.-­‐479A>G	   289	   5'UTR	   0/370	   0.000	  
	  
1/562	   0.002	  
	  
0/48	   0.000	  
rs41282522	   c.-­‐221G>C	   547	   5'UTR	   52/370	   0.141	  
	  
81/562	   0.144	  
	  
6/48	   0.125	  
rs41282520	   c.-­‐105A>C	   663	   5'UTR	   1/370	   0.003	  
	  
4/562	   0.007	  
	  
0/48	   0.000	  
	  
c.-­‐85G>A	   683	   5'UTR	   0/370	   0.000	  
	  
1/562	   0.002	  
	  
0/48	   0.000	  
rs35789323	   c.265C>T	   1,032	   Leu89Leu	   1/370	   0.003	  
	  
0/562	   0.000	  
	  
0/48	   0.000	  
rs77883500	   c.268C>G	   1,035	   Leu90Val	   3/370	   0.008	  
	  
0/562	   0.000	  
	  
0/48	   0.000	  
rs76934313	   c.345C>T	   1,112	   Thr115Thr	   2/370	   0.006	  
	  
3/562	   0.005	  
	  
0/48	   0.000	  
rs2789537	   c.390C>T	   1,157	   Ala130Ala	   6/370	   0.016	  
	  
5/562	   0.009	  
	  
1/48	   0.021	  
rs139935750	   c.511G>A	   1,278	   Val171Ile	   3/370	   0.008	  
	  
0/562	   0.000	  
	  
0/48	   0.000	  
	  
c.582C>T	   1,349	   Cys194Cys	   1/370	   0.003	  
	  
1/562	   0.002	  
	  
0/48	   0.000	  
rs143962803	   c.583G>A	   1,350	   Ala195Thr	   0/370	   0.000	  
	  
1/562	   0.002	  
	  
0/48	   0.000	  
rs35511654	   c.742A>C	   1,509	   Ile248Leu	   54/370	   0.146	  
	  
84/562	   0.158	  
	  
6/48	   0.125	  
rs2800889	   c.797T>A	   1,564	   Met266Lys	   6/370	   0.016	  
	  
5/562	   0.009	  
	  
1/48	   0.021	  
rs2229155	   c.897T>C	   1,664	   Ala299Ala	   52/370	   0.154	  
	  
100/562	   0.178	  
	  
9/48	   0.188	  
	  
c.*97C>A	   1,821	   3'UTR	   0/370	   0.000	  
	  
1/562	   0.002	  
	  
0/48	   0.000	  
rs923	   c.*189C>T	   1,913	   3'UTR	   51/370	   0.149	  
	  
100/562	   0.178	  
	  
9/48	   0.188	  
rs1415793	   c.*336C>T	   2,060	   3'UTR	   51/370	   0.149	  
	  
100/562	   0.178	  
	  
9/48	   0.188	  
rs75048140	   c.*350A>G	   2,074	   3'UTR	   2/370	   0.005	  
	  
0/562	   0.000	  
	  
0/48	   0.000	  
rs1415792	   c.*377A>G	   2,101	   3'UTR	   50/370	   0.146	  
	  
100/562	   0.178	  
	  
9/48	   0.188	  
	  
c.*409C>T	   2,133	   3'UTR	   0/370	   0.000	  
	  
1/562	   0.002	  
	  
0/48	   0.000	  
rs3393	   c.*423G>A	   2,147	   3'UTR	   123/370	   0.435	  
	  
258/562	   0.459	  
	  
9/48	   0.188	  
rs3394	   c.*441A>G	   2,165	   3'UTR	   51/370	   0.149	  
	  
99/562	   0.176	  
	  
9/48	   0.188	  
	  
	  
a	  Human	  Genome	  Variation	  Society	  (HGVS)	  recommended	  nomenclature	  
b	  Indicates	  base-­‐pair	  position	  within	  mRNA	  structure.	  	  RefSeq	  Accession	  number	  is	  given	  in	  parenthesis.	  
c	  Indicates	  location	  within	  mRNA	  structure	  (Exon).	  Negative	  (-­‐)	  numbers	  indicate	  base	  pair	  position	  5'	  to	  mRNA.	  
Amino	  acid	  substitutions	  are	  shown	  relative	  to	  protein	  position.	  
d	  Indicates	  the	  number	  of	  minor	  allele	  counts	  over	  the	  total	  number	  of	  chromosomes	  sequenced.	  
e	  MAF	  indicates	  minor	  allele	  frequency	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Figure	  4.2.	  Pedigree	  structure	  of	  ASD	  families	  harboring	  the	  Leu90Val	  or	  Val171Ile	  variant.	  An	  asterisk	  indicates	  subjects	  harboring	  
either	  variant.	  Individuals	  for	  whom	  DNA	  was	  not	  available	  are	  labeled	  NA.	  Individuals	  with	  ASD	  re	  indicated	  by	  filled	  circles	  or	  
squares,	  while	  unfilled	  elements	  reflect	  individuals	  without	  an	  ASD	  diagnosis.	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Figure	  4.3.	  Structure	  of	  the	  A2a	  adenosine	  receptor	  identifying	  corresponding	  
positions	  of	  Leu90	  and	  Val171	  residues	  in	  the	  A3	  receptor.	  The	  structure	  of	  the	  
thermostabilized	  A2a	  receptor,	  A2aAR-­‐GL31	  (PDB	  code	  2YDO),	  is	  depicted	  as	  a	  cartoon	  
in	  rainbow	  coloration	  (N-­‐terminus	  in	  blue,	  C-­‐terminus	  in	  red),	  viewed	  either	  (A)	  parallel	  
to	  the	  membrane	  plane	  or	  (B)	  from	  the	  extracellular	  surface	  perpendicular	  to	  the	  
membrane	  plane.	  The	  endogenous	  ligand	  adenosine	  is	  shown	  as	  a	  stick	  model	  (C,	  
yellow,	  N,	  blue,	  O,	  red)	  as	  is	  the	  side	  chain	  for	  Phe168	  (C,	  green).	  The	  transmembrane	  
helices	  are	  labeled	  H1-­‐H7,	  the	  extracellular	  loop	  2	  (EL2)	  is	  indicated	  and	  H8	  is	  the	  C-­‐
terminal	  amphipathic	  helix	  lying	  parallel	  to	  the	  membrane	  plane.	  A3AR	  residues	  Leu90	  
and	  Val171	  correspond	  to	  Val84	  and	  Val171	  in	  A2aAR,	  and	  they	  are	  both	  shown	  as	  
space-­‐filling	  models	  (grey)	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predicting	  a	  functional	  effect.	  Figure	  4.4	  demonstrates	  consistent	  cross-­‐species	  
conservation	  in	  mammals	  for	  Leu90	  and	  Val171,	  while	  Ala195	  is	  less	  conserved.	  
Functional	  studies	  therefore	  focused	  solely	  on	  the	  two	  variants	  identified	  in	  cases.	  
	  
Functional	  analysis	  of	  Leu90Val-­‐	  and	  Val171Ile-­‐A3AR	  effects	  on	  cGMP	  Production	  and	  
SERT	  activity	  
To	  test	  for	  potential	  functional	  effects	  produced	  by	  the	  Leu90Val	  and	  Val171Ile	  
substitutions,	  we	  engineered	  human	  A3AR	  cDNA	  expression	  constructs	  to	  harbor	  either	  
Leu90Val	  or	  Val171Ile	  variants	  in	  a	  heterologous	  transfection	  system.	  Western	  blot	  
analysis	  of	  cell	  lysates	  confirmed	  equivalent	  expression	  of	  myc-­‐tagged	  wildtype	  A3AR	  
compared	  to	  both	  variant	  A3AR	  constructs.	  cGMP	  levels	  for	  A3AR/SERT	  variants,	  before	  
and	  after	  A3AR	  activation	  with	  IB-­‐MECA,	  demonstrate	  cells	  transfected	  with	  the	  
Leu90Val	  variant	  display	  elevated	  basal	  cGMP	  levels	  compared	  to	  wildtype	  transfected	  
cells	  (L90V:	  207.85%	  ±	  45.71	  vs.	  WT:	  100.0%	  ±	  0.02;	  P=0.015,	  n=3)	  (Figure	  4.5A)	  
Stimulation	  of	  the	  Leu90Val	  A3AR	  by	  IB-­‐MECA	  (1	  µM)	  revealed	  that	  the	  elevated	  cGMP	  
production	  seen	  in	  the	  basal	  state	  persisted	  over	  the	  full	  time	  course	  and	  production	  
paralleled	  wildtype	  A3AR	  with	  both	  returning	  to	  their	  respective	  basal	  states	  after	  40	  
minutes	  (Figure	  4.5A).	  	  
In	  contrast	  with	  Leu90Val,	  cells	  co-­‐transfected	  with	  Val171Ile-­‐A3AR/SERT	  displayed	  
similar	  basal	  cGMP	  levels	  to	  those	  observed	  in	  wildtype	  A3AR/SERT	  transfected	  cells	  
(V171I:	  116.1%	  ±16.3	  vs.	  WT:	  100.0%	  ±	  9.2,	  P=n.s.,	  n=3).	  IB-­‐MECA	  treatment	  on	  
Val171Ile/SERT	  cells	  failed	  to	  induce	  significant	  cGMP	  production	  compared	  to	  that	  seen	  	  




Figure	  4.4.	  Cross-­‐species	  conservation	  at	  ADORA3	  variant	  sites	  detected	  by	  Sanger	  
sequencing.	  Amino	  acid	  sequences	  of	  the	  A3AR	  protein	  encoded	  by	  ADORA3	  are	  aligned	  
for	  the	  three	  variants	  and	  their	  flanking	  residues:	  Leu90Val,	  Val171Ile	  (cases),	  and	  
Ala195Thr	  (controls).	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Figure	  4.5:	  Functional	  consequences	  of	  the	  A3AR	  specific	  agonist	  IB-­‐MECA	  in	  WT-­‐A3AR	  
and	  Leu90Val-­‐A3AR	  or	  Val171Ile-­‐A3AR	  expressing	  cells.	  CHO	  cells	  co-­‐transfected	  with	  
either	  WT-­‐A3AR	  or	  Leu90Val-­‐A3AR	  or	  Val171Ile-­‐A3AR	  and	  SERT	  and	  were	  stimulated	  
using	  IB-­‐MECA	  (1	  μM).	  (A)	  Levels	  of	  cGMP	  production	  from	  wildtype-­‐A3AR	  and	  
Leu90Val-­‐A3AR	  cells	  were	  measured	  prior	  to	  and	  after	  IB-­‐MECA	  stimulation.	  Leu90Val-­‐
A3AR	  cells	  display	  elevated	  basal	  cGMP	  production	  revealing	  enhanced	  overall	  
production	  of	  cGMP.	  (B)	  60	  min	  time-­‐course	  of	  IB-­‐MECA	  induced	  5-­‐HT	  uptake	  as	  
measured	  as	  percent	  of	  control	  (wildtype;	  time	  =	  0	  min).	  CHO	  cells	  were	  co-­‐transfected	  
with	  either	  wildtype-­‐A3AR	  and	  SERT	  or	  Leu90Val-­‐A3AR	  and	  SERT,	  and	  5-­‐HT	  uptake	  was	  
stimulated	  using	  IB-­‐MECA	  (1	  μM).	  Cells	  were	  incubated	  with	  [3H]5-­‐HT	  (20	  nM)	  for	  the	  
indicated	  period.	  Over	  the	  time	  course	  (0-­‐60	  min)	  in	  Leu90Val-­‐A3AR/SERT	  expressing	  
cells,	  5-­‐HT	  uptake	  is	  elevated	  compared	  with	  the	  wildtype	  A3AR	  counterpart.	  (C)	  At	  the	  
time	  when	  the	  control	  cells	  had	  already	  returned	  to	  baseline	  levels,	  greater	  5-­‐HT	  uptake	  
was	  seen	  in	  Leu90Val	  A3AR	  cells	  compared	  to	  wildtype	  A3AR/SERT.	  (D)	  [3H]5-­‐HT	  
accumulation	  into	  A3AR/SERT	  cells	  was	  and	  indicate	  a	  failure	  of	  IB-­‐MECA	  treatment	  of	  
Val171Ile-­‐A3AR	  to	  induce	  SERT	  dependent	  5-­‐HT	  re-­‐uptake	  across	  all	  tested	  
concentrations.	  Compared	  to	  the	  peak	  concentrations	  (0.8	  μM	  and	  1.0	  μM).	  P<0.05	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with	  wildtype	  A3AR/SERT.	  This	  inability	  of	  the	  Val171Ile	  receptor	  to	  be	  stimulated	  by	  IB-­‐
MECA	  resulted	  in	  a	  non-­‐significant	  reduction	  in	  cGMP	  synthesis	  compared	  with	  wildtype	  
(V171I:	  90.14%	  ±	  12.22	  vs.	  WT:	  100.0%	  ±	  16.18;	  1-­‐tailed	  t-­‐test	  P=n.s.)	  	  
Maximum	  5-­‐HT	  uptake	  (i.e.	  at	  10	  min)	  in	  Leu90Val	  A3AR/SERT	  cells	  was	  equivalent	  
to	  that	  of	  wildtype	  A3AR/SERT	  (L90V:	  148.5%	  ±	  7.1	  vs.	  WT:	  140.3%	  ±	  4.5;	  n=4),	  however,	  
cells	  expressing	  Leu90Val	  A3AR/SERT	  displayed	  a	  persistent	  increase	  in	  IB-­‐MECA-­‐
induced	  5-­‐HT	  uptake	  (Figure	  4.5B).	  At	  the	  time	  which	  wildtype	  A3AR-­‐stimulated	  SERT	  
activity	  had	  already	  returned	  to	  baseline	  levels,	  Leu90Val	  A3AR/SERT	  cells	  were	  elevated	  
in	  comparison	  (L90V:	  131.3%	  ±	  7.1	  vs.	  WT:	  108.3%	  ±	  3.7;	  two	  way	  ANOVA	  p=0.001,	  n=4).	  
Overall,	  greater	  5-­‐HT	  uptake	  was	  seen	  in	  Leu90Val	  A3AR/SERT	  cells	  compared	  to	  
wildtype	  A3AR/SERT	  cells	  (Figure	  4.5C;	  L90V:	  112.2%	  ±	  8.80	  vs.	  WT:	  100.0%	  ±	  3.22;	  1-­‐
tailed	  t-­‐test	  p=0.020,	  n=4)	  
In	  striking	  contrast	  to	  the	  enhanced	  SERT	  activity	  observed	  with	  Val90	  co-­‐
transfected	  cells,	  IB-­‐MECA	  treatment	  of	  Ile171	  failed	  to	  stimulate	  SERT	  activity	  (Figure	  
4.5D)	  across	  all	  doses	  tested.	  
	  
Replication	  test	  of	  an	  increased	  rate	  of	  rare	  functional	  variants	  in	  ASD	  cases	  vs.	  controls	  
Examining	  whole	  exome	  sequence	  data	  from	  339	  cases	  and	  pair-­‐matched	  controls	  of	  
European	  ancestry,	  generated	  by	  the	  NIH	  ARRA	  Autism	  Sequencing	  Consortium,	  
revealed	  numerous	  functional	  variants	  at	  ADORA3.	  Nine	  case	  subjects	  were	  found	  to	  
harbor	  nonsynonymous	  variants	  compared	  to	  three	  in	  controls.	  Although	  trending,	  this	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increase	  in	  variants	  seen	  in	  cases	  was	  not	  statistically	  significant	  (Fisher’s	  Exact	  1-­‐tailed	  
p=0.071;	  OR	  =	  3.06,	  CI:	  0.82-­‐10.99;	  Table	  4.5B).	  
In	  more	  detail,	  Leu90Val	  was	  identified	  in	  one	  additional	  ASD	  case	  and	  in	  zero	  
controls,	  and	  Val171Ile	  was	  found	  in	  two	  ASD	  cases	  and	  one	  control.	  Of	  the	  remainder,	  
four	  additional	  missense	  variants	  (Ile22Thr,	  Phe48Ser,	  Ala69Ser,	  and	  Leu294Thr)	  were	  
found	  in	  one	  case	  each	  and	  no	  controls,	  and	  a	  single	  read-­‐through	  mutation	  (*319Gln)	  
predicted	  to	  add	  an	  additional	  38	  residues	  (>10%	  of	  the	  native	  protein)	  was	  found	  in	  
two	  cases	  and	  zero	  controls.	  Two	  more	  missense	  variants	  were	  detected	  in	  controls	  
(Phe180Leu	  and	  Ala273Thr).	  All	  variant	  calls	  passed	  quality	  control	  thresholds	  and	  have	  
a	  high	  positive	  predictive	  value	  for	  being	  valid	  calls,	  although	  they	  have	  not	  been	  
experimentally	  validated.	  	  
Combining	  both	  discovery	  and	  replication	  findings	  strengthens	  the	  evidence	  for	  an	  
increase	  of	  “functional”	  variants	  in	  ASD.	  In	  total,	  15	  out	  of	  524	  cases	  compared	  to	  4	  out	  
of	  644	  controls	  carried	  rare	  ADORA3	  nonsynonymous	  alleles	  (Fisher’s	  Exact	  1-­‐tailed,	  
Bonferroni-­‐corrected	  p=0.0025;	  OR	  =	  4.72,	  CI:	  1.56-­‐14.30).	  Likewise,	  the	  enrichment	  of	  
the	  Val90	  allele	  in	  ASD	  cases	  vs.	  controls	  becomes	  statistically	  significant	  when	  taking	  
into	  account	  replication	  data,	  (Fisher’s	  Exact	  1-­‐tailed	  p=0.040).	  Although	  present	  in	  
greater	  numbers	  in	  ASD	  cases,	  enrichment	  for	  Leu171Ile	  by	  itself	  did	  not	  reach	  
significance	  (Fisher’s	  Exact	  1-­‐tailed	  p=0.068).	  
Examination	  of	  available	  phenotype	  data	  showed	  no	  consistent	  pattern	  of	  
elevated	  or	  diminished	  ADI-­‐R	  domain	  scores	  in	  carriers	  vs.	  non-­‐carriers.	  A	  similar	  lack	  of	  	  
	  




Table	  4.5A	  The	  cohort	  allelic	  sums	  test	  on	  rare	  ADORA3	  variants	  in	  the	  discovery	  
sample	  
rs#	   mRNA	   Cases	   Controls	  
rs77883500	   Leu90Val	   3	   0	  
rs139935750	   Val171Ile	   3	   0	  
rs143962803	   Ala195Thr	   0	   1	  
	   Carriers	   6	   1	  
	   Non-­‐carriers	   179	   304	  
P=0.013	  (OR=10.19,	  CI:	  1.22-­‐85.37)	  
	  
Table	  4.5B	  The	  cohort	  allelic	  sums	  test	  on	  rare	  ADORA3	  variants	  in	  the	  replication	  
sample	  
rs#	   mRNA	   Cases	   Controls	  
rs112045912	   Ile22Thr	   1	   0	  
	   Phe48Ser	   1	   0	  
	   Ala69Ser	   1	   0	  
rs77883500	   Leu90Val	   1	   0	  
rs139935750	   Val171Ile	   2	   1	  
	   Phe180Leu	   0	   1	  
	   Ala273Thr	   0	   1	  
	   Leu294Phe	   1	   0	  
rs112042574	   *319Gln	   2	   0	  
	   Carriers	   9	   3	  
	   Non-­‐carriers	   330	   336	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correlation	  existed	  upon	  examination	  of	  subsets	  of	  the	  ADI-­‐derived	  principal	  
components	  analysis-­‐derived	  scores	  (Appendix	  A)	  [226].	  Of	  the	  15	  ASD	  subjects	  with	  
rare	  ADORA3	  variants	  CNV	  data	  were	  available	  on	  six	  cases.	  A	  single	  de	  novo	  duplication	  
of	  approximately	  211	  kb	  (hg18:	  ChrX:153263157-­‐153474401)	  was	  found	  in	  the	  male	  
proband	  (NIMH	  ID:	  217-­‐14216-­‐3470)	  harboring	  a	  Ala69Ser	  substitution	  in	  ADORA3,	  
however,	  most	  CNVs	  also	  corresponded	  to	  regions	  detected	  in	  controls.	  
	  
Discussion	  
Given	  that	  (i)	  SERT	  is	  an	  essential	  regulator	  of	  5-­‐HT	  signaling,	  (ii)	  SERT	  and	  5-­‐HT	  have	  
a	  longstanding	  connection	  to	  ASD,	  and	  (iii)	  A3AR	  can	  regulate	  SERT	  via	  PKG	  and	  p38	  
MAPK	  signaling	  pathways,	  I	  postulated	  that	  rare	  ADORA3	  variants	  would	  be	  enriched	  in	  
an	  ASD	  sample,	  and	  these	  A3AR	  rare	  ASD-­‐associated	  variants	  would	  confer	  functional	  
consequences	  on	  SERT	  activity.	  These	  experiments	  were	  largely	  premised	  on	  the	  
findings	  of	  elevated	  SERT-­‐dependent	  5-­‐HT	  uptake	  activity	  seen	  with	  multiple	  rare,	  ASD-­‐
associated	  SERT	  coding	  variants	  [81,	  144,	  187,	  188].	  	  
Consistent	  with	  results	  from	  large-­‐scale	  GWA	  scans	  for	  common	  allele	  risk	  loci	  I	  
found	  no	  evidence	  to	  support	  a	  main	  effect	  on	  ASD	  attributable	  to	  common	  variants	  at	  
ADORA3.	  Since	  1000	  families	  provides	  limited	  power	  to	  detect	  alleles	  of	  small	  effect	  size	  
(e.g.	  OR	  <	  1.3),	  the	  possibility	  that	  common	  ADORA3	  variants	  confer	  small	  effect	  sizes	  
(or	  interact	  with	  alleles	  at	  other	  genes)	  to	  confer	  risk	  is	  very	  real.	  
Mechanistically	  speaking,	  the	  most	  expected	  scenario	  was	  for	  ADORA3	  to	  harbor	  
coding	  variants,	  likely	  ≥5%	  minor	  allele	  frequency,	  that	  would	  impact	  A3	  function	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directly	  and	  SERT	  function	  indirectly.	  Numerous	  studies	  have	  documented	  that	  rare	  
variation	  affecting	  a	  large	  number	  of	  genes	  is	  collectively	  a	  substantial	  source	  of	  genetic	  
liability	  in	  ASD.	  As	  noted	  in	  the	  Methods,	  there	  is	  low	  power	  to	  detect	  rare	  variants	  of	  
only	  modest	  risk	  in	  the	  sequencing	  sample.	  Nevertheless,	  a	  nominal	  increase	  in	  rare	  
“functional”	  variants	  was	  discovered	  in	  the	  discovery	  case	  vs.	  control	  sample	  (p=0.013).	  
These	  results	  are	  consistent	  with	  ADORA3	  contributing	  genetic	  liability	  in	  the	  form	  of	  
rare	  variation	  in	  a	  small	  number	  of	  ASD	  individuals.	  Subsequent	  availability	  and	  analysis	  
of	  exome	  sequence	  data	  from	  cases	  and	  clinically	  screened	  controls	  showed	  a	  greater	  
number	  of	  “functional”	  variants	  at	  ADORA3	  in	  cases	  compared	  with	  controls.	  While	  the	  
replication	  stage	  merely	  suggested	  an	  increase	  in	  rare	  “functional”	  variants	  (p=0.07),	  
combining	  Sanger	  discovery	  and	  WES	  data	  strengthened	  evidence	  for	  association,	  even	  
after	  Bonferroni	  correction	  for	  multiple	  comparisons	  (Fisher’s	  exact	  1-­‐tailed	  p=0.0025;	  
OR	  =	  4.72,	  CI:	  1.56-­‐14.30).	  	  
Encouraged	  by	  the	  initial	  discovery	  of	  Leu90Val	  and	  Val171Ile,	  functional	  studies	  
focused	  on	  these	  two	  nonsynonymous	  variants.	  Analysis	  of	  Leu90Val	  and	  Val171Ile	  
entailed	  examining	  the	  effect	  of	  receptor	  stimulation	  to	  induce	  cGMP	  synthesis	  or	  on	  
downstream	  SERT-­‐dependent	  5-­‐HT	  uptake.	  IB-­‐MECA	  stimulation	  of	  the	  Val90-­‐encoded	  
A3AR	  showed	  enhanced	  cGMP	  synthesis	  under	  basal	  conditions,	  and	  enhanced	  cGMP	  
levels	  extended	  over	  the	  full	  time	  course	  ending	  with	  a	  return	  to	  the	  elevated	  baseline.	  
Furthermore,	  IB-­‐MECA	  treatment	  prompted	  an	  overall	  increase	  in	  SERT-­‐dependent	  5-­‐HT	  
uptake	  activity	  demonstrating	  a	  delayed	  return	  to	  baseline	  in	  cells	  transfected	  with	  
Leu90Val	  A3AR/SERT.	  Increases	  in	  both	  cGMP	  and	  5-­‐HT	  uptake	  activity	  parallel	  the	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recent	  report	  by	  Zhu	  and	  colleagues	  of	  enhanced	  Leu90Val-­‐A3AR/SERT	  complex	  
formation	  [213].	  These	  data	  imply	  enhanced	  basal	  A3AR	  receptor-­‐G	  protein	  coupling,	  
and/or	  reduced	  receptor	  desensitization,	  and/or	  possible	  differences	  in	  the	  binding	  
kinetics	  of	  IB-­‐MECA	  to	  Val90-­‐A3AR	  as	  a	  consequence	  of	  its	  location	  proximal	  to	  the	  
A3AR	  ligand-­‐binding	  site.	  Taken	  together,	  the	  Leu90Val-­‐A3AR	  increases	  on	  SERT	  activity	  
are	  consistent	  with	  prior	  data	  on	  increased	  5-­‐HT	  uptake	  caused	  by	  rare	  SERT	  ASD-­‐
associated	  mutations	  [81,	  144,	  187,	  188].	  
In	  contrast	  to	  the	  functional	  consequences	  of	  Leu90Val,	  the	  Val171Ile	  variant	  
rendered	  A3AR	  insensitive	  to	  induce	  cGMP	  synthesis	  and	  a	  downstream	  increase	  in	  
SERT-­‐dependent	  5-­‐HT	  uptake,	  as	  a	  response	  to	  the	  IB-­‐MECA	  agonist.	  The	  molecular	  
mechanism	  underlying	  this	  effect	  is	  not	  yet	  clear,	  however,	  similar	  to	  Leu90Val,	  the	  
proximity	  of	  the	  Val171	  residue	  to	  the	  ligand	  binding	  pocket	  may	  hinder	  the	  adenosine	  
analog	  IB-­‐MECA	  to	  bind	  A3AR.	  This	  effect	  may	  result	  in	  a	  more	  rapid	  dissociation	  and/or	  
less	  efficient	  (or	  absence	  of)	  receptor-­‐G	  protein	  coupling.	  	  
Additional	  experiments	  are	  required	  to	  fully	  elucidate	  the	  molecular	  mechanisms	  of	  
these	  two	  coding	  variants	  on	  receptor	  function.	  Although	  the	  functional	  impact	  of	  the	  
two	  ASD	  associated	  variants	  on	  SERT	  are	  in	  opposite	  directions,	  it	  is	  possible	  that	  both	  
elevated	  and	  diminished	  capacity	  for	  regulation	  of	  SERT	  will	  influence	  ASD	  risk.	  
Therefore	  it	  is	  conceivable	  that	  A3AR-­‐related	  alterations	  in	  SERT	  activty	  may	  disrupt	  5-­‐
HT’s	  ability	  to	  coordinate	  brain	  development	  and/or	  adult	  5-­‐HT	  signaling	  [227-­‐230].	  	  
I	  recognize	  that	  the	  statistical	  association	  of	  rare	  ADORA3	  variants	  (especially	  
Leu90Val)	  requires	  additional	  validation	  in	  a	  larger	  ASD	  cohort;	  however,	  this	  confound	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is	  characteristic	  of	  rare	  variant	  analysis	  in	  complex	  disease.	  The	  predominant	  challenge	  
moving	  forward	  is	  in	  detecting	  susceptibility	  variants	  from	  those	  of	  normal	  human	  
variation.	  This	  challenge	  is	  complicated	  by	  the	  recent	  appreciation	  that	  all	  ASD	  
implicated	  loci	  will	  be	  littered	  with	  rare	  variation	  prompting	  many	  investigators	  to	  
emphasize	  the	  network	  as	  a	  better	  model	  to	  elucidate	  the	  underlying	  mechanisms	  (and	  
genes)	  implicated	  in	  autism	  spectrum	  disorders.	  
A	  single	  male	  case	  harboring	  an	  Ala69Ser	  variant	  (of	  unknown	  functional	  effect)	  at	  
ADORA3	  possessed	  a	  de	  novo	  duplication	  of	  an	  X-­‐linked	  interval	  including	  RPL10,	  a	  gene	  
that	  has	  been	  previously	  associated	  with	  ASD	  and	  ID	  [231].	  While	  the	  duplication	  effects	  
of	  RPL10	  are	  unknown,	  this	  CNV	  is	  likely	  to	  confer	  risk.	  	  
While	  compelling,	  the	  precise	  magnitude	  of	  risk	  conferred	  by	  the	  ADORA3	  variants	  is	  
uncertain	  and	  there	  are	  some	  caveats	  regarding	  the	  studies	  presented.	  First,	  while	  the	  
discovery	  sequence	  sample	  was	  ethnically	  matched,	  a	  subset	  of	  individuals	  were	  not	  
matched	  based	  on	  genome-­‐wide	  genotype	  data	  but	  instead	  on	  self-­‐report.	  It	  is	  possible	  
that	  subtle	  population	  stratification	  effects	  could	  lead	  to	  inflation	  of	  the	  observed	  
increase	  in	  numbers	  of	  rare	  nonsynonymous	  variants	  in	  cases	  vs.	  controls,	  and	  evidence	  
for	  gene	  based	  association	  in	  the	  discovery	  (p=0.0143)	  and	  combined	  (p=0.0025)	  sample	  
sets	  should	  be	  interpreted	  with	  caution.	  Secondly,	  while	  multiple	  comparisons	  were	  
conducted	  in	  functional	  experiments,	  the	  parallel	  increases	  in	  cGMP	  production	  and	  5-­‐
HT	  uptake	  support	  my	  conclusion	  regarding	  the	  ability	  of	  Leu90Val	  A3AR	  to	  augment	  
SERT-­‐dependent	  5-­‐HT	  uptake	  over	  time.	  Finally,	  all	  functional	  experiments	  were	  
conducted	  in	  vitro	  in	  CHO	  cells,	  and	  may	  not	  accurately	  reflect	  the	  function	  in	  vivo.	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While	  this	  is	  certainly	  possible,	  existing	  data	  on	  multiple	  variants	  in	  SLC6A4	  and	  in	  
proteins	  that	  influence	  SERT	  present	  a	  consistent	  picture	  from	  in	  vitro	  based	  




The	  results	  presented	  in	  this	  chapter	  support	  the	  hypothesis	  that	  SERT	  
regulatory	  proteins	  harbor	  an	  excess	  of	  rare,	  functional	  variants	  in	  an	  ASD	  sample	  that	  
impact	  SERT	  activity	  and	  regulation.	  Taken	  together	  with	  previous	  data	  on	  the	  functional	  
implications	  of	  an	  ASD-­‐associated	  SNP	  in	  ITGB3	  (also	  a	  SERT	  regulator),	  and	  several	  in	  
SLC6A4	  itself,	  this	  data	  is	  consistent	  with	  my	  hypothesis	  that	  monoamine	  dysregulation	  
represents	  one	  subset	  of	  biological	  risk	  in	  ASD	  individuals.	  These	  results	  encourage	  
further	  investigation	  of	  the	  SERT-­‐regulatory	  network,	  and	  more	  broadly	  dysfunction	  of	  
monoamine	  transporters,	  as	  potential	  genetic	  and	  biologically	  relevant	  ASD	  risk	  factors.	  
The	  studies	  presented	  herein	  add	  to	  the	  growing	  body	  of	  data	  implicating	  specific	  
gene/protein	  networks	  in	  contributing	  to	  ASD	  liability.	  It	  is	  hoped	  that	  in	  the	  future,	  
additional	  studies	  within	  the	  SERT	  regulatory	  network	  may	  provide	  new	  leads	  to	  ASD	  
therapeutics.	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CHAPTER	  V	  
	  
De	  novo	  mutation	  in	  the	  dopamine	  transporter	  gene	  associated	  dopamine	  dysfunction	  
with	  autism	  spectrum	  disorder	  
	  
Introduction	  
The	  functional	  characterization	  of	  a	  de	  novo	  DAT	  variant	  identified	  in	  a	  simplex	  ASD	  
family	  is	  the	  focus	  of	  this	  chapter.	  The	  majority	  of	  this	  work	  can	  be	  found	  in	  Hamilton	  
and	  Campbell	  et	  al.	  2013	  [233].	  The	  publication	  of	  this	  manuscript	  encompasses	  AIM2	  of	  
my	  thesis	  and	  is	  summarized	  here.	  
As	  discussed	  in	  Chapter	  2,	  genetic	  factors	  have	  been	  implicated	  as	  important	  
components	  in	  the	  etiology	  of	  autism	  spectrum	  disorder	  (ASD).	  It	  is	  now	  accepted	  that	  
rare	  genetic	  variation	  affecting	  single	  nucleotides	  of	  protein	  coding	  DNA	  as	  well	  as	  rare	  
genomic	  copy	  number	  variants	  are	  significant	  ASD	  risk	  factors	  [34,	  112,	  114,	  126].	  In	  
particular,	  increasing	  evidence	  suggests	  that	  de	  novo	  genetic	  variation,	  both	  SNV	  and	  
CNV,	  comprise	  a	  considerable	  class	  of	  risk	  factors	  in	  ASD	  and	  other	  neuropsychiatric	  
diseases	  [34,	  101,	  111,	  113,	  114].	  Several	  groups	  have	  conducted	  whole-­‐exome	  
sequencing	  (WES)	  on	  ASD	  families,	  and	  collectively,	  these	  studies	  indicate	  that	  discrete	  
de	  novo	  mutation	  (single	  nucleotide	  variation	  or	  small	  insertions	  and	  deletions)	  
contribute	  to	  the	  overall	  genetic	  risk	  of	  ASD	  [124-­‐127].	  Among	  these	  variations	  is	  the	  
first	  ASD-­‐associated,	  de	  novo	  mutation	  found	  in	  the	  human	  dopamine	  (DA)	  transporter	  
(DAT)	  gene	  (SLC6A3)	  [125].	  This	  mutation	  results	  in	  a	  Thr	  to	  Met	  substitution	  at	  position	  
356	  (DAT	  T356M).	  The	  consequences	  of	  this	  de	  novo	  mutation	  and	  its	  impact	  on	  DA	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neurotransmission	  have	  yet	  to	  be	  elucidated.	  
The	  neurotransmitter	  DA	  has	  an	  important	  role	  in	  the	  central	  nervous	  system	  by	  
regulating	  a	  variety	  of	  functions,	  including	  motor	  activity,	  motivation,	  attention	  and	  
reward	  [192-­‐195].	  Disrupted	  DA	  function	  is	  implicated	  in	  a	  number	  of	  neuropsychiatric	  
disorders,	  including	  bipolar	  disorder,	  schizophrenia,	  attention	  deficit	  hyperactivity	  
disorder	  (ADHD)	  [234-­‐236]	  and,	  more	  recently,	  ASD.	  (See	  Chapter	  3)	  The	  dopamine	  
transporter	  (DAT)	  is	  a	  presynaptic	  membrane	  protein	  that	  regulates	  DA	  
neurotransmission	  via	  the	  high-­‐affinity	  reuptake	  of	  synaptically	  released	  DA	  [237].	  It	  is	  
the	  major	  molecular	  target	  of	  cocaine	  (COC),	  amphetamine	  (AMPH;	  Adderall)	  and	  
methylphenidate	  (Ritalin)	  [238-­‐242].	  Owing	  to	  DAT’s	  role	  in	  DA	  neurotransmission,	  
SLC6A3	  variants	  have	  been	  a	  focus	  of	  genetic	  association	  studies	  linking	  the	  etiology	  of	  
brain	  disorders	  to	  dysregulated	  DA	  neurotransmission	  [243,	  244].	  Recent	  studies	  have	  
identified	  a	  rare,	  inherited,	  functional	  missense	  SLC6A3	  variant,	  DAT	  A559V	  
(rs28364997),	  and	  that	  has	  been	  associated	  with	  ADHD,	  a	  phenotype	  commonly	  
comorbid	  in	  ASD	  subjects	  [8,	  201-­‐204,	  245,	  246].	  These	  studies	  point	  to	  a	  contribution	  of	  
DAT	  genetic	  variants	  in	  complex	  brain	  disorders.	  
Although	  an	  important	  role	  for	  DA	  in	  ADHD	  has	  been	  established	  [247].	  DA’s	  role	  
in	  ASD	  is	  poorly	  understood.	  [248]	  Many	  individuals	  with	  ASD	  exhibit	  co-­‐occurrence	  of	  
ADHD	  symptoms	  (~20–45%).	  The	  comorbid	  nature	  of	  ADHD	  with	  ASD	  points	  to	  
dysregulation	  of	  common	  signaling	  pathways	  (for	  example,	  DA)	  as	  a	  mechanism	  
underlying	  these	  neuropsychiatric	  disorders.	  [249]	  
In	  this	  chapter,	  I	  present	  the	  characterization	  of	  the	  first	  ASD-­‐identified,	  de	  novo	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mutation	  in	  DAT	  by	  structural,	  functional	  and	  behavioral	  analysis.	  These	  results	  
implicate	  altered	  DA	  homeostasis	  as	  a	  potential	  liability	  in	  ASD	  risk.	  
	  
Methods	  
Subjects	  and	  clinical	  assessment	  	  
Subjects	  from	  this	  family	  include	  the	  proband,	  both	  parents	  and	  an	  unaffected	  
sibling	  who	  were	  recruited	  by	  the	  Boston	  Autism	  Consortium	  as	  described	  previously	  
[125,	  250].	  Clinical	  assessment	  followed	  standard	  research	  criteria	  for	  ASD	  diagnosis.	  
The	  proband	  was	  classified	  as	  having	  a	  comparatively	  narrow	  “autism”	  diagnosis	  (as	  
opposed	  to	  a	  “broader	  ASD”)	  on	  the	  basis	  of	  diagnostic	  algorithms	  from	  the	  Autism	  
Diagnostic	  Interview	  Revised	  (ADI-­‐R)	  [2]	  using	  criteria	  described	  by	  Risi	  et.	  al	  [251],	  and	  
classification	  resulting	  from	  the	  diagnostic	  algorithm	  of	  the	  Autism	  Diagnostic	  
Observational	  Schedule	  (ADOS)	  [3].	  Proband	  IQ	  was	  assessed	  at	  age	  5	  years,	  9	  months	  of	  
age	  using	  the	  Wechsler	  Preschool	  and	  Primary	  Scale	  of	  Intelligence	  (WPPSI;	  Wechsler,	  D.	  
(1967)).	  The	  Social	  Responsiveness	  Scale	  (SRS;	  Western	  Psychological	  Services)	  was	  
performed	  on	  both	  parents	  to	  index	  the	  presence	  and	  severity	  of	  broader	  autism	  
phenotype	  traits.	  The	  biological	  mother	  provided	  medical	  and	  family	  history.	  
	  
SLC6A3	  T356M	  de	  novo	  discovery	  
Methodological	  details	  and	  results	  for	  the	  discovery	  and	  validation	  of	  the	  T356M	  
de	  novo	  mutation	  were	  published	  by	  Neale	  et	  al	  [125].	  In	  brief,	  DNA	  derived	  from	  whole	  
blood	  on	  both	  parents	  and	  the	  proband	  were	  exome	  captured,	  sequenced,	  putative	  de	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novo	  variation	  called,	  and	  subsequently	  validated.	  Exons	  were	  captured	  in	  this	  trio	  using	  
the	  Agilent	  38Mb	  SureSelect	  v2	  and	  sequenced	  using	  the	  IlluminaHiSeq2000	  at	  the	  
Broad	  Institute	  (Boston,	  MA).	  Read	  processing	  was	  performed	  using	  Picard	  
(http://picard.sourceforge.net),	  mapped	  to	  RefSeq19	  using	  BWA,	  and	  variable	  sites	  
called	  using	  GATK	  [252].	  The	  T356M	  variant,	  identified	  as	  a	  heterozygote	  in	  the	  proband	  
and	  absent	  in	  both	  parents,	  was	  experimentally	  validated	  and	  confirmed	  to	  be	  a	  de	  novo	  
mutation	  that	  does	  not	  appear	  in	  the	  unaffected	  sibling.	  
	  
Cell	  culture	  and	  transfection	  
The	  GFP-­‐synDAT-­‐pCIHygro	  expression	  vectors	  containing	  GFP-­‐tagged	  DAT	  WT	  
and	  DAT	  T356M	  sequence	  were	  engineered	  and	  amino	  acid	  substitution	  was	  confirmed	  
by	  direct	  sequencing.	  Expression	  vectors	  were	  transiently	  transfected	  into	  Chinese	  
hamster	  ovary	  (CHO)	  cells	  using	  the	  FuGENE-­‐6	  (Promega)	  system	  in	  a	  6:1	  transfection	  
reagent:DNA	  ratio.	  Cells	  were	  stored	  in	  a	  5%	  CO2	  incubator	  at	  37°C	  and	  maintained	  in	  
Ham’s	  F-­‐12	  medium	  supplemented	  with	  10%	  fetal	  bovine	  serum	  (FBS),	  1	  mM	  l-­‐
glutamine,	  100	  U/mL	  penicillin,	  and	  100	  μg/mL	  streptomycin.	  Assays	  were	  conducted	  
24-­‐48	  hr	  post-­‐transfection.	  
	  
Amperometry	  and	  patch	  clamp	  electrophysiology	  
Wildtype	  DAT	  and	  T356M	  DAT	  expressing	  cells	  were	  plated	  at	  a	  density	  of	  
~30,000	  per	  35-­‐mm	  culture	  dish	  and	  experiments	  conducted	  as	  described	  in	  Bowton	  et	  
al.	  [199,	  200].	  Patch	  pipettes	  for	  loading	  of	  DA	  were	  generated	  using	  a	  programmable	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puller,	  model	  P-­‐2000	  (Sutter	  Instruments),	  to	  confer	  a	  resistance	  of	  5	  MΩ.	  	  The	  pipettes	  
were	  filled	  with	  a	  2	  mM	  DA	  containing	  internal	  solution	  (120	  mM	  KCl,	  10	  mM	  HEPES,	  0.1	  
mM	  CaCl2,	  2	  mM	  MgCl2,	  1.1	  mM	  EGTA,	  30	  mM	  Dextrose,	  pH	  7.35,	  and	  275	  mOsm).	  	  Cells	  
were	  washed	  with	  the	  external	  bath	  solution	  (130	  mM	  NaCl,	  10	  mM	  HEPES,	  34	  mM	  D-­‐
glucose,	  1.5	  mM	  CaCl2,	  0.5	  mM	  MgSO4,	  1.3	  mM	  KH2PO4,	  adjusted	  pH	  to	  7.35,	  and	  300	  
mOsm).	  	  Following	  internal	  access	  to	  the	  transfected	  cells,	  the	  DA	  containing	  solution	  
was	  allowed	  to	  diffuse	  into	  the	  cell	  for	  10	  minutes.	  	  A	  carbon	  fiber	  electrode	  (ProCFE;	  
fiber	  diameter	  of	  5	  µm)	  was	  located	  neighboring	  the	  plasma	  membrane	  and	  held	  at	  
+700	  mV	  (a	  potential	  greater	  than	  the	  oxidation	  potential	  of	  DA).	  Amperometric	  
currents	  were	  recorded	  using	  an	  Axopatch	  200B	  amplifier	  (Molecular	  Devices)	  in	  
response	  to	  an	  addition	  of	  10	  µM	  AMPH	  or	  10	  µM	  COC.	  Amperometric	  traces	  were	  
digitally	  filtered	  offline	  at	  1	  Hz	  using	  Clampex9	  software	  (Molecular	  Devices).	  	  DA	  efflux	  
was	  quantified	  as	  the	  peak	  value	  (in	  picoamperes)	  of	  the	  amperometric	  current.	  	  	  	  
	  
[3H]Dopamine	  uptake	  	  
Wildtype	  and	  T356M	  DAT	  expressing	  cells	  were	  seeded	  into	  polyornithine	  
coated,	  24-­‐well	  plates	  48	  hr	  before	  assaying	  performed	  as	  previously	  described	  [253,	  
254].	  Prior	  to	  measurement,	  cells	  were	  washed	  with	  KRH	  buffer	  (130	  mM	  NaCl,	  1.3	  mM	  
KCl,	  2.2	  mM	  CaCl2,	  10	  mM	  HEPES,	  and	  1.2	  mM	  KH2PO4	  supplemented	  with	  10	  mM	  D-­‐
glucose,	  0.1	  mM	  ascorbic	  acid,	  1	  mM	  tropolone,	  and	  0.1	  mM	  pargyline,	  pH	  7.4).	  DAT	  
activity	  was	  assayed	  with	  50	  nM	  [3H]DA	  (dihydroxyphenylethylamine	  3,4-­‐[ring-­‐2,5,6-­‐3H])	  
for	  15	  min	  at	  37°C	  .	  Nonspecific	  activity	  was	  determined	  by	  5	  min	  pretreatment	  with	  10	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μM	  COC.	  [3H]DA	  uptake	  was	  quantified	  with	  the	  TopCount	  NXT™	  Microplate	  Scintillation	  
Counter	  (PerkinElmer).	  	  All	  data	  are	  presented	  as	  non-­‐specific	  subtracted.	  
	  
Amphetamine	  uptake	  
Plated	  wildtype	  and	  T356M	  DAT	  expressing	  were	  washed	  three	  times	  with	  KRH	  
buffer	  and	  incubated	  for	  5	  min	  at	  37°C	  in	  the	  presence	  of	  10	  nM	  AMPH.	  Cells	  were	  
washed	  three	  times	  with	  ice-­‐cold	  KRH.	  After	  solubilization	  in	  extraction	  buffer,	  AMPH	  
was	  quantified	  using	  HPLC.	  
	  
Cell	  surface	  biotinylation	  and	  western	  blot	  
For	  cell	  surface	  biotinylation	  assays	  and	  western	  blots,	  CHO	  cells	  were	  cultures	  in	  
6-­‐well	  plates	  and	  transiently	  transfected	  with	  wildtype	  DAT	  or	  T356M	  DAT	  expression	  
constructs.	  For	  cell	  surface	  biotinylation	  assays,	  cells	  were	  labeled	  with	  sulfo-­‐NHS-­‐SS-­‐
biotin	  (1.0	  mg/ml)	  and	  analysis	  conducted	  as	  in	  Mazei	  et	  al	  [200].	  DAT	  protein	  was	  
detected	  using	  a	  rat	  monoclonal	  primary	  antibody	  to	  the	  N-­‐terminus	  of	  hDAT	  (1:1000)	  
and	  a	  goat-­‐anti-­‐rat-­‐HRP-­‐conjugated	  secondary	  antibody	  (1:5000)	  	  
	  
Double	  Electron	  Electron	  Resonance	  
Cysteine	  residues	  were	  introduced	  using	  site	  directed	  mutagenesis	  into	  LeuT	  and	  
LeuT	  A289M	  constructs	  and	  experiments	  conducted	  as	  described	  in	  Claxton	  et	  al.	  [255].	  
In	  Figure	  5.4,	  Apo	  refers	  to	  ion	  Na+	  and	  leucine-­‐free	  transporter	  while	  the	  +NaL	  state	  
was	  obtained	  by	  addition	  of	  200	  mM	  NaCl	  and	  4-­‐fold	  molar	  excess	  of	  Leu	  relative	  to	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LeuT.	  Double	  electron	  electron	  resonance	  [256]	  was	  performed	  at	  83K	  on	  a	  Bruker	  580	  
pulsed	  EPR	  spectrometer	  operating	  at	  Q-­‐band	  frequency	  [257]	  using	  a	  standard	  4-­‐pulse	  
sequence	  as	  previously	  described.	  Double	  electron	  electron	  resonance	  echo	  decays	  
were	  analyzed	  to	  obtain	  distance	  distributions	  [258].	  	  
	   	  
Drosophila	  genetics	  
Drosophila	  homozygotes	  for	  the	  DAT	  null	  allele	  DATfmn	  (dDAT	  KO)	  [259]	  and	  flies	  
harboring	  TH-­‐Gal4	  [260]	  were	  outcrossed	  to	  a	  control	  line	  (Bloomington	  Indiana	  (BI)	  
6326)	  and	  selected	  by	  PCR	  or	  by	  eye	  color.	  TH-­‐GAL4	  (Bl	  8848)	  and	  M[vas-­‐int.Dm]ZH-­‐2A,	  
M[3xP3-­‐RFP.attP']	  ZH-­‐22A	  (Bl	  24481)	  were	  obtained	  from	  the	  BI	  stock	  center	  and	  
outcrossed	  to	  dDAT	  KO	  flies	  carrying	  the	  white	  (w1118)	  mutation	  (BI	  stock	  number	  6236)	  
for	  5–10	  generations.	  Transgenes	  (hDAT	  or	  hDAT	  T356M)	  were	  cloned	  into	  pBI-­‐UASC	  
[261]	  and	  constructs	  were	  injected	  into	  embryos	  from	  M[vas-­‐int.Dm]ZH-­‐2A,	  M[3xP3-­‐
RFP.attP']ZH-­‐22A	  (Bl	  24481).	  Initial	  potential	  transformants	  were	  isolated,	  selected,	  and	  
maintained	  by	  standard	  methods.	  	  
	  	  
Behavioral	  analysis	  
Three-­‐day	  post	  eclosion,	  male	  Drosophila	  were	  collected	  and	  placed	  into	  tubes	  
with	  food	  for	  72	  hr.	  Locomotion	  was	  recorded	  by	  beam	  breaks	  and	  analyzed	  using	  
equipment/software	  from	  Trikinetics	  (www.trikinetics.com).	  For	  the	  AMPH-­‐induced	  
locomotion,	  males	  were	  starved	  for	  6	  hr	  and	  then	  fed	  sucrose	  (5	  mM)	  containing	  either	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AMPH	  (10	  mM)	  or	  vehicle.	  Data	  were	  analyzed	  by	  one-­‐way	  analysis	  of	  variance	  followed	  
by	  a	  Newman-­‐Keuls	  Multiple	  Comparison	  Post-­‐test.	  	  
	  
Results	  
T356M	  de	  novo	  DAT	  variant	  has	  impaired	  function	  
A	  recent	  study	  assessed	  the	  role	  of	  de	  novo	  variation	  in	  ASD	  by	  using	  whole-­‐
exome	  sequencing	  in	  175	  ASD	  parent–child	  trios	  [125].	  In	  the	  data	  presented	  in	  this	  
chapter,	  a	  de	  novo	  SLC6A3	  variant	  was	  identified,	  resulting	  in	  a	  Thr	  to	  Met	  substitution	  
at	  site	  356.	  Given	  the	  rarity	  of	  non-­‐synonymous	  de	  novo	  events,	  it	  is	  not	  surprising	  that	  
this	  mutation	  was	  absent	  in	  the	  ~1000	  unrelated	  ASD	  cases	  and	  controls	  and	  has	  not	  
been	  deposited	  in	  1000	  genomes	  [262],	  single-­‐nucleotide	  polymorphism	  database	  (build	  
137)	  [263],	  or	  the	  NHLBI	  (National	  Heart,	  Lung,	  and	  Blood	  Institute)	  Exome	  Sequencing	  
Project.	  The	  subject	  carried	  no	  other	  coding	  de	  novo	  mutations.	  The	  T356	  residue	  is	  
completely	  conserved	  across	  several	  species	  (Figure	  5.1A).	  Importantly,	  residue	  356	  is	  
located	  in	  the	  seventh	  transmembrane	  domain	  of	  DAT	  and	  resides	  in	  a	  highly	  conserved	  
region	  implicated	  in	  ion	  binding	  [264].	  In	  silico	  molecular	  modeling	  of	  the	  T356	  mutant	  
protein	  is	  shown	  in	  Figure	  5.1B.	  
The	  subject	  harboring	  this	  de	  novo	  mutation	  is	  the	  elder	  male	  child	  of	  healthy	  
non-­‐consanguineous	  Caucasian	  parents	  (proband	  has	  a	  healthy	  younger	  sibling).	  There	  
is	  no	  immediate	  family	  history	  of	  ASD	  or	  related	  psychiatric	  conditions.	  The	  subject	  has	  a	  
normal	  IQ	  (94)	  and	  has	  no	  history	  of	  seizures	  or	  other	  co-­‐morbidities.	  By	  the	  age	  of	  6	  
years,	  the	  proband	  was	  diagnosed	  with	  ASD	  (see	  Appendix	  B	  for	  full	  clinical	  reports).	  
	   84	  
	  
Figure	  5.1:	  Cross-­‐species	  conservation	  and	  in	  silico	  mutagenesis	  of	  T356.	  (A)	  Alignment	  
of	  the	  dopamine	  transporter	  (DAT),	  amino-­‐acid	  sequence	  across	  multiple	  species.	  
Threonine	  356	  is	  represented	  in	  red.	  (B)	  In	  an	  equilibrated	  three-­‐dimensional	  homology	  
model	  of	  hDAT,	  the	  T356M	  mutation	  is	  located	  on	  transmembrane	  domain	  7	  (TM7).	  
Top:	  schematic	  views	  representing	  a	  180°	  rotation	  show	  T356M	  with	  respect	  to	  the	  TM	  
helices.	  TM7	  is	  shown	  in	  dark	  blue.	  Bottom:	  critical	  resides	  that	  interact	  with	  dopamine	  
(DA)	  are	  shown,	  as	  well	  as	  the	  bound	  Na+	  and	  Cl-­‐	  ions.	  The	  methionine	  is	  rendered	  
together	  at	  position	  356	  with	  the	  wildtype	  threonine	  (green).	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To	  evaluate	  the	  T356M	  variant,	  the	  activities	  of	  wildtype	  and	  T356M	  DAT	  were	  
compared	  in	  a	  heterologous	  expression	  system	  and	  radioactive	  [3H]DA	  uptake	  and	  
affinity	  were	  calculated.	  In	  DAT	  T356M	  cells,	  the	  maximal	  velocity	  of	  DA	  influx	  (Vmax)	  was	  
significantly	  reduced,	  whereas	  the	  apparent	  DA	  affinity	  (Km)	  of	  hDAT	  T356M	  was	  not	  
significantly	  different	  from	  that	  of	  hDAT	  (Figure	  5.2A,	  top).	  A	  representative	  plot	  of	  DA	  
uptake	  kinetics	  for	  DAT	  and	  DAT	  T356M	  is	  shown	  in	  Figure	  5.2A,	  bottom.	  The	  reduced	  
[3H]DA	  transport	  capacity	  was	  not	  associated	  with	  a	  reduction	  in	  either	  total	  or	  DAT	  
surface	  expression	  (Figure	  5.2B,	  top),	  as	  assessed	  by	  measuring	  changes	  in	  DAT	  proteins	  
in	  the	  total	  and	  biotinylated	  fraction,	  respectively.	  The	  total	  fraction	  for	  DAT	  and	  DAT	  
T356M	  contained	  both	  glycosylated	  and	  non-­‐glycosylated	  forms	  of	  the	  DAT.	  Surface	  
fractions	  were	  quantitated,	  normalized	  to	  total	  DAT	  (glycosylated)	  and	  expressed	  as	  a	  
percent	  of	  DAT	  (Figure	  5.2B;	  bottom).	  Furthermore,	  normalizing	  the	  total	  DAT	  fraction	  
(glycosylated)	  to	  actin-­‐loading	  control	  yielded	  no	  significant	  differences	  between	  DAT	  
and	  DAT	  T356M	  total	  expression.	  Data	  are	  expressed	  as	  a	  percentage	  of	  wiltdtype	  DAT	  
(wildtype	  DAT	  100±17.6%	  vs	  T356M	  DAT	  96.4±13.7%;	  P	  ≥	  0.87	  by	  Student’s	  t-­‐test;	  n	  =	  8–
11).	  
	  
DAT	  T356M	  displays	  anomalous	  DA	  efflux	  
Although	  DAT	  T356M	  displays	  similar	  surface	  expression	  to	  that	  of	  DAT,	  it	  
demonstrates	  reduced	  ability	  to	  accumulate	  intracellular	  DA.	  One	  possibility	  is	  that	  
constitutive	  DA	  efflux,	  here	  referred	  to	  as	  anomalous	  DA	  efflux	  (ADE),	  contributes	  to	  this	  
reduced	  DA	  uptake	  in	  the	  DAT	  T356M	  cells.	  This	  efflux	  would	  impede	  the	  intracellular	  	  




Figure	  5.2:	  Human	  dopamine	  transporter	  (DAT)	  T356M	  has	  impaired	  function.	  (A)	  Top:	  
kinetic	  parameters	  (Vmax	  and	  Km)	  for	  DAT	  and	  DAT	  T356M	  (Vmax:	  P≥0.005;	  by	  Student’s	  t-­‐
test;	  n=3,	  in	  triplicate;	  Km:	  P=0.20;	  by	  Student’s	  t-­‐test;	  n=3,	  in	  triplicate).	  Bottom:	  
representative	  plot	  of	  [3H]DA	  uptake	  kinetics	  in	  DAT	  (filled	  squares)	  or	  DAT	  T356M	  
(empty	  squares)	  cells	  (**=P≥0.01,	  ***=P≥0.001;	  by	  two-­‐way	  analysis	  of	  variance	  
(ANOVA)	  followed	  by	  Bonferroni	  post-­‐test;	  n=3,	  in	  triplicate).	  (B)	  Representative	  
immunoblots	  for	  biotinylated	  (surface)	  and	  total	  protein	  fractions	  from	  DAT	  and	  DAT	  
T356M	  cells.	  Surface	  fractions	  were	  quantitated,	  normalized	  to	  total	  DAT	  (glycosylated)	  
and	  expressed	  as	  a	  percent	  of	  DAT	  (P=0.05;	  by	  Student’s	  t-­‐test;	  n=8–11).	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accumulation	  of	  DA.	  To	  determine	  whether	  DAT	  T356M	  exhibits	  ADE,	  cells	  were	  whole-­‐
cell	  patch	  clamped	  and	  perfused	  for	  10	  min	  with	  an	  internal	  solution	  containing	  2	  mM	  
DA	  [199].	  The	  electrode,	  in	  current	  clamp	  configuration,	  allows	  the	  cell	  to	  control	  its	  
membrane	  voltage.	  In	  addition,	  this	  technique	  ensures	  that	  cells	  expressing	  either	  DAT	  
or	  DAT	  T356M	  were	  equally	  loaded	  with	  DA.	  DA	  efflux	  was	  quantified	  via	  amperometry	  
[199].	  It	  has	  been	  previously	  shown	  that,	  in	  the	  presence	  of	  ADE,	  COC	  decreases	  the	  
amperometric	  signal	  through	  blockade	  of	  DAT	  [200].	  In	  DAT	  cells,	  amperometric	  
currents	  were	  unaffected	  by	  the	  application	  of	  COC	  (Figure	  5.3A,	  top	  right)	  indicating	  no	  
ADE.	  In	  contrast,	  amperometric	  signals	  from	  DAT	  T356M	  cells	  were	  significantly	  reduced	  
by	  the	  application	  of	  COC,	  revealing	  ADE	  (Figure	  5.3A,	  top	  left).	  DAT	  T356M-­‐expressing	  
cells	  displayed	  a	  significant	  increase	  in	  ADE	  compared	  with	  DAT-­‐transfected	  cells	  (Figure	  
5.3A,	  bottom).	  	  
Cell	  membrane	  depolarization	  has	  been	  shown	  to	  support	  DA	  efflux	  [265].	  Figure	  
5.3B	  reveals	  that	  there	  is	  not	  a	  significant	  difference	  in	  resting	  membrane	  potential	  
(measured	  in	  current	  clamp)	  between	  cells	  expressing	  DAT	  or	  DAT	  T356M.	  This	  indicates	  
that	  differences	  in	  the	  function	  of	  DAT	  and	  DAT	  T356M	  are	  not	  a	  result	  of	  resting	  
membrane	  potential.	  
To	  examine	  potential	  changes	  in	  AMPH	  to	  induce	  DA	  efflux,	  cells	  were	  patch	  
clamped	  and	  DA	  dopamine	  delivered	  into	  either	  wildtype	  DAT	  or	  DAT	  T356M	  expressing	  
cells	  while	  recording	  DA	  efflux	  with	  amperometry.	  AMPH	  dose-­‐response	  assays	  
(measuring	  the	  peak	  of	  the	  amperometric	  current	  at	  different	  AMPH	  concentrations)	  
revealed	  that	  DAT	  T356M	  and	  DAT	  cells	  have	  comparable	  AMPH	  EC50	  (EC50;	  DAT:	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Figure	  5.3:	  Human	  dopamine	  transporter	  (DAT)	  T356M	  exhibits	  robust	  ADE.	  (A)	  Top:	  
representative	  amperometric	  currents	  recorded	  from	  DAT	  and	  DAT	  T356M	  cells.	  Arrows	  
indicate	  application	  of	  10	  μM	  cocaine	  (COC).	  Bottom:	  quantitation	  of	  the	  COC-­‐induced	  
reduction	  in	  the	  amperometric	  current	  (ADE).	  Data	  are	  reported	  as	  maximal	  current	  
(***=P≤0.001	  by	  Student’s	  t-­‐test;	  n=4–5).	  (B)	  DAT	  T356M	  cells	  do	  not	  display	  altered	  
resting	  membrane	  potential	  with	  respect	  to	  DAT	  cells	  (P≥0.05	  by	  Student’s	  t-­‐test,	  n=9–
25).	  (C)	  Representative	  amphetamine	  (AMPH)-­‐induced	  amperometric	  currents	  recorded	  
from	  hDAT	  and	  DAT	  T356M	  cells.	  Arrows	  indicate	  application	  of	  10	  μM	  AMPH.	  Bottom:	  
quantitation	  of	  AMPH-­‐induced	  dopamine	  (DA)	  efflux.	  Data	  are	  represented	  as	  maximal	  
current	  expressed	  as	  percent	  of	  the	  current	  recorded	  in	  hDAT	  cells	  (**=P≤0.01	  by	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0.15±0.05	  μM;	  DAT	  T356M:	  0.16±0.07	  μM;	  n=4;	  p≥0.95	  by	  Student’s	  t-­‐test).	  Then,	  using	  
a	  saturating	  AMPH	  concentration	  (10	  μM),	  DA	  efflux	  was	  calculated	  in	  either	  DAT	  or	  DAT	  
T356M	  cells	  (Figure	  5.3C,	  top).	  AMPH-­‐induced	  DA	  efflux	  was	  significantly	  reduced	  in	  DAT	  
T356M	  cells	  compared	  with	  wildtype	  DAT	  cells	  (Figure	  5.3C,	  bottom).	  These	  results	  
strongly	  suggest	  that	  ADE	  does	  not	  share	  common	  mechanisms	  with	  AMPH-­‐induced	  DA	  
efflux.	  	  
	  
Substitution	  of	  LeuT	  Ala289Met	  promotes	  an	  outward	  facing	  conformation	  
	   To	  investigate	  the	  structural	  consequences	  of	  the	  T356M	  de	  novo	  mutation	  in	  a	  
DAT	  homolog	  with	  a	  known	  crystal	  structure,	  we	  analyzed	  changes	  in	  the	  
conformational	  cycle	  of	  the	  leucine	  transporter	  (LeuT).	  We	  substituted	  A289	  (the	  
homologous	  amino	  acid	  to	  T356)	  with	  a	  Met	  (LeuT	  A289M).	  We	  measured	  distances	  
between	  pairs	  of	  spin	  labels	  (r	  (Å))	  and	  the	  distance	  distribution	  (P(r),	  the	  probability	  of	  
a	  given	  distance	  between	  the	  two	  labels)	  monitoring	  the	  intra-­‐	  and	  extracellular	  gates	  
by	  double	  electron	  electron	  resonance	  [266].	  First,	  we	  examined	  the	  pair	  309/480	  
(Figure	  5.4A,	  left)	  that	  monitors	  the	  relative	  movement	  of	  the	  extracellular	  loop	  4	  in	  
LeuT.	  This	  loop	  obstructs	  the	  permeation	  pathway	  in	  the	  Apo	  conformation	  [266],	  as	  
indicated	  by	  the	  close	  proximity	  of	  the	  pair	  309/480	  (Figure	  5.4A,	  middle	  Apo	  black	  line).	  
Upon	  Na+	  binding,	  the	  distance	  between	  extracellular	  loop	  4	  and	  TM12	  increases	  [266],	  
indicating	  opening	  of	  the	  extracellular	  vestibule	  and	  enabling	  substrate	  access.	  
Subsequent	  Leu	  binding	  resets	  the	  closed	  extracellular	  loop	  4	  conformation	  in	  the	  
occluded	  conformation	  of	  the	  transporter	  (Na+	  and	  Leu	  bound	  in	  the	  vestibule)	  (Figure	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5.4A,	  right;	  +Na/L	  black	  line).	  The	  extracellular	  Apo	  site	  (Figure	  5.4A,	  middle;	  Apo;	  
compare	  red	  and	  black	  lines)	  as	  well	  as	  Na+-­‐bound	  state	  is	  similar	  in	  LeuT	  and	  LeuT	  
A289M.	  Yet,	  LeuT	  A289M	  with	  Na+	  and	  Leu	  bound	  in	  the	  vestibule	  has	  a	  destabilized	  
bound	  structure	  with	  fluctuations	  on	  the	  extracellular	  side	  (Figure	  5.4A,	  right;	  +Na/L;	  
compare	  red	  and	  black	  lines).	  The	  probability	  distribution	  in	  the	  Na/Leu-­‐bound	  state	  
contains	  distinct	  populations	  of	  conformations	  that	  indicate	  fluctuations	  of	  LeuT	  A289M	  
to	  a	  permeation	  pathway	  that	  has	  increased	  probability	  to	  be	  open	  to	  the	  outside,	  
relative	  to	  LeuT	  (Figure	  5.4A,	  right;	  red	  line,	  arrows).	  
We	  then	  examined	  the	  pair	  7/86	  (Figure	  5.4B,	  left)	  to	  determine	  the	  distance	  
between	  the	  N-­‐terminus	  and	  intracellular	  loop	  1	  (IL1)	  and	  to	  monitor	  fluctuation	  
dynamics	  on	  the	  intracellular	  side.	  This	  is	  necessary	  to	  describe	  changes	  in	  the	  
population	  of	  transporters	  with	  an	  inward-­‐facing	  conformation	  [266].	  In	  the	  LeuT	  
background,	  distance	  distributions	  between	  spin	  [267]	  or	  fluorescent	  probes	  [268]	  in	  
the	  Apo	  state	  are	  bimodal,	  reflecting	  the	  equilibrium	  of	  this	  intracellular	  gate	  between	  
closed	  and	  open	  conformations	  (Figure	  5.4B,	  middle;	  Apo;	  black	  lines).	  Introduction	  of	  
the	  A289M	  leads	  to	  a	  shift	  in	  the	  equilibrium	  to	  favor	  the	  closed	  conformation	  side	  
(Figure	  5.4B,	  middle;	  Apo;	  compare	  red	  and	  black	  lines,	  arrow).	  Na+	  binding	  does	  not	  
alter	  the	  equilibrium	  between	  the	  two	  conformations	  (data	  not	  shown),	  whereas	  Na.	  
and	  Leu	  binding	  resets	  this	  shift	  to	  LeuT-­‐like	  conformations	  (Figure	  5.4B,	  middle;	  +Na/L;	  
compare	  red	  and	  black	  lines).	  
	  
	  




Figure	  5.4:	  In	  leucine	  transporter	  (LeuT),	  substitution	  of	  Ala289	  with	  a	  Met	  supports	  an	  
outward-­‐open	  facing	  conformation.	  Distance	  distributions	  of	  extracellular	  and	  
intracellular	  spin	  labeled	  Cys	  pairs	  in	  LeuT	  reveal	  changes	  in	  the	  conformational	  
equilibrium	  caused	  by	  mutating	  Ala289	  to	  a	  Met.	  (A)	  Left:	  extracellular	  reporter	  pairs	  
(309–480)	  tagged	  on	  three-­‐dimensional	  structure	  of	  LeuT.	  Right:	  distance	  of	  the	  
extracellular	  reporter	  pair	  for	  LeuT	  (black)	  and	  A289M	  (red),	  in	  the	  Apo	  conformation	  
(Apo)	  and	  in	  the	  presence	  of	  Na+	  and	  Leu	  (+NaL).	  (B)	  Left:	  intracellular	  reporter	  pairs	  (7–
86)	  tagged	  on	  the	  three-­‐dimensional	  structure	  of	  LeuT.	  Right:	  distance	  of	  the	  
intracellular	  reporter	  pair	  for	  LeuT	  (black)	  and	  A289M	  (red),	  in	  the	  Apo	  conformation	  
(Apo)	  and	  in	  the	  presence	  of	  Na+	  and	  Leu	  (+NaL).	  The	  LeuT	  structure	  was	  obtained	  from	  
PDB	  2A65.	  The	  structures	  were	  generated	  using	  PyMOL.	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Our	  results	  demonstrate	  that,	  because	  of	  the	  A289M,	  the	  presence	  of	  substrate	  
and	  Na+	  fails	  to	  completely	  close	  the	  extracellular	  pathway	  as	  in	  LeuT,	  inducing	  
fluctuations	  on	  the	  extracellular	  side.	  These	  fluctuations	  to	  an	  open-­‐to-­‐the-­‐outside	  
permeation	  pathway	  persist,	  possibly	  enabling	  substrate	  release.	  This	  is	  in	  contrast	  to	  
LeuT,	  where	  substrate	  binding	  closes	  the	  extracellular	  permeation	  pathway.	  
	  
Drosophila	  expressing	  hDAT	  T356M	  in	  DA	  neurons	  are	  hyperactive	  
	   Locomotion	  is	  a	  fundamental	  behavior	  regulated	  across	  species	  by	  DA	  [269-­‐271]	  
therefore,	  locomotion	  in	  flies	  offers	  a	  powerful	  model	  for	  exposing	  a	  behavioral	  impact	  
of	  ADE	  associated	  with	  the	  DAT	  T356M.	  To	  use	  locomotion	  as	  a	  behavioral	  output,	  flies	  
expressing	  either	  hDAT	  or	  hDAT	  T356M	  in	  DA	  neurons	  were	  generated	  using	  a	  Gal4/UAS	  
system	  in	  a	  dDAT	  KO	  mutant	  background.	  To	  generate	  these	  transgenic	  flies,	  the	  
phiC31-­‐based	  integration	  was	  used,	  which	  promotes	  equivalent	  expression	  of	  mRNA	  
levels	  for	  the	  relevant	  transgenes.	  Locomotion	  was	  calculated	  by	  beam	  crossings	  over	  a	  
>24	  hr	  period	  and	  data	  binned	  in	  15	  min	  intervals	  during	  both	  the	  light	  and	  dark	  cycles.	  
Consistent	  with	  previous	  reports	  [259],	  dDAT	  KO	  flies	  in	  this	  study	  are	  hyperactive	  as	  
compared	  to	  flies	  expressing	  hDAT	  in	  DA	  neurons,	  validating	  the	  approach	  used	  (Figure	  
5.5A,	  compare	  hDAT	  with	  dDAT	  KO).	  Flies	  expressing	  hDAT	  T356M	  show	  a	  significant	  
increase	  in	  locomotion	  (Figure	  5.5A),	  predicted	  to	  be	  a	  consequence	  of	  increase	  
extracellular	  DA	  as	  a	  result	  of	  persistent	  ADE.	  Total	  activity	  of	  hDAT	  T356M	  and	  dDAT	  KO	  
flies	  are	  significantly	  higher	  than	  that	  of	  wildtype	  hDAT	  flies.	  This	  is	  illustrated	  in	  Figure	  
5.5B,	  which	  shows	  total	  locomotor	  activity	  over	  a	  24	  hr	  period	  across	  the	  different	  fly	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lines.	  
Since	  it	  was	  shown	  in	  Figure	  5.3	  that	  hDAT	  T356M	  cells	  display	  compromised	  
AMPH-­‐induced	  DA	  efflux,	  it	  was	  reasoned	  that	  a	  reduced	  increase	  in	  locomotion	  in	  
response	  to	  AMPH	  would	  be	  seen	  in	  flies	  expression	  hDAT	  T356M.	  To	  test	  this,	  changes	  
in	  locomotion	  were	  determined	  upon	  AMPH	  or	  vehicle	  exposure	  (15	  min)	  and	  calculated	  
as	  beam	  crosses.	  No	  significant	  increase	  in	  locomotion	  was	  seen	  in	  hDAT	  T356M	  flies	  
when	  exposed	  to	  AMPH	  as	  compared	  with	  vehicle	  control	  (hDAT	  T356M	  (vehicle)	  9.7	  ±	  
0.7	  beam	  breaks	  vs.	  hDAT	  T356M	  (AMPH)	  12.7	  ±	  1.6	  beam	  breaks;	  n	  =	  24,	  P	  ≥	  0.05).	  This	  
is	  in	  contrast	  to	  flies	  expressing	  hDAT,	  where	  AMPH	  induced	  a	  significant	  increase	  in	  
locomotion	  (hDAT	  (vehicle)	  6.2	  ±	  0.9	  beam	  breaks	  vs	  hDAT	  (AMPH)	  18.2	  ±	  1.0	  beam	  
breaks;	  n	  =	  24;	  P	  ≤	  0.001).	  In	  the	  dDAT	  KO	  flies,	  AMPH	  failed	  to	  provoke	  a	  significant	  
increase	  in	  locomotion,	  a	  result	  similar	  to	  that	  of	  hDAT	  T356M.	  
	  
Discussion	  
	   Alterations	  in	  DA	  tone	  underlie	  multiple	  neuropsychiatric	  disorders,	  including	  
bipolar	  disorder,	  schizophrenia	  and	  ADHD	  [234-­‐236].	  With	  respect	  to	  ADHD,	  altered	  DA	  
signaling,	  including	  changes	  in	  DAT	  function,	  may	  contribute	  to	  the	  cognitive	  and	  
hyperactive	  traits	  of	  the	  disorder	  [199,	  200]	  ASD,	  like	  ADHD,	  is	  phenotypically	  and	  
etiologically	  complex,	  with	  evidence	  residing,	  at	  least	  in	  part,	  to	  dopaminergic	  factors.	  
Genes	  harboring	  de	  novo	  events	  are	  highly	  meaningful	  to	  better	  our	  understanding	  the	  
etiology	  of	  ASD	  [124-­‐127].	  Therefore,	  the	  biological	  networks	  identified	  from	  these	  de	  
novo	  events,	  and	  the	  broader	  pathways	  they	  function	  within,	  are	  candidate	  risk	  factors	  	  






	   Figure	  5.5:	  Expression	  of	  human	  dopamine	  transporter	  (hDAT)	  T356M	  in	  
Drosophila	  leads	  to	  hyperactivity.	  hDAT	  or	  hDAT	  T356M	  was	  expressed	  in	  DA	  neurons	  
of	  dDAT	  KO	  flies.	  (a)	  Locomotor	  activity	  was	  assayed	  over	  32	  h	  during	  the	  light	  
(horizontal	  white	  bars)	  or	  dark	  (horizontal	  black	  bars)	  cycle.	  Flies	  expressing	  hDAT	  
T356M	  (red	  squares),	  as	  well	  as	  dDAT	  KO	  flies	  (blue	  squares),	  were	  hyperactive	  
throughout	  the	  32	  h	  period	  with	  respect	  to	  flies	  expressing	  wild-­‐type	  hDAT	  (black	  
squares)	  (n=32;	  beam	  breaks	  binned	  in	  15	  min	  intervals).	  (B)	  Quantitation	  of	  total	  beam	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for	  ASD.	  The	  motivation	  for	  the	  study	  presented	  here	  was	  to	  characterize	  the	  mutant	  
transporter	  using	  a	  diverse	  array	  of	  approaches.	  
The	  amperometric	  recordings	  demonstrate	  that	  the	  de	  novo	  DAT	  T356M	  
mutation	  confers	  COC	  sensitive	  ADE.	  It	  is	  intriguing	  to	  speculate	  that	  anomalous	  
transporter	  mediated	  neurotransmitter	  efflux	  may	  be	  an	  unappreciated	  source	  of	  risk	  
for	  mental	  illness,	  especially	  in	  disorders	  associated	  with	  altered	  DA	  signaling.	  It	  is	  
possible	  that	  ADE,	  driven	  by	  DAT	  variants	  or	  variants	  in	  other	  genes	  in	  the	  DAT	  
regulatory	  network,	  could	  impact	  risk	  for	  ASD.	  This	  point	  has	  been	  made	  in	  the	  context	  
of	  ADHD	  for	  the	  DAT	  A559V	  variant	  [199,	  200].	  
To	  address	  how	  the	  T356M	  de	  novo	  point	  mutation	  perturbs	  transporter	  
structure	  to	  trigger	  ADE,	  this	  study	  leveraged	  the	  DAT	  bacterial	  homolog,	  LeuT.	  As	  the	  
crystal	  structure	  of	  hDAT	  is	  unavailable,	  changes	  we	  analyzed	  in	  the	  conformational	  
cycle	  of	  LeuT.	  In	  LeuT	  A289M,	  we	  measured	  the	  distances	  between	  pairs	  of	  spin	  labels	  
monitoring	  the	  intra-­‐	  and	  extracellular	  gates	  by	  double	  electron	  electron	  resonance.	  In	  
contrast	  to	  LeuT,	  the	  spin	  labels	  monitoring	  the	  extracellular	  gate	  to	  LeuT	  A289M	  show	  
that	  the	  presence	  of	  Na+	  and	  leucine	  promotes	  a	  permeation	  pathway	  unoccluded	  to	  
the	  outside.	  By	  no	  means	  definitive,	  this	  study	  strongly	  suggests	  that	  the	  mechanism	  of	  
ADE	  for	  DAT	  T356M	  is	  distinct	  from	  that	  of	  DAT	  A559V,	  which	  is	  a	  result	  of	  a	  tonic	  
activation	  of	  DRD2	  and	  the	  downstream	  kinase	  CaMKII	  [126].	  One	  intriguing	  possibility	  is	  
that	  there	  may	  be	  multiple	  mechanistic	  routes	  to	  promote	  DAT-­‐mediated	  ADE,	  and	  ADE	  
might	  support	  a	  common	  convergent	  point	  in	  the	  shared	  etiology	  of	  ASD	  and	  ADHD.	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In	  vivo	  hDAT	  T356M	  may	  alter	  extracellular	  DA	  levels	  and,	  as	  a	  consequence,	  
increase	  locomotion	  [259].	  dDAT	  KO	  flies	  were	  engineered	  to	  selectively	  expressed	  
hDAT	  T356M	  specifically	  in	  DA	  neurons.	  Drosophila	  expressing	  hDAT	  T356M	  exhibited	  
prominent	  hyperactivity	  compared	  to	  Drosophila	  expressing	  hDAT.	  Lastly,	  AMPH	  has	  an	  
diminished	  ability	  to	  increase	  locomotion	  in	  hDAT	  T356M	  (and	  dDAT	  KO)	  flies,	  




The	  results	  presented	  in	  this	  chapter	  support	  the	  hypothesis	  that	  dysfunction	  of	  
DAT,	  a	  monoamine	  transporter,	  may	  influence	  ASD	  susceptibility.	  These	  results	  
encourage	  further	  genetic	  investigation	  of	  DAT,	  and	  proteins	  that	  exert	  influence	  on	  
DAT,	  as	  candidate	  ASD	  risk	  genes.	  By	  reporting	  the	  functional,	  structural	  and	  behavioral	  
consequences	  of	  the	  first	  identified	  de	  novo	  DAT	  variant	  associated	  with	  ASD	  the	  work	  
presented	  herein	  adds	  to	  the	  growing	  body	  of	  data	  implicating	  dopamine	  transporter	  
dysfunction,	  and	  more	  broadly	  dopamine	  dysfunction,	  in	  psychiatric	  illness.	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CHAPTER	  VI	  
	  
Whole	  exome	  sequencing	  reveals	  minimal	  differences	  between	  cell	  line	  and	  whole	  
blood	  derived	  DNA	  
	  
Introduction	  
The	  data	  presented	  in	  this	  chapter	  reflect	  a	  significant	  amount	  of	  method	  
validation	  and	  the	  results	  influenced	  much	  of	  the	  conclusions	  drawn	  from	  the	  manuscript	  
by	  Schafer	  et	  al.	  [272].	  
	   Next-­‐generation	  sequencing	  (NGS)	  has	  become	  an	  affordable	  tool	  to	  probe	  the	  
human	  genome	  for	  rare	  variants	  affecting	  risk	  for	  disease.	  Association	  analyses	  are	  
being	  applied	  to	  NGS	  data	  to	  discover	  loci	  with	  rare	  variants	  that	  affect	  the	  risk	  of	  a	  wide	  
spectrum	  of	  diseases.	  Nevertheless,	  it	  is	  becoming	  increasingly	  apparent	  that	  very	  large	  
sample	  sizes	  and	  widespread	  availability	  will	  be	  required	  to	  attain	  significant	  results	  in	  
many	  of	  these	  studies.	  To	  attain	  large	  samples,	  scientists	  would	  make	  use	  of	  large	  
collections	  of	  DNA	  from	  subjects	  with	  immortalized	  lymphoblastoid	  cell	  lines	  (LCLs)	  in	  
repositories	  such	  as	  the	  NIMH	  Center	  for	  Collaborative	  Genomic	  Disorders	  on	  Mental	  
Disorders	  (hereafter	  the	  “NIMH	  Repository”)	  at	  the	  Rutgers	  Cell	  and	  DNA	  Repository	  
(RUCDR).	  However,	  due	  to	  reports	  of	  large	  numbers	  (20	  per	  exome)	  of	  non-­‐germline	  
mutations	  in	  LCLs	  [273],	  concerns	  now	  exist	  about	  the	  use	  of	  LCL-­‐derived	  DNA	  for	  
sequencing	  studies.	  The	  concern	  is	  well	  founded,	  because	  immortalization	  involves	  
transformation	  of	  lymphocytes	  with	  cytomegalovirus	  (CMV)	  and	  this,	  combined	  with	  
extensive	  serial	  passaging	  of	  cells,	  could	  lead	  to	  DNA	  sequence	  changes.	  Ultimately,	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mutation	  underlies	  all	  heritable	  genetic	  variation	  but	  it	  has	  recently	  become	  apparent	  
that	  mutations	  that	  have	  arising	  de	  novo	  can	  be	  highly	  informative	  in	  identifying	  genetic	  
risk	  factors	  for	  disorders	  such	  as	  autism	  and	  schizophrenia	  [124-­‐127,	  274,	  275].	  Non-­‐
germline	  mutations	  (and	  potential	  artifacts)	  are	  particularly	  troubling	  in	  this	  setting,	  
thus	  motivating	  a	  careful	  investigation	  of	  the	  quality	  of	  LCLs	  as	  a	  basis	  for	  such	  studies.	  
	   The	  work	  presented	  in	  this	  chapter,	  sought	  to	  empirically	  test	  the	  degree	  to	  
which	  mutations	  that	  arise	  in	  LCLs	  might	  impact	  results	  from	  WES	  studies.	  Therefore,	  
WES	  on	  paired	  DNA	  samples	  derived	  from	  whole	  blood	  (WB)	  and	  LCL	  of	  low	  passage	  
number	  for	  16	  subjects	  were	  compared.	  Cell	  lines	  were	  obtained	  from	  the	  NIMH	  
Repository	  at	  RUCDR	  or	  from	  the	  Icahn	  School	  of	  Medicine	  at	  Mount	  Sinai.	  Specifically,	  
LCLs	  had	  been	  cultured	  through	  a	  maximum	  of	  four	  passages,	  in	  which	  a	  relatively	  small	  
number	  of	  cells	  seed	  a	  new	  culture	  to	  greatly	  expand	  the	  cell	  populations.	  These	  cell	  
populations	  are	  used	  for	  DNA	  isolation	  or	  cryopreservation	  of	  multiple	  new	  culture	  
aliquots.	  This	  chapter	  presents	  1)	  initial	  detection	  of	  genotype	  calls	  discordant	  between	  
paired	  WB	  and	  LCL	  samples;	  2)	  a	  novel	  filtering	  and	  prioritization	  algorithm	  that	  
effectively	  assigns	  putative	  differences	  into	  categories	  of	  “confidence”	  as	  demonstrated	  
by	  subsequent	  validation	  experiments;	  3)	  that	  the	  vast	  majority	  of	  called	  WB/LCL	  
differences	  are	  false	  positives	  and	  that	  those	  that	  do	  validate	  reflect	  DNA	  mutations	  
that	  arose	  in	  the	  cell	  line;	  4)	  in	  nearly	  all	  cases	  true	  positives	  appear	  as	  low	  level	  mosaic	  
non-­‐reference	  alleles;	  and	  finally	  5)	  only	  3-­‐4	  valid	  sequence	  differences	  per	  subject	  exist.	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Methods	  
Validation	  of	  selected	  candidates	  
	   Validation	  of	  the	  selected	  variant	  calls	  was	  carried	  out	  using	  standard	  Sanger	  
dye-­‐terminator	  sequencing	  of	  amplimers	  for	  regions	  containing	  putative	  WB/LCL	  
sequence	  differences.	  Primers	  were	  designed	  using	  Primer	  3	  software	  and	  subjected	  to	  
a	  BLAST-­‐like	  alignment	  tool	  to	  ensure	  amplification	  specificity.	  PCR	  products	  were	  
amplified	  from	  ~20	  ng	  DNA	  using	  AmpliTaq	  Gold	  PCR	  MasterMix	  (Life	  Technologies;	  
Carlsbad,	  CA)	  with	  individually	  optimized	  PCR	  conditions	  in	  a	  total	  volume	  of	  20	  μl.	  
Genomic	  and	  LCL	  DNA	  from	  the	  same	  subject	  were	  amplified	  simultaneously.	  Amplified	  
DNA	  fragments	  were	  then	  purified	  using	  Multiscreen	  PCR	  filtration	  plates	  (Millipore;	  
Billerica,	  MA)	  and	  yields	  were	  determined	  using	  a	  NanoDrop	  spectrophotomer	  ND-­‐1000.	  
Sequencing	  reactions	  were	  carried	  out	  using	  the	  BigDye	  Terminator	  v3.1	  Cycle	  
Sequencing	  Kit,	  and	  reactions	  were	  subjected	  to	  analysis	  on	  an	  ABI	  3730xl	  DNA	  analyzer.	  
Sequence	  electropherogram	  data	  were	  viewed	  to	  examine	  sites	  of	  putative	  difference	  
using	  the	  computer	  software	  Sequencer	  v5.0.1	  (GeneCodes;	  Ann	  Arbor,	  MI).	  
	   All	  variants	  in	  Groups	  0,	  1,	  and	  2	  were	  sequenced.	  In	  addition	  validation	  of	  a	  
subset	  of	  Group	  3	  were	  conducted.	  Instead	  of	  validating	  a	  random	  subset	  of	  Group	  3,	  
results	  from	  the	  first	  three	  groups	  were	  exploited	  to	  determine	  what,	  if	  any,	  features	  of	  
the	  candidates	  increased	  their	  chances	  of	  being	  real	  mismatches.	  It	  was	  determined	  that	  
among	  the	  confirmed	  mismatches,	  almost	  all	  shared	  two	  characteristics:	  first,	  the	  
proportion	  of	  the	  WB	  DNA	  calls	  that	  corresponded	  to	  the	  reference	  allele	  was	  either	  
very	  close	  to	  zero	  or	  very	  close	  to	  one.	  Second,	  the	  cell	  line	  reads	  for	  both	  alleles	  were	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well	  represented	  on	  both	  the	  forward	  and	  reverse	  strands.	  Hence,	  a	  filter	  was	  applied	  
that	  labeled	  a	  candidate	  as	  “strong”	  if	  (1)	  the	  homozygous	  call	  the	  proportion	  of	  reads	  
for	  the	  reference	  allele	  was	  either	  larger	  than	  0.97	  or	  smaller	  than	  0.03	  and	  (2)	  the	  
proportion	  of	  reads	  in	  a	  single	  direction	  did	  not	  exceed	  0.95	  for	  either	  allele	  present	  in	  
the	  cell	  line.	  The	  remaining	  candidates	  were	  labeled	  “weak.”	  Group	  3	  validation	  was	  
therefore	  pursued	  chiefly	  for	  “strong”	  candidates.	  	  
	  
Results	  
Segregation	  of	  the	  candidate	  disagreements	  between	  the	  16	  WB	  and	  LCL	  pairs	  	  
In	  total	  15,099	  call	  pairs	  were	  candidates	  for	  disagreement	  between	  the	  WB	  and	  
LCL	  pairs.	  Filtering	  of	  the	  15,099	  candidates	  resulted	  in	  864	  candidate	  differences.	  These	  
864	  candidates	  were	  segregated	  into	  four	  groups	  of	  “confidence”	  based	  on	  inspection	  of	  
read	  quality,	  evidence	  for	  strand	  bias,	  and	  the	  relative	  balance	  of	  reference/alternative	  
calls,	  and	  also	  by	  whether	  the	  heterozygote	  fell	  in	  blood	  or	  cell	  line.	  The	  candidates	  in	  
each	  of	  Group	  0,	  1,	  and	  2	  are	  shown	  in	  Appendix	  C.	  Overall	  44%	  of	  the	  entries	  in	  Table	  
6.1	  declare	  blood	  heterozygous	  and	  cell	  homozygous,	  it	  is	  notable	  that	  only	  19%	  of	  the	  
confident	  differences	  (levels	  0-­‐2)	  differ	  in	  this	  direction.	  	  
	  
Validation	  of	  selected	  candidates	  
	   For	  Group	  0,	  all	  ten	  of	  the	  candidates	  for	  blood/cell	  line	  differences	  were	  
confirmed	  to	  be	  mismatches	  by	  follow-­‐up	  Sanger	  sequencing	  (see	  Table	  6.1),	  which	  
revealed	  small	  amplitude	  non-­‐reference	  peaks	  on	  both	  forward	  and	  reverse	  strands.	  For	  	  






Table	  6.1	  Summary	  of	  validation	  results	  for	  candidate	  mismatches	  sorted	  by	  decreasing	  level	  of	  confidence	  
Group	  
Total	  	  	  
count	   Valid	  attempt	  
Valid	  	  	  	  	  	  
success	  
Confirmed	  
mismatch	   Confirmed	  rate	  
Blood	  
heterozygous	   Ti/Tv	  ratio	  
0	   10	   10	   10	   10	   100%	   0	   4.00	  
1	   28	   28	   26	   18	   695	   2	   2.11	  
2	   107	   107	   104	   15	   14%	   26	   0.91	  
3	  "Strong"	   34	   24	   13	   3	  
1.1%a	   352	   0.47	  
	  	  	  "Weak"	   685	   9	   9	   0	  
a	  Percent	  is	  estimated	  based	  on	  a	  weighted	  average	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Groups	  1	  and	  2,	  however,	  the	  percentage	  validated	  was	  69%	  and	  14%	  respectively.	  
There	  are	  a	  handful	  of	  instances	  for	  which	  the	  validation	  was	  unsuccessful	  due	  to	  
sequencing	  problems;	  these	  are	  excluded	  from	  the	  count	  in	  “Validations	  Successful”	  
column.	  
The	  results	  from	  the	  validation	  of	  Group	  3	  candidates	  are	  also	  shown	  in	  Table	  
6.1,	  divided	  into	  “strong”	  and	  “weak”	  candidates,	  as	  described	  in	  the	  methods	  of	  
Schafer	  et	  al.	  [272].	  Taking	  a	  weighed	  average	  of	  the	  two	  subgroups,	  the	  estimated	  rate	  
of	  mismatch	  in	  Group	  3	  is	  1.1%.	  Assessing	  the	  Ti/Tv	  ratio	  of	  all	  candidates	  in	  each	  of	  the	  
groups,	  there	  is	  a	  clear	  decreasing	  trend	  as	  quality	  decreases.	  Among	  all	  confirmed	  
mismatches,	  the	  Ti/Tv	  ratio	  is	  3.18.	  
	   For	  each	  candidate	  validated	  we	  determined	  that	  WB	  was	  actually	  homozygous,	  
or	  LCL	  was	  heterozygous	  leading	  to	  concordant	  calls.	  This	  supports	  our	  conjecture	  that	  
in	  the	  process	  of	  creating	  LCL	  from	  WB,	  errors	  are	  much	  more	  likely	  to	  result	  in	  
homozygous	  loci	  becoming	  heterozygous.	  
	  
Inferences	  
	   A	  notable	  feature	  of	  the	  validation	  results	  is	  that	  in	  those	  cases	  for	  which	  a	  
blood/cell	  line	  disagreement	  was	  confirmed,	  the	  locus	  was	  homozygous	  for	  the	  allele	  on	  
blood,	  but	  then,	  with	  only	  one	  possible	  exception,	  displayed	  the	  characteristics	  of	  
mosaicism	  within	  the	  cell	  line.	  The	  mosaic	  nature	  of	  these	  loci	  is	  evident	  not	  only	  in	  the	  
results	  of	  the	  targeted	  validation	  via	  Sanger	  sequencing,	  but	  also	  in	  the	  original	  WES	  
results.	  For	  example,	  consider	  one	  of	  the	  candidates	  in	  Group	  2	  (Individual	  4,	  on	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chromosome	  10	  at	  position	  103772671).	  In	  a	  pileup	  diagram	  showing	  the	  individual	  NGS	  
reads	  as	  horizontal	  lines	  (Figure	  6.1),	  all	  but	  one	  of	  the	  reads	  in	  the	  blood	  sample	  were	  
for	  T,	  the	  reference	  allele;	  yet	  the	  cell	  line	  sample,	  a	  majority	  (62	  of	  73)	  of	  the	  reads	  
were	  for	  T,	  but	  a	  quarter	  returned	  C.	  This	  is	  far	  from	  the	  50/50	  split	  one	  would	  expect	  if	  
the	  site	  were	  homozygous.	  Sanger	  sequencing	  results	  were	  consistent	  in	  that	  the	  
electropherogram	  (Figure	  6.2)	  reveals	  a	  peak	  for	  both	  T	  and	  C	  for	  the	  cell	  line	  sample.	  
This	  example	  of	  relative	  over-­‐representation	  of	  the	  reference	  allele	  is	  consistent	  with	  
virtually	  all	  of	  the	  other	  instances	  of	  validated	  blood/cell	  line	  disagreements.	  The	  
exception	  is	  a	  single	  candidate	  for	  what	  the	  Sanger	  trace	  is	  balanced	  in	  one	  direction	  
and	  unbalanced	  in	  the	  other	  direction.	  
In	  addition	  there	  were	  no	  confirmed	  mismatches	  among	  the	  candidates	  for	  
which	  blood	  was	  called	  heterozygous	  and	  cell	  line	  called	  homozygous.	  Hence,	  the	  
overall	  mismatch	  rate	  per	  person	  is	  also	  our	  estimate	  of	  the	  overall	  rate	  of	  mosaics	  per	  
person.	  This	  estimate	  can	  be	  obtained	  by	  taking	  a	  weighted	  average	  of	  the	  rate	  within	  
each	  group	  with	  weight	  calculated	  using	  the	  proportion	  of	  the	  candidates	  within	  that	  
group	  (Table	  6.1).	  Hence,	  the	  probability	  of	  a	  randomly	  chosen	  candidate	  being	  a	  mosaic	  
is	  approximately	  6.1%.	  	  
The	  estimated	  number	  of	  mosaics	  per	  individual	  is	  0.0609	  x	  864/16	  =	  3.29.	  This	  
estimate	  is	  predicated	  on	  the	  assumption	  that	  loci	  that	  were	  filtered	  in	  the	  initial	  steps	  
of	  the	  processing	  consist	  entirely	  of	  mismatches	  that	  can	  be	  attributed	  to	  variant	  caller	  
errors	  and	  poor	  quality	  reads.	  (Recall	  that	  the	  list	  of	  864	  candidates	  was	  culled	  form	  the	  
initial	  set	  of	  15,099	  blood/cell	  line	  differences).	  It	  is	  natural	  to	  assume	  of	  the	  14,235	  loci	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that	  were	  excluded	  from	  the	  focused	  read-­‐level	  analysis	  as	  forming	  a	  fifth	  group,	  “Group	  
4”,	  whose	  
	  
Figure	  6.1:	  Pileup	  diagram	  from	  the	  sequencing	  results	  of	  Individual	  4,	  on	  
chromosome	  10	  at	  position	  103772671,	  a	  confirmed	  mosaic.	  Note	  that	  although	  there	  
is	  a	  large	  number	  of	  reads	  for	  the	  alternative	  allele	  on	  the	  cell	  line,	  the	  proportion	  of	  
such	  reads	  is	  much	  less	  than	  one	  half	  of	  all	  the	  reads.	  The	  dashed	  line	  under	  “Blood	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Alternative”	  represents	  a	  read	  that	  did	  not	  match	  either	  the	  reference	  or	  alternative	  
allele	  for	  this	  site.	  The	  dashed	  line	  under	  “Cell	  Line	  Alternative”	  represents	  reads	  that	  







Figure	  6.2:	  Results	  from	  Sanger	  sequencing	  of	  a	  confirmed	  mosaic.	  Sequence	  trace	  is	  
from	  Individual	  4,	  on	  chromosome	  10	  at	  position	  103772671,	  as	  were	  the	  results	  from	  
Figure	  6.1.	  Note	  the	  additional	  peak	  in	  the	  chromatogram	  on	  the	  right.	  This	  result	  
confirmed	  that	  this	  site	  was	  a	  mosaic	  as	  suggested	  in	  Figure	  6.1.	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quality	  metrics	  are	  even	  worse	  than	  the	  weak	  candidates	  in	  Group	  3,	  and	  that	  among	  
this	  group,	  a	  very	  small	  percentage	  would	  be	  true	  blood/cell	  line	  mismatches.	  
	  
Discussion	  
	   To	  identify	  mutations	  in	  LCLs,	  results	  from	  WES	  of	  DNA	  from	  both	  whole	  blood	  
and	  LCLs	  for	  16	  subjects	  were	  analyzed.	  All	  LCLs	  were	  at	  low	  passage	  (<5)	  and,	  
therefore,	  the	  samples	  are	  much	  more	  likely	  to	  be	  representative	  of	  those	  in	  widely	  
accessed	  public	  repositories.	  After	  filtering,	  864	  discordant	  genotype	  calls	  between	  
blood	  and	  LCL	  samples	  (approximately	  50/subject)	  were	  selected.	  These	  candidates	  
were	  further	  prioritized	  based	  on	  read	  depth,	  base-­‐call,	  mapping	  quality	  and	  read	  
directions.	  This	  permitted	  segregation	  of	  candidate	  WB/LCL	  differences	  into	  four	  
categories	  of	  decreasing	  “confidence.”	  Sanger	  sequencing	  to	  evaluate	  each	  candidate	  
variant	  in	  the	  top	  3	  confidence	  levels	  (N=145	  variants)	  as	  well	  as	  some	  of	  the	  lower	  level	  
candidates	  was	  preformed.	  The	  results	  of	  this	  validation	  study	  yielded	  few	  observations	  
of	  confirmed	  WB/LCL	  differences,	  and	  in	  virtually	  every	  instance	  the	  difference	  
manifested	  as	  low-­‐level	  mosaicism	  in	  the	  LCL.	  Aside	  from	  these	  apparently	  mosaic	  loci,	  
there	  was	  only	  one	  instance	  of	  a	  sequencing	  variant	  arising	  in	  the	  cell	  line	  and	  showing	  
approximately	  equal	  allelic	  representation.	  The	  evidence	  for	  mosaicism	  was	  present	  not	  
only	  in	  the	  Sanger	  sequencing,	  but	  also	  in	  the	  WES	  results.	  Hence,	  most	  of	  the	  864	  
candidate	  differences	  were	  false	  positives	  and	  the	  remainder	  had	  characteristics	  that	  
would	  cause	  them	  to	  be	  filtered	  by	  standard	  variant	  calling	  procedures.	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   There	  are	  two	  possible	  sources	  for	  the	  mosaicism.	  First	  there	  is	  a	  possibility	  that	  
mutations	  accumulate	  in	  the	  cell	  lines	  during	  transformation	  and	  subsequent	  serial	  
passaging.	  Second,	  lymphocytes	  represent	  a	  mixture	  of	  different	  cells	  that	  have	  been	  
undergoing	  genomic	  changes	  from	  the	  clonal	  progeny	  they	  are	  derived.	  Any	  of	  these	  
clones	  may	  have	  a	  point	  mutation	  that	  could	  be	  amplified	  during	  subsequent	  culturing.	  
In	  either	  case,	  low	  passage	  of	  the	  LCLs	  and	  the	  careful	  analysis	  of	  sequencing	  traces	  for	  
mosaicism	  would	  help	  identify	  such	  instances.	  
	   Although	  we	  have	  not	  tested	  higher	  passage	  LCLs,	  our	  results	  do	  point	  towards	  
an	  elevated	  risk	  of	  using	  such	  samples.	  We	  identified	  46	  mosaic	  LCL	  mutations	  in	  the	  
exomes	  of	  16	  subjects	  and	  predict	  fewer	  than	  ten	  remain	  in	  the	  unvalidated	  sample	  
suggesting	  a	  rate	  of	  3.3	  per	  person	  per	  exome.	  Prior	  studies	  predict	  a	  rate	  of	  1	  germline	  
mutation	  per	  exome	  per	  person.	  Our	  estimate	  of	  3.3:1	  non-­‐germline	  to	  germline	  de	  
novo	  mutation	  compares	  well	  with	  a	  prior	  estimate	  of	  1:1	  and	  differs	  sharply	  from	  the	  
estimate	  20:1	  reported	  from	  HapMap	  Samples	  [273].	  As	  noted,	  a	  difference	  in	  mutation	  
rate	  could	  be	  caused	  by	  number	  of	  passages	  of	  the	  cell	  line	  as	  well	  as	  other	  factors,	  
including	  external	  factors	  affecting	  mutation	  rate.	  The	  reduced	  and	  tractable	  number	  of	  
mutations	  we	  observed	  likely	  reflects	  the	  focus	  on	  lower	  passage	  cells.	  
	   In	  earlier	  research,	  the	  suitability	  of	  LCL	  for	  use	  in	  genetic	  studies	  was	  evaluated	  
in	  the	  context	  of	  SNP	  arrays	  [276].	  To	  test	  for	  genotypic	  errors	  potentially	  induced	  by	  
the	  Epstein-­‐Barr	  virus	  transformation	  process,	  this	  study	  compared	  SNP	  genotype	  calls	  
in	  WB	  vs.	  LCLC	  from	  the	  same	  individual	  using	  cells	  that	  were	  not	  passaged	  after	  
immortalization.	  Genotypic	  discrepancies	  found	  in	  the	  matched	  WB	  and	  LCL	  pairs	  were	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not	  notable	  relative	  to	  differences	  observed	  among	  control	  pairs,	  suggesting	  that	  most	  
genotypic	  discrepancies	  were	  due	  to	  technical	  artifacts	  rather	  than	  the	  transformation	  
process.	  Prior	  studies	  also	  supported	  the	  conclusion	  that	  LCL	  have	  a	  minor	  effect	  on	  
genomic	  structural	  variation	  [277-­‐279].	  Even	  in	  the	  HapMap	  samples,	  putative	  LCL-­‐
specific	  genomic	  errors	  accounted	  for	  less	  that	  0.5%	  of	  observed	  deletions	  [277].	  
The	  results	  of	  this	  work	  could	  be	  used	  to	  identify	  mosaic	  loci	  in	  studies	  that	  make	  
use	  of	  LCL	  DNA.	  In	  particular,	  the	  evidence	  for	  mosaicism	  is	  most	  clearly	  defined	  by	  
significant	  imbalance	  in	  the	  Sanger	  sequence	  trace	  showing	  the	  reference	  and	  variant	  
allele,	  but	  it	  is	  also	  frequently	  apparent	  in	  WES	  statistics.	  Even	  without	  further	  filtering,	  
the	  number	  of	  mosaics	  is	  sufficiently	  modest	  such	  that	  LCL-­‐derived	  DNA	  is	  appropriate	  
for	  gene	  discovery	  using	  case-­‐control	  analyses	  of	  rare	  variants.	  If	  the	  mosaic	  loci	  were	  
called	  as	  variant	  alleles,	  there	  would	  be	  minimal	  loss	  of	  power	  in	  gene	  discovery	  studies	  
in	  complex	  genetics,	  because	  many	  samples	  are	  used	  and	  multiple	  independent	  hits	  are	  
required	  for	  statistical	  evidence	  of	  association.	  For	  analyses	  of	  de	  novo	  variants	  in	  
families,	  the	  statistics	  are	  more	  sensitive	  to	  errors.	  Nevertheless,	  multiple	  hits	  in	  the	  
same	  gene	  are	  required	  for	  implicating	  a	  novel	  gene	  as	  one	  affecting	  risk	  [126],	  
providing	  some	  measure	  of	  protection	  against	  false	  discoveries.	  Moreover,	  it	  is	  standard	  
practice	  to	  validate	  de	  novo	  calls	  and	  this	  would	  typically	  identify	  mosaics.	  Important	  
findings	  can	  be	  further	  validated	  in	  blood	  samples,	  when	  available,	  as	  well	  as	  
independent	  samples.	  If	  validation	  in	  blood	  is	  not	  feasible,	  observations	  derived	  from	  
individuals	  with	  numerous	  de	  novo	  mutations	  could	  be	  down	  weighted	  in	  analysis.	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Summary	  
In	  summary,	  the	  results	  in	  this	  chapter	  strongly	  support	  the	  use	  of	  LCL-­‐derived	  
DNA	  for	  high-­‐throughput	  sequencing	  in	  research,	  provided	  the	  cell	  lines	  have	  not	  been	  
subject	  to	  extended	  serial	  passages.	  This	  work	  demonstrates	  DNA	  derived	  from	  low	  
passage	  number	  LCL	  samples	  are	  appropriate	  for	  use	  in	  WES	  studies,	  and	  in	  turn	  
validates	  many	  of	  the	  NGS	  studies	  where	  DNA	  derived	  from	  low	  passage	  number	  LCLs	  
were	  used.	  This	  work	  also	  highlights	  the	  utility	  for	  rigorous	  filtering	  algorithms	  when	  
handling	  and	  discriminating	  variants	  most	  likely	  to	  later	  validate	  from	  NGS	  raw	  reads.	  	  	  
	  
	  
	   	  





	   Interdisciplinary	  by	  design,	  this	  thesis	  sought	  to	  use	  genetics	  as	  a	  tool	  to	  gain	  
insight	  into	  the	  biological	  complexity	  of	  autism	  spectrum	  disorder	  (ASD),	  through	  the	  
lens	  of	  monoamine	  transporter	  dysfunction.	  In	  order	  to	  achieve	  my	  thesis	  goals,	  two	  
independent	  aims	  were	  addressed	  in	  this	  thesis.	  In	  conclusion,	  the	  results	  are	  highly	  
supportive	  that	  both	  a	  genetic	  and	  functional	  liability	  exists	  within	  the	  broad	  context	  of	  
monoamine	  dysfunction	  and	  ASD.	  The	  results	  of	  this	  work	  add	  to	  the	  growing	  literature	  
of	  monoamine	  dysfunction	  in	  psychiatric	  disease,	  specifically	  ASD.	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APPENDIX	  
A.	  Autism	  phenotypic	  profile	  of	  rare	  variants	  in	  the	  ADORA3	  gene	  
	  
	   Leu90Val	  
	  
Val171Ile	  
	  NIMH	  Sample	  ID1	   165-­‐3551-­‐0001	   2103_256200
*	   60-­‐1072-­‐008	   218-­‐20036-­‐1233001	  
	   165-­‐3583-­‐
001	   2220_1
*	   60-­‐1001-­‐001	   72-­‐0899-­‐03	   72-­‐0907-­‐302	  
	  
Discovery	  vs.	  Replication	   D	   D	   D	   R	   	   D	   D	   D	   R	   R	  
Gender	   M	   M	   M	   M	   	   M	   M	   M	   M	   M	  
Ancestry2	   AA	   EUR	   AA	   EUR	   	   EUR	   EUR	   EUR	   EUR	   EUR	  
ASD	  diagnostic	  Classification3	   Strict	   ASD	   Strict	   Strict	   	   Strict	   Strict	   ASD	   Strict	   Strict	  
ADI-­‐R	   	  	   	  	   	  	   	  	   	   	  	   	  	   	  	   	  	   	  	  
Age	  ADI-­‐R	  (mo)	   45	   36	   139	   65	   	   66	   48	   113	   118	   98	  
Social	  domain	   18	   24	   29	   25	   	   13	   11	   9	   20	   14	  
Communication	  domain	  
verbal/non	  verbal	  	   16	  (v)	   10	  	   16	  (v)	   10	   	   15	  (v)	   13	  (v)	   16	  (v)	   19	  (v)	   9	  (v)	  
Restricted,	  repetitive	  behavior	  
domain	   5	   6	   4	   6	   	   10	   5	   10	   3	   5	  
Abnormality	  of	  Development	   5	   2	   4	   5	   	   3	   5	   4	   3	   3	  
	  
	  
1Samples	  labeled	  with	  an	  asterisk	  (*)	  are	  not	  in	  the	  NIMH	  Repository	  and	  Autism	  Genome	  Project	  (AGP)	  IDs	  are	  provided	  
2Ancestry	  based	  on	  eigenvector	  analyses	  determined	  to	  be	  European	  (EUR)	  or	  African-­‐American	  (AA)	  
3Autism	  corresponds	  to	  an	  AGP	  classification	  of	  “strict”	  or	  “narrow”	  autism;	  ASD	  corresponds	  to	  an	  AGP	  “spectrum”	  classification	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2403	   74-­‐0580-­‐03	   215-­‐13003-­‐43	  
Discovery	  vs.	  Replication	   R	   R	   R	   R	   R	   R	  
Gender	   M	   F	   M	   M	   M	   M	  
Ancestry2	   EUR	   EUR	   EUR	   EUR	   EUR	   EUR	  
ASD	  diagnostic	  Classification3	   Strict	   Strict	   Strict	   Strict	   Strict	   Strict	  
ADI-­‐R	   	  	   	  	   	  	   	  	   	  	   	  	  
Age	  ADI-­‐R	  (mo)	   62	   70	   67	   157	   185	   71	  
Social	  domain	   25	   24	   18	   26	   29	   20	  
Communication	  domain	  
verbal/non	  verbal	  	   10	  (nv)	   20	  (v)	   8	  (nv)	  	   21	  (v)	   16	  (v)	   18	  (v)	  
Restricted,	  repetitive	  behavior	  
domain	   3	   6	   3	   8	   11	   8	  
Abnormality	  of	  Development	   3	   2	   3	   3	   3	   3	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B.	  Clinical	  history	  on	  the	  nuclear	  family	  of	  T356M	  SLC6A3	  proband	  
	  	  
Clinical	  Information:	  Proband	  (male)	  is	  the	  eldest	  of	  two	  children	  and	  heterozygous	  for	  
the	  SLC6A3	  de	  novo	  Thr356Met	  mutation	  described	  in	  Chapter	  5.	  
	  
Patient	  ID:	  AC04-­‐0029-­‐01	  (proband)	  
At	   the	   time	   of	   testing,	   patient	   was	   a	   66-­‐69-­‐month-­‐old	   non-­‐Hispanic	   male	   Caucasian	  
diagnosed	   with	   autism	   (on	   both	   ADOS	   and	   ADIR).	   Maternal	   interview	   on	   pregnancy	  
provided	   the	   following	   details:	   Mother	   experienced	   anemia	   during	   pregnancy	  
(gestational	  age	  =	  39	  weeks).	   Labor	  was	   induced	   (use	  of	  Pitocin)	  because	  of	   failure	   to	  
progress	  (Note:	  no	  C-­‐section	  was	  done).	  Child	  was	  born	  8	  lbs	  6	  oz	  (134	  ounces),	  with	  no	  
other	  delivery	  issues.	  	  
	  
Subset	   and	   composite	   scores	   on	   the	   Wechsler	   Preschool	   and	   Primary	   Scale	   of	  
Intelligence	  (WPPSI)	  indicate	  normal	  intelligence.	  Full	  Scale	  IQ	  was	  Average	  (94),	  and	  the	  
subsets	  of	  Verbal-­‐IQ	  and	  Performance-­‐IQ	  was	  scored	  as	  Average	  (101)	  and	  Low	  Average	  
(86)	  respectively,	  indicating	  normal	  intelligence.	  	  
	  
ADIR	  revealed	  deficits	  across	  all	  four	  subsets:	  (1)	  Reciprocal	  Social	  Interaction	  (score=13;	  
cutoff=10);	   (2)	   Abnormalities	   in	   Communication	   (score=13;	   cutoff=8);	   (3)	   Restricted,	  
Repetitive	  and	  Stereotyped	  Patterns	  of	  Behavior	   (score=4;	   cutoff=3);	   (4)	  Development	  
Evident	  at	  or	  before	  36	  Months	  (score=1;	  cutoff=1).	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Patient	   experienced	   a	   delay	   in	   speech	   requiring	   therapy.	   No	   history	   of	   seizures,	  
gastrointestinal	   conditions,	   sleep	   deficits,	   and	   no	   diet	   restrictions.	   Currently	   taking	  
multivitamins,	   with	   no	   use	   of	   other	   medications	   (besides	   amoxicillin,	   Tylenol,	   and	  
Benadryl).	  	  
	  
No	   family	   history	   for	   psychiatric	   illness	   requiring	   hospitalization.	   Known	   history	   of	  
Asperger’s	  Disorder	  (Mother’s	  cousin’s	  son),	  and	  depression	  (Father’s	  paternal	  uncle).	  
	  
Patient	  ID:	  AC04-­‐0029-­‐02	  (father)	  
Father	   is	   an	   adult	   non-­‐Hispanic	   Caucasian	  male.	   Age	   at	   conception	   of	   proband	   is	   36.	  
Slightly	   above	   normative	   range	   of	   intelligence	   (IQ=118;	   Wechsler	   Adult	   Intelligence	  
Scale).	   No	   presence	   of	   broader	   autism	   phenotype,	   and	   no	   psychiatric	  medication	   use	  
current	  or	  past.	  No	  co-­‐morbid	  diagnoses.	  He	  holds	  a	  postgraduate	  degree	  and	  reports	  
an	  annual	  household	  income	  of	  $81-­‐101k.	  	  
	  
Patient	  ID:	  AC04-­‐0029-­‐03	  (mother)	  
Mother	  is	  an	  adult	  non-­‐Hispanic	  Caucasian	  female.	  Age	  at	  conception	  of	  proband	  is	  32.	  
Above	  normative	   range	  of	   intelligence	   (IQ=131;	  Wechsler	  Adult	   Intelligence	  Scale);	  no	  
presence	   of	   broader	   autism	  phenotype,	   and	   no	   psychiatric	  medication	   use	   current	   or	  
past.	  No	  co-­‐morbid	  diagnoses.	  She	  holds	  a	  postgraduate	  degree	  and	  reports	  an	  annual	  
household	  income	  of	  $81-­‐101k.	  No	  medication	  use	  reported	  for	  mother	  before,	  during,	  
or	  after	  pregnancy	  except	  for	  epidural	  during	  labor.	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Patient	  ID:	  AC04-­‐0029-­‐04	  (sibling)	  
Sibling	  is	  a	  non-­‐Hispanic	  Caucasian	  3	  year	  old	  (37	  months)	  of	  unspecified	  sex.	  Normative	  
intelligence	   (IQ=118;	   WPPSI).	   No	   behavioral	   problems	   reported.	   No	   medication	   use	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C.	  Detailed	  validation	  results	  on	  putative	  differences	  in	  whole	  blood	  vs.	  cell	  line	  
derived	  DNA	  
	  
Group	  0:	  Validation	  results	  
Indiv.	   Chr.	   Position	   Blood	  Call	   Validation	   Cell	  Call	   Validation	   Comment	  
3	   X	   90691093	   AAC[C/C]GCC	   TRUE	   AAC[C/T]GCC	   TRUE	   MOSAIC	  
6	   X	   123538932	   CCT[C/C]TGC	   TRUE	   CCT[C/T]TGC	   TRUE	   MOSAIC	  
7	   4	   123533877	   TTC[A/A]CTT	   TRUE	   TTC[A/G]CTT	   TRUE	   MOSAIC	  
11	   2	   228882979	   ACC[G/G]TTG	   TRUE	   ACC[G/A]TTG	   TRUE	   MOSAIC	  
11	   8	   42256366	   AAA[T/T]CTC	   TRUE	   AAA[T/A]CTC	   TRUE	   MOSAIC	  
12	   6	   131188570	   GCT[C/C]GAA	   TRUE	   GCT[C/T]GAA	   TRUE	   MOSAIC	  
12	   20	   13846164	   CTG[T/T]ACA	   TRUE	   CTG[T/G]ACA	   TRUE	   MOSAIC	  
16	   1	   167403251	   AAC[A/A]CTC	   TRUE	   AAC[A/G]CTC	   TRUE	   MOSAIC	  
16	   12	   109684116	   CTG[C/C]GGG	   TRUE	   CTG[C/T]GGG	   TRUE	   MOSAIC	  
16	   18	   58038892	   TGC[C/C]GGG	   TRUE	   TGC[C/T]GGG	   TRUE	   MOSAIC	  
	  
Group	  1:	  Validation	  results	  
Indiv.	   Chr.	   Position	   Blood	  Call	   Validation	   Cell	  Call	   Validation	   Comment	  
1	   4	   69180008	   GAC[G/G]AAG	   TRUE	   GAC[G/A]AAG	   TRUE	   MOSAIC	  
4	   1	   10706375	   AGG[C/C]AAG	   TRUE	   AGG[C/A]AAG	   TRUE	   MOSAIC	  
4	   6	   32629194	   AAC[G/G]CCA	   	   AAC[G/A]CCA	   	  
Impossible	  primer	  
design.	  
4	   6	   32629199	   CAC[T/T]CAG	   	   CAC[T/C]CAG	   	  
Impossible	  primer	  
design.	  
4	   10	   98078170	   CTT[C/C]AAG	   TRUE	   CTT[C/T]AAG	   FALSE	   All	  “C”	  reads	  on	  forward	  strand.	  
4	   11	   47644317	   CAT[C/C]CAC	   TRUE	   CAT[C/A]CAC	   TRUE	   MOSAIC	  
4	   11	   56143156	   AGA[C/C]CAT	   TRUE	   AGA[C/T]CAT	   FALSE	  
Possibly	  an	  alignment	  
problem?	  Note	  next	  
candidate	  is	  adjacent.	  
4	   11	   56143158	   ACC[A/A]TCA	   TRUE	   ACC[A/G]TCA	   FALSE	   See	  previous.	  
4	   12	   57662804	   CTG[C/C]TGG	   TRUE	   CTG[C/G]TGG	   FALSE	   All	  “G”	  reads	  on	  the	  forward	  strand.	  
4	   12	   77424135	   TAA[C/T]GAA	   FALSE	   TAA[C/C]GAA	   TRUE	   Almost	  all	  reads	  on	  the	  
reverse	  strand.	  
4	   22	   50553671	   GAC[G/G]GAA	   TRUE	   GAC[G/T]GAA	   FALSE	   All	  “T”	  reads	  on	  the	  reverse	  strand.	  
4	   X	   55249176	   GAA[G/G]CAG	   TRUE	   GAA[G/A]CAG	   TRUE	   MOSAIC	  
5	   11	   67378012	   CCC[G/T]CCT	   FALSE	   CCC[G/G]CCT	   TRUE	  
All	  “T”	  reads	  on	  reverse	  
strand.	  
5	   16	   89246670	   GGA[T/T]GAG	   TRUE	   GGA[T/C]GAG	   FALSE	   All	  but	  one	  “C”	  read	  is	  highly	  skewed.	  
6	   X	   99661793	   TCG[G/G]CCA	   TRUE	   TCG[G/A]CCA	   TRUE	   MOSAIC	  
6	   X	   118767373	   GGA[C/C]GAA	   TRUE	   GGA[C/T]GAA	   TRUE	   MOSAIC	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7	   12	   54803111	   GTG[C/C]GCC	   TRUE	   GTG[C/T]GCC	   TRUE	   MOSAIC	  
7	   20	   210435	   ACT[C/C]CAA	   TRUE	   ACT[C/T]CAA	   TRUE	   MOSAIC	  
8	   5	   137801559	   GAG[G/G]AGA	   TRUE	   GAG[G/C]AGA	   TRUE	   MOSAIC	  
8	   9	   119106793	   CTC[C/C]TTC	   TRUE	   CTC[C/T]TTC	   TRUE	   MOSAIC	  
9	   2	   198299652	   TTA[G/G]GCT	   TRUE	   TTA[G/C]GCT	   TRUE	   MOSAIC,	  but	  noisy	  background	  
9	   11	   134241679	   AAT[C/C]GTG	   TRUE	   AAT[C/T]GTG	   TRUE	   MOSAIC	  
11	   2	   116599816	   ATC[T/T]GAG	   TRUE	   ATC[T/G]GAG	   TRUE	   MOSAIC	  
11	   7	   72397315	   ACA[G/G]CTA	   TRUE	   ACA[G/A]CTA	   TRUE	  
MOSAIC	  (very	  small	  
additional	  peak)	  
11	   19	   56300185	   TTA[A/A]GTA	   TRUE	   TTA[A/G]GTA	   TRUE	   MOSAIC	  
12	   11	   27389932	   TTT[C/C]GGG	   TRUE	   TTT[C/T]GGG	   TRUE	   MOSAIC	  
15	   11	   116797981	   AGC[T/T]TTT	   TRUE	   AGC[T/C]TTT	   TRUE	   MOSAIC	  
16	   11	   18313224	   GTC[G/G]TTC	   TRUE	   GTC[G/T]TTC	   TRUE	   MOSAIC	  
	  
Group	  2:	  Validation	  results	  
Indiv.	   Chr.	   Position	   Blood	  Call	   Validation	   Cell	  Call	   Validation	   Comment	  
1	   1	   65313240	   GGG[T/T]CTA	   TRUE	   GGG[T/G]CTA	   FALSE	  
All	  “G”	  reads	  on	  the	  
forward	  strand,	  and	  
these	  reads	  are	  skewed.	  
1	   3	   122354873	   ACA[C/C]GAT	   TRUE	   ACA[C/T]GAT	   TRUE	   MOSAIC	  
1	   4	   46264063	   GTC[C/C]ATG	   TRUE	   GTC[C/A]ATG	   FALSE	  
Large	  total	  depth,	  and	  
very	  few	  “A”	  reads	  on	  
cell	  line.	  
1	   9	   135982045	   CTT[C/C]CCA	   TRUE	   CTT[C/T]CCA	   FALSE	   All	  “T”	  reads	  on	  the	  forward	  strand.	  
1	   11	   62378536	   CCG[C/A]CAC	   FALSE	   CCG[C/C]CAC	   TRUE	   Blood	  “A”	  reads	  are	  
skewed,	  and	  few.	  
1	   12	   132623810	   GAG[C/A]CCC	   FALSE	   GAG[C/C]CCC	   TRUE	   Blood	  “A”	  reads	  are	  skiewed,	  and	  few.	  
1	   17	   78931437	   GGT[G/G]GTG	   TRUE	   GGT[G/T]GTG	   FALSE	  
The	  forward	  “T”	  reads	  
are	  skewed	  to	  the	  left,	  
the	  reverse	  “T”	  reads	  
are	  skewed	  to	  the	  right.	  
1	   19	   15278133	   TGG[T/T]GCC	   TRUE	   TGG[T/G]GCC	   FALSE	   All	  “G”	  reads	  are	  on	  the	  
forward	  strand.	  
1	   19	   51958638	   AGG[T/T]GTG	   TRUE	   AGG[T/G]GTG	   FALSE	  
All	  “G”	  reads	  are	  on	  the	  
forward	  strand.	  
1	   20	   3928845	   GGG[A/A]AAA	   TRUE	   GGG[A/G]AAA	   FALSE	  
All	  but	  one	  “G”	  read	  is	  
on	  the	  forward	  strand,	  
and	  are	  highly	  skewed.	  
1	   20	   61459302	   CCC[G/G]GAG	   TRUE	   CCC[G/T]GAG	   FALSE	  
The	  forward	  “T”	  reads	  
are	  skewed	  to	  the	  left,	  
the	  reverse	  “T”	  reads	  
are	  skewed	  to	  the	  right.	  
1	   Y	   14958873	   TCC[C/C]CAA	   TRUE	   TCC[C/T]CAA	   TRUE	   MOSAIC	  
2	   7	   44613258	   CGA[G/G]CCA	   TRUE	   CGA[G/T]CCA	   FALSE	  
All	  “T”	  reads	  are	  
skewed,	  and	  there	  are	  
few.	  
2	   9	   8484293	   TAT[G/G]ATT	   TRUE	   TAT[G/T]ATT	   FALSE	  
Low	  proportion	  of	  “T”	  
reads	  on	  cell	  line,	  and	  
almost	  all	  are	  skewed.	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2	   9	   101498842	   TGG[C/A]ACT	   FALSE	   TGG[C/C]ACT	   TRUE	  
The	  forward	  “A”	  reads	  
are	  skewed	  to	  the	  left,	  
the	  reverse	  “A”	  reads	  
are	  skewed	  to	  the	  right.	  
2	   9	   101498847	   CTG[C/A]TCT	   FALSE	   CTG[C/C]TCT	   TRUE	  
The	  forward	  “A”	  reads	  
are	  skewed	  to	  the	  left,	  
the	  reverse	  “A”	  reads	  
are	  skewed	  to	  the	  right.	  
Also,	  note	  proximity	  to	  
previous.	  
2	   18	   63511013	   AAC[C/C]GGT	   TRUE	   AAC[C/T]GGT	   TRUE	   MOSAIC	  
2	   19	   54725995	   GCT[A/A]TAG	   FALSE	   GCT[G/A]TAG	   TRUE	  
This	  appears	  to	  be	  a	  
mosaic	  on	  both	  blood	  
and	  cell	  line.	  Large	  
imbalance	  in	  “A”	  versus	  
“G”	  calls,	  but	  consistent	  
between	  blood	  and	  cell	  
line.	  
2	   21	   35169715	   TGG[A/A]GCA	   TRUE	   TGG[A/G]GCA	   FALSE	   All	  “G”	  reads	  are	  on	  the	  forward	  strand.	  
2	   X	   10107414	   AAT[C/C]AAT	   TRUE	   AAT[C/A]AAT	   FALSE	   All	  “A”	  reads	  are	  on	  the	  
forward	  strand.	  
3	   1	   2441539	   TGA[G/G]GGA	   TRUE	   TGA[G/A]GGA	   FALSE	   	  
3	   1	   27995021	   GTC[C/A]GAG	   FALSE	   GTC[C/C]GAG	   TRUE	   	  
3	   15	   75970085	   GCA[G/T]CCT	   FALSE	   GCA[G/G]CCT	   TRUE	  
	  
3	   17	   33459447	   CTT[C/C]GGG	   TRUE	   CTT[C/T]GGG	   FALSE	   	  
3	   19	   55148043	   GTC[T/T]GGG	   TRUE	   GTC[T/C]GGG	   FALSE	   	  
3	   21	   33077817	   TTA[C/C]TTA	   TRUE	   TTA[C/T]TTA	   FALSE	  
	  
4	   1	   16748468	   CTC[T/T]GGA	   TRUE	   CTC[T/G]GGA	   FALSE	   	  
4	   1	   35870652	   TGG[A/A]GCC	   TRUE	   TGG[A/G]GCC	   FALSE	   	  
4	   1	   46499441	   TCC[A/A]GCT	   TRUE	   TCC[A/C]GCT	   FALSE	  
	  
4	   1	   57398975	   CTT[C/C]CAC	   TRUE	   CTT[C/T]CAC	   FALSE	   	  
4	   1	   94461686	   TCC[A/A]GCA	   TRUE	   TCC[A/C]GCA	   FALSE	   	  
4	   2	   11780500	   CAG[T/T]TCC	   TRUE	   CAG[T/G]TCC	   FALSE	  
	  
4	   2	   242204025	   TGG[A/A]CCA	   TRUE	   TGG[A/C]CCA	   FALSE	   	  
4	   5	   43173577	   GTT[C/C]TTA	   TRUE	   GTT[C/T]TTA	   FALSE	   	  
4	   6	   11735807	   CTG[A/A]TGT	   TRUE	   CTG[A/G]TGT	   FALSE	  
	  
4	   6	   32632795	   CTC[C/C]GTC	   TRUE	   CTC[C/T]GTC	   FALSE	   	  
4	   6	   32632850	   GCG[G/G]GGA	   TRUE	   GCG[G/A]GGA	   FALSE	   	  





4	   7	   6461451	   CGT[T/T]GCA	   TRUE	   CGT[T/G]GCA	   FALSE	   	  
4	   7	   44151241	   CTG[T/T]GGG	   TRUE	   CTG[T/G]GGG	   FALSE	   	  
4	   8	   2020398	   GCC[C/C]TGA	   TRUE	   GCC[C/A]TGA	   FALSE	  
	  
4	   9	   100315518	   CTG[T/T]TCC	   TRUE	   CTG[T/G]TCC	   FALSE	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4	   10	   94822655	   TGG[A/A]CGA	   TRUE	   TGG[A/G]CGA	   FALSE	  
	  
4	   10	   97397146	   TCC[A/A]CTG	   TRUE	   TCC[A/C]CTG	   FALSE	   	  
4	   10	   103772671	   CAG[T/T]AGC	   TRUE	   CAG[T/C]AGC	   TRUE	   MOSAIC	  
4	   11	   68131385	   AGG[T/T]GCT	   TRUE	   AGG[T/G]GCT	   FALSE	  
	  
4	   11	   116706900	   TCC[A/A]CCT	   TRUE	   TCC[A/C]CCT	   FALSE	   	  
4	   13	   21063460	   GGG[A/A]GAC	   TRUE	   GGG[A/G]GAC	   FALSE	   	  
4	   14	   23564357	   CTT[C/C]GGG	   TRUE	   CTT[C/T]GGG	   FALSE	  
	  
4	   14	   23867949	   CAG[T/T]TGC	   TRUE	   CAG[T/G]TGC	   FALSE	   	  
4	   14	   54416937	   TGG[T/T]CAG	   TRUE	   TGG[T/C]CAG	   FALSE	   	  
4	   14	   57085352	   CCG[T/T]CCT	   TRUE	   CCG[T/G]CCT	   FALSE	  
	  
4	   16	   2498902	   CTC[A/A]CGG	   TRUE	   CTC[A/C]CGG	   FALSE	   	  
4	   16	   4445265	   CCC[A/A]CCC	   TRUE	   CCC[A/C]CCC	   FALSE	   	  
4	   17	   7707597	   AGG[A/A]GCT	   TRUE	   AGG[A/G]GCT	   FALSE	  
	  
4	   17	   21319369	   ACC[G/G]AGG	   TRUE	   ACC[G/A]AGG	   FALSE	   	  
4	   19	   313490	   CCC[A/A]CCT	   TRUE	   CCC[A/C]CCT	   FALSE	   	  
4	   19	   44252108	   CCC[T/T]CCT	   TRUE	   CCC[T/C]CCT	   FALSE	  
	  
4	   19	   50322605	   GTG[A/A]ATG	   TRUE	   GTG[A/C]ATG	   FALSE	   	  
4	   20	   47592567	   CTC[A/A]CGG	   TRUE	   CTC[A/C]CGG	   FALSE	   	  
4	   21	   46640865	   AGC[T/T]GGG	   TRUE	   AGC[T/G]GGG	   FALSE	  
	  
5	   3	   179527471	   AAA[G/A]AAG	   TRUE	   AAA[G/G]AAG	   FALSE	   	  
5	   5	   140079996	   TCC[A/C]AGC	   FALSE	   TCC[A/A]AGC	   TRUE	   	  
5	   5	   148712424	   CAA[G/G]CCC	   TRUE	   CAA[G/T]CCC	   FALSE	  
	  
5	   6	   7405175	   TAT[C/C]ATT	   TRUE	   TAT[C/A]ATT	   FALSE	   	  
5	   7	   66648157	   GAA[C/T]GTG	   TRUE	   GAA[T/T]GTG	   FALSE	   	  
5	   11	   117789342	   GCC[T/C]GGG	   TRUE	   GCC[T/T]GGG	   FALSE	  
	  
5	   11	   117789345	   TGG[G/C]CTG	   TRUE	   TGG[G/G]CTG	   FALSE	   	  
5	   15	   43712957	   GGA[G/A]AAG	   FALSE	   GGA[G/G]AAG	   TRUE	   	  
5	   20	   62658494	   CGG[G/A]AAG	   FALSE	   CGG[G/G]AAG	   TRUE	  
	  
6	   6	   32632598	   CGG[A/T]ACG	   	   CGG[A/A]ACG	   	   Failure	  
6	   16	   135354	   GAG[G/T]ACA	   FALSE	   GAG[G/G]ACA	   TRUE	   	  
6	   22	   24583727	   GTG[G/C]CAG	   FALSE	   GTG[G/G]CAG	   TRUE	  
	  
7	   9	   4663267	   CAC[C/C]ATC	   TRUE	   CAC[C/A]ATC	   TRUE	   MOSAIC	  
7	   9	   72006567	   CTC[G/G]CGG	   TRUE	   CTC[G/A]CGG	   TRUE	   MOSAIC	  
7	   9	   87425462	   TTT[G/G]TTT	   TRUE	   TTT[G/A]TTT	   TRUE	   MOSAIC	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7	   10	   15138591	   CGA[C/C]TTT	   TRUE	   CGA[C/T]TTT	   TRUE	   MOSAIC	  
7	   22	   42912029	   CTT[G/G]GGA	   TRUE	   CTT[G/T]GGA	   FALSE	   	  
8	   1	   54360125	   AGC[G/G]ACT	   TRUE	   AGC[G/A]ACT	   TRUE	   MOSAIC	  
8	   11	   63672427	   GTG[A/C]CCC	   TRUE	   GTG[A/A]CCC	   FALSE	  
	  
8	   20	   10036141	   TTT[C/T]TTT	   TRUE	   TTT[C/C]TTT	   FALSE	   	  
9	   2	   130912789	   CAA[A/A]CAA	   TRUE	   CAA[A/C]CAA	   FALSE	   	  
9	   5	   840785	   GAG[C/A]CAC	   TRUE	   GAG[C/C]CAC	   FALSE	  
	  
9	   6	   75823294	   CAT[G/G]TGC	   TRUE	   CAT[G/A]TGC	   TRUE	   MOSAIC	  
9	   11	   2416725	   AGG[C/C]TGT	   TRUE	   AGG[C/A]TGT	   FALSE	   	  
9	   15	   48459567	   ATC[C/C]TTA	   TRUE	   ATC[C/T]TTA	   TRUE	   MOSAIC	  
10	   1	   68942568	   CTT[C/T]ATT	   TRUE	   CTT[C/C]ATT	   FALSE	   	  
10	   5	   60241142	   GAA[A/A]GAG	   TRUE	   GAA[G/A]GAG	   FALSE	   	  
10	   7	   128483043	   TGC[A/C]CCT	   TRUE	   TGC[A/A]CCT	   FALSE	  
	  
10	   10	   3174669	   CTC[A/A]CCG	   	   CTC[A/C]CCG	   	   Failure	  
10	   19	   46375892	   GCC[A/A]GAA	   TRUE	   GCC[A/G]GAA	   FALSE	   	  
11	   1	   12921127	   ATT[A/G]GAA	   TRUE	   ATT[A/A]GAA	   FALSE	   All	  G	  calls	  are	  in	  a	  single	  
direction	  
11	   2	   139318349	   AAC[A/A]TTT	   TRUE	   AAC[A/T]TTT	   FALSE	   All	  T	  calls	  are	  in	  a	  single	  direction	  
11	   3	   48464209	   AAG[C/C]GAT	   TRUE	   AAG[C/T]GAT	   TRUE	   MOSAIC	  
12	   3	   100091564	   GCG[G/T]TAC	   FALSE	   GCG[G/G]TAC	   TRUE	  
All	  T	  calls	  are	  in	  a	  single	  
direction	  
12	   4	   155506864	   CAC[G/G]GGA	   TRUE	   CAC[G/A]GGA	   TRUE	   MOSAIC	  
12	   10	   117825111	   GCC[C/C]GAC	   TRUE	   GCC[C/T]GAC	   TRUE	  
All	  T	  calls	  are	  in	  a	  single	  
direction	  
12	   19	   33467325	   TTC[A/A]TTG	   TRUE	   TTC[A/G]TTG	   TRUE	   MOSAIC	  
13	   17	   21318770	   CGC[G/A]GCG	   FALSE	   CGC[G/G]GCG	   TRUE	   All	  A	  calls	  are	  in	  a	  single	  
direction	  
13	   17	   21318773	   GGC[G/A]CAG	   FALSE	   GGC[G/G]CAG	   TRUE	   All	  A	  calls	  are	  in	  a	  single	  direction	  
14	   7	   26251843	   GTT[C/T]TTT	   FALSE	   GTT[C/C]TTT	   TRUE	   Very	  slight	  bump	  for	  T	  
on	  blood	  
14	   15	   20588693	   CAA[C/C]ATC	   FALSE	   CAA[C/T]ATC	   TRUE	   Appears	  to	  be	  mosaic	  on	  both	  
15	   14	   96180232	   AAG[C/C]TCC	   TRUE	   AAG[C/T]TCC	   FALSE	   All	  T	  calls	  are	  in	  a	  single	  
direction	  
16	   3	   48505302	   GGC[A/A]TCT	   TRUE	   GGC[A/G]TCT	   FALSE	   No	  clear	  explanation	  for	  mistake	  
16	   6	   151334926	   TGG[T/T]GTT	   TRUE	   TGG[T/G]GTT	   FALSE	  	   All	  G	  calls	  are	  in	  a	  single	  
direction	  
16	   11	   19251484	   TGG[T/T]TTG	   TRUE	   TGG[T/G]TTG	   TRUE	   MOSAIC	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Group	  3:	  Validation	  results	  
Indiv.	   Chr.	   Position	   Blood	  Call	   Validation	   Cell	  Call	   Validation	   Comment	  
1	   7	   44099733	   TGC[C/C]CTG	   TRUE	   TGC[C/A]CTG	   FALSE	   Strong	  Candidate	  
1	   20	   1895794	   CGT[G/G]TTG	   	   CGT[G/A]TTG	   	  
Strong	  Candidate;	  
Failure	  
1	   20	   1895797	   GTT[G/G]GTT	   	   GTT[G/A]GTT	   	   Strong	  Candidate;	  
Failure	  
2	   1	   185137463	   TAT[T/T]TAT	   	   TAT[T/A]TAT	   	  
Strong	  Canddiate;	  
Failure	  
2	   3	   16264288	   AGA[G/G]CCT	   TRUE	   AGA[G/T]CCT	   FALSE	   Strong	  Candidate	  
2	   7	   912157	   CAC[G/G]TAT	   TRUE	   CAC[G/T]TAT	   FALSE	   Strong	  Candidate	  
2	   8	   73480055	   TCC[G/G]GAG	   TRUE	   TCC[G/A]GAG	   FALSE	   Strong	  Candidate	  
3	   1	   240371031	   AGC[A/A]GGA	   	   AGC[A/G]GGA	   	  
Strong	  Candidate;	  
Failure	  
4	   5	   115230799	   ACA[T/T]TAG	   TRUE	   ACA[T/A]TAG	   FALSE	   Strong	  Candidate	  
4	   5	   115230800	   CAT[T/T]AGA	   TRUE	   CAT[T/C]AGA	   FALSE	   Strong	  Candidate	  
4	   6	   32712996	   AGT[A/A]CAC	   TRUE	   AGT[A/T]CAC	   FALSE	   Strong	  Candidate	  
4	   X	   154721357	   AAA[C/C]AGA	   	   AAA[G/C]AGA	   	   Strong	  Candidate;	  
Failure	  
5	   6	   148861617	   CTC[G/G]TTG	   TRUE	   CTC[G/A]TTG	   TRUE	   Strong	  Candidate;	  MOSAIC	  
6	   19	   51919894	   CAC[A/A]CCC	   TRUE	   CAC[A/G]CCC	   FALSE	   Strong	  Candidate	  
7	   19	   54942009	   CAG[C/C]GAG	   	   CAG[C/A]GAG	   	  
Strong	  Candidate;	  
Failure	  
8	   12	   51740409	   CCA[T/T]AAA	   	   CCA[T/G]AAA	   	   Strong	  Candidate;	  Failure	  
8	   12	   51740410	   CAT[A/A]AAG	   	   CAT[A/G]AAG	   	  
Strong	  Candidate;	  
Failure	  
9	   6	   32609368	   CTT[A/A]AGT	   	   CTT[A/G]AGT	   	   Strong	  Candidate;	  Failure	  
9	   8	   28651299	   CAA[A/A]AAA	   TRUE	   CAA[A/C]AAA	   FALSE	   Strong	  Candidate	  
11	   2	   27840357	   TGG[A/G]AAA	   FALSE	   TGG[A/A]AAA	   TRUE	   	  
11	   3	   10114944	   GAA[A/C]CAA	   FALSE	   GAA[A/A]CAA	   TRUE	   	  
11	   5	   180335598	   AGG[T/T]GTT	   TRUE	   AGG[T/G]GTT	   FALSE	   	  
12	   4	   72319317	   CAT[T/T]TAT	   TRUE	   CAT[T/G]TAT	   TRUE	   Strong	  Candidate;	  MOSAIC	  
12	   16	   88926388	   GCC[C/C]TAC	   TRUE	   GCC[C/T]TAC	   FALSE	  
	  
16	   1	   15808767	   TCC[G/G]GGA	   	   TCC[G/A]GGA	   	  
Strong	  Candidate;	  
Failure	  
16	   1	   202743892	   ATC[T/T]CAT	   TRUE	   ATC[T/C]CAT	   FALSE	   	  
16	   5	   120022221	   GAT[T/T]CCT	   TRUE	   GAT[T/C]CCT	   TRUE	   Strong	  Candidate;	  
MOSAIC	  
16	   7	   99361466	   GTA[T/T]CAT	   TRUE	   GTA[C/T]CAT	   FALSE	   	  
16	   8	   7718187	   AAT[T/G]AGA	   TRUE	   AAT[G/G]AGA	   FALSE	   	  
16	   8	   87229948	   CGA[A/A]GAT	   	   CGA[T/A]GAT	   	   Strong	  Candidate;	  
Failure	  
16	   9	   135153668	   CAA[T/T]AGT	   TRUE	   CAA[C/T]AGT	   FALSE	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16	   19	   52249211	   AAC[G/G]CCA	   TRUE	   AAC[T/G]CCA	   FALSE	   Strong	  Candidate	  
16	   21	   15516948	   TTT[T/T]TGG	   TRUE	   TTT[C/T]TGG	   FALSE	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